Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), lists tumor-like lesions beside thyroid neoplasms for differential diagnosis. Developmental abnormalities include thyroglossal duct cyst, thyroid dysgenesis and dyshormonogenetic goiter. Thyroid follicular nodular disease (FND; formerly multinodular goiter) is listed among the benign follicular cell-derived lesions without an ICD-O code because its nodules are not regarded as neoplasms (Jung et al. 2022). The CAP Thyroid protocol, version 4.4.0.0, records follicular nodular disease, diffuse hyperplasia (Graves disease), thyroiditis by type and C-cell hyperplasia as optional additional findings in carcinoma resections (CAP 2023).
Median anlage. The median anlage forms at about 22 days post-conception as a thickened endodermal bud at the foramen cecum on the floor of the tongue. It expands laterally into a bilobed gland and migrates down the neck, connected to the foramen cecum by an epithelial stalk, the thyroglossal duct, which atrophies between 28 and 40 days post-conception (Stoupa et al. 2025).
Ultimobranchial bodies. The paired ultimobranchial bodies derive from a more posterior portion of the pharyngeal apparatus and merge with the midline primordium. The merger produces both the thyroid follicles and the parafollicular C cells (Lobo et al. 2026). The two lateral anlagen (ultimobranchial bodies) derive from the ventral recess of the fourth pharyngeal pouch (Stoupa et al. 2025). Lineage tracing has firmly established that C cells are endoderm-derived. They were formerly presumed to arise from the neural crest (Lobo et al. 2026).
Thyroid hormone synthesis. NKX2-1, FOXE1 and PAX8 activate SLC5A5 (sodium-iodide symporter), TPO and TG. Thyroid peroxidase oxidizes iodide, iodinates tyrosyl residues of thyroglobulin to monoiodotyrosine and diiodotyrosine and couples them to thyroxine and triiodothyronine. DUOX2 with DUOXA2 generates the hydrogen peroxide for this reaction, and pendrin (SLC26A4) moves iodide into the follicular lumen (Stoupa et al. 2025).
Solid cell nests. Solid cell nests are ultimobranchial remnants about 1 mm across, usually in the middle third of the lateral lobes. They consist of non-keratinizing epidermoid cells without intercellular bridges, positive for high and low molecular weight keratins and CEA. Peripheral calcitonin-positive C cells are present in up to 54% of cases. A central lumen lined by mucinous cells and "mixed follicles" lined by both epidermoid and follicular cells can be present (Harach 1988). Solid cell nests were found in 3.3% of 118 completion thyroidectomies (Fuchs et al. 2019). Solid cell nests share p63 positivity and thyroglobulin negativity with sclerosing mucoepidermoid carcinoma with eosinophilia, which is presumed to arise from them (Jung et al. 2022).
Calcium oxalate crystals. Birefringent calcium oxalate crystals are present in the colloid of normal thyroid follicles and are rare in parathyroid tissue. Polarized light examination of frozen sections helps separate follicular-patterned parathyroid from thyroid tissue (Wong et al. 2014).
Developmental anomalies of the thyroid
Ectopic and lingual thyroid. About 90% of ectopic thyroid tissue occurs at the base of the tongue, and orthotopic thyroid tissue is absent in 70%–80% of patients with lingual thyroid (Patel and Bhatt 2019). Ectopic thyroid tissue is distinguished from metastatic deposits of an orthotopic carcinoma and from other neck masses (Noussios et al. 2011).
Thyroglossal duct cyst. In 685 thyroglossal duct remnant cysts, age was bimodal (first and fifth decades; mean 31.3 years) and 76% were infrahyoid. The lining was respiratory and squamous in 51%, respiratory only in 38%, squamous only in 10% and absent in 1%. Thyroid tissue was present in 71% of specimens. Carcinoma was found in 3.2%, all papillary thyroid carcinoma. Recurrence occurred in 3% of patients and followed simple cystectomy far more often than the Sistrunk procedure (Thompson et al. 2016).
Lateral aberrant thyroid. Bland thyroid follicles in the capsule of a lateral neck lymph node can coexist with nodal metastases of papillary carcinoma. In one case the intranodal follicles were negative for BRAF VE1 while the primary carcinoma and its overt metastases were positive, suggesting the bland follicles were not metastases. The origin of such benign-appearing intranodal thyroid tissue remains unresolved (Wallace et al. 2022).
Dyshormonogenetic goiter
Dyshormonogenesis is congenital hypothyroidism caused by defective thyroid hormone synthesis in a structurally intact gland. Variants in TG, TPO, SLC26A4, SLC5A5, DUOX2, DUOXA2, IYD and SLC26A7 cause it (Stoupa et al. 2025).
Gene
Defect and clinical clue
Source
TPO
Commonest cause of a total iodide organification defect: release of >90% of accumulated intrathyroidal radioiodine on perchlorate discharge testing
Stoupa et al. 2025
DUOX2 and DUOXA2
Partial organification defect; permanent or transient congenital hypothyroidism
Stoupa et al. 2025
TG
Serum thyroglobulin inappropriately low for the elevated TSH; goiter size variable
Stoupa et al. 2025
SLC26A4 (pendrin)
Pendred syndrome: congenital sensorineural hearing impairment with enlarged vestibular aqueduct, and diffuse or multinodular goiter with a partial organification defect from about adolescence
Stoupa et al. 2025
IYD
Normal perchlorate discharge test and raised urinary monoiodotyrosine and diiodotyrosine
Stoupa et al. 2025
Morphology. In 56 dyshormonogenetic goiters (median age 16 years; 75% before age 24), every gland was enlarged and multinodular, weighing up to 600 g. Nodules were markedly cellular with solid and microfollicular patterns, papillary and insular areas, minimal colloid and marked nuclear atypia. Fibrosis made nodule edges irregular and simulated capsular invasion (Ghossein et al. 1997).
Carcinoma mimicry. In 18% of these glands the hyperplasia and atypia led to a mistaken diagnosis of follicular, papillary, medullary or undifferentiated carcinoma. The only other condition with a similar picture is goiter induced by antithyroid drugs (Ghossein et al. 1997).
Definition. FND is the WHO 2022 term for the multifocal hyperplastic and neoplastic follicular nodules that present clinically as multinodular goiter. The nodules show the histologic findings of nodular hyperplasia. Some are molecularly clonal and resemble adenomas, and encapsulated cellular nodules in FND cannot be separated from follicular adenoma by histology (Jung et al. 2022). The term achieved consensus in the WHO 2022 working group (Baloch et al. 2022). Previous rule (4th edition, 2017): no collective term existed. The WHO 2022 text allows adenomatous nodule, adenomatous hyperplasia, nodular hyperplasia and multinodular goiter as synonyms (Jung et al. 2022).
Clonality. In an X-chromosome inactivation study, four of six nodules from multinodular goiters were polyclonal and the two largest were monoclonal, while all six follicular adenomas were monoclonal (Namba et al. 1990). DNA from a multinodular goiter was polyclonal, and three solitary follicular nodules were monoclonal (Hicks et al. 1990).
Degenerative changes. Long-standing iodine-deficiency goiters show follicles distended with colloid, fibrosis and calcification (Sande et al. 2023).
Pathology and antibodies. In 28 thyroidectomies for Graves disease, severe follicular hyperplasia showed diffuse crowding of small follicles, papillary structures lined by cuboidal cells with round nuclei and scalloping of the colloid. Mild hyperplasia showed little variation in follicle size with scattered thin pseudopapillary projections. The degree of hyperplasia correlated with TSH-receptor antibody levels, while the extent of lymphocytic infiltration, including lymphoid aggregates with germinal centers, correlated with thyroglobulin and thyroid peroxidase antibody levels (Brancatella et al. 2023).
Scalloped colloid. Thyroid-stimulating immunoglobulins increased peripheral colloid vacuoles in human thyroid tissue, producing the scalloped colloid of hyperactive glands (Nilsson et al. 1988).
Iodide preparation. Preoperative potassium iodide (Lugol solution) was given for 2–3 weeks to increase colloid storage and decrease papillary hyperplasia and vascularity. The histologic evidence for these effects is weak, and the practice is regarded as obsolete (Sande et al. 2023).
Antithyroid drug effect. Propylthiouracil produces clear and vesicular change in follicular cells. One case of marked follicular cell pleomorphism after methimazole has been reported, and whether it reflected the drug or the atypia of long-standing hyperthyroidism is unclear (Sande et al. 2023).
Radioiodine effect. Radioiodine for hyperthyroidism causes mild acute inflammation and follicular destruction. Long-term effects are severe follicular atrophy, minimal colloid, stromal fibrosis, focal oncocytic metaplasia and random marked nuclear atypia, which can mimic carcinoma on cytology and histology. The changes are diffuse in Graves disease and uneven in toxic nodular goiter (Sande et al. 2023).
Carcinoma in Graves disease. In a meta-analysis of 33 surgical series, carcinoma was found in 7% of glands resected for Graves disease (95% CI 4%–12%), without higher odds than in toxic multinodular or toxic uninodular goiter. Of these carcinomas, 88% were papillary and 23% of all carcinomas were solitary papillary microcarcinomas. Patients with coexisting nodules were almost 5 times more likely to have carcinoma (Staniforth et al. 2016).
Related page: Papillary thyroid carcinoma (papillary carcinoma nuclear features that separate it from the papillary hyperplasia of Graves disease)
Chronic lymphocytic (Hashimoto) thyroiditis
Spectrum. Hashimoto thyroiditis includes the classic lymphoid goiter, the fibrous variant, the IgG4-related variant, the juvenile form, hashitoxicosis and painless thyroiditis (sporadic or postpartum). All forms show interstitial infiltration by mononuclear cells, mainly lymphocytes. Follicular cells undergo atrophy or oncocytic (formerly Hürthle cell) change. Most forms evolve to hypothyroidism, and the diagnosis rests on thyroid peroxidase and thyroglobulin antibodies with reduced echogenicity on ultrasound (Caturegli et al. 2014).
Histology. The parenchyma is effaced by lymphocytes and plasma cells forming lymphoid follicles with activated germinal centers. Fibrous septa accentuate the lobular pattern, fibrosis with follicular atrophy develops in advanced disease, and follicular cells typically undergo oncocytic change (Uccella et al. 2023).
IgG4 thyroiditis. Among 105 Hashimoto thyroiditis cases, 28 were IgG4 thyroiditis. Patients were younger, with a lower female-to-male ratio, rapid progression, higher antibody titers, subclinical hypothyroidism and diffuse low echogenicity. Histology showed severe lymphoplasmacytic infiltration, dense stromal fibrosis, follicular cell degeneration, many microfollicles and giant cell or histiocyte infiltration. Predominant interfollicular fibrosis was significantly associated with IgG4 thyroiditis. Interfollicular, interlobular and scar patterns of fibrosis were described, and IgG4 thyroiditis did not completely overlap with the fibrous variant (Li et al. 2012). IgG4 thyroiditis is reported most often in Asian populations (Li et al. 2020).
Proposed criteria for IgG4-related thyroid disease. Thyroid enlargement, hypoechoic lesions on ultrasound, elevated serum IgG4 and histology with >20 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio >30% are the core items. A definitive diagnosis requires all four. A probable diagnosis requires enlargement, hypoechoic lesions and either the histologic item or involvement of other organs (Takeshima et al. 2021). The category includes IgG4-associated Hashimoto thyroiditis, Graves disease and Riedel thyroiditis.
Lymphoma risk. Thyroid extranodal marginal zone (MALT) lymphoma arises in a background of Hashimoto thyroiditis, and chronic antigenic stimulation with acquired lymphoid tissue is the proposed mechanism (Teixeira Mendes and Wotherspoon 2017). Diffuse large B-cell lymphoma is the most frequent primary thyroid lymphoma, followed by MALT lymphoma (Pavlidis and Pavlidis 2019).
Lithium. Long-term lithium is associated with diffuse lymphocytic thyroiditis with lymphoid follicles, follicular atrophy and variable fibrosis in both hypothyroid and hyperthyroid patients (Sande et al. 2023). A 29-year-old patient on lithium had thyroid antibodies, diffuse goiter, germinal centers and oncocytic cells, and painless thyroiditis and autoimmune thyroiditis were the histologic differential (Shimizu et al. 1997).
Clinical features. Subacute thyroiditis had an age- and sex-adjusted incidence of 4.9 per 100,000 per year in Olmsted County. Pain was the presenting symptom in 96%. Early transient hypothyroidism was common, permanent hypothyroidism developed in 15%, and recurrence occurred in 4% after 6–21 years (Fatourechi V et al. 2003).
Etiology. The disease follows viral infection, including coxsackievirus, adenovirus, mumps virus and echovirus infection, and most patients carry the HLA-B*35 haplotype. Erythrocyte sedimentation rate and C-reactive protein are elevated without leukocytosis, and radioiodine uptake is reduced in the thyrotoxic phase (Toschetti et al. 2025).
Gross findings. The gland is asymmetrically enlarged and firm, with a tan-white cut surface and ill-defined nodularity. A localized firm lesion can mimic carcinoma (Prajapati and Hernandez-Prera 2019).
Histologic phases. The early phase shows destruction of follicular epithelium, colloid leakage and neutrophil microabscesses, matching the thyrotoxic stage. Lymphocytes, histiocytes and multinucleated giant cells engulfing colloid follow. Interfollicular fibrosis increases in the late phase, matching the hypothyroid stage. Multinucleated giant cells are the histologic hallmark but also occur in other non-neoplastic conditions (Prajapati and Hernandez-Prera 2019).
Giant cell lesion of the thyroid
Distribution and morphology
Clinical setting
Source
Subacute granulomatous thyroiditis
Follicle-centered inflammation; giant cells engulfing colloid; early microabscesses; late fibrosis
Painful gland after viral illness
Prajapati and Hernandez-Prera 2019
Palpation thyroiditis
Multifocal; giant cells and macrophages inside isolated follicles
Incidental in resections
Prajapati and Hernandez-Prera 2019; Carney et al. 1975
Sarcoidosis
Interstitial non-necrotizing granulomas without colloid colonization or follicle destruction
Systemic disease without thyroid symptoms
Prajapati and Hernandez-Prera 2019
Mycobacterial and fungal infection
Necrotizing granulomas, caseation, abscesses and acute inflammation; acid-fast or Grocott stains
Mainly immunosuppressed patients
Prajapati and Hernandez-Prera 2019
Papillary thyroid carcinoma
Giant cells in neoplastic follicles or beside papillae; carcinoma nuclear features
Painless cold nodule
Prajapati and Hernandez-Prera 2019
Type 2 amiodarone-associated thyrotoxicosis
Histiocytes and multinucleated cells around disrupted follicles; no lymphocytic infiltrate
Amiodarone therapy in a previously normal gland
Sande et al. 2023
Other forms of thyroiditis
Entity
Clinical setting
Pathology
Course
Source
Postpartum thyroiditis
De novo autoimmune thyroid disease, excluding Graves disease, in the first year after delivery; incidence 5.4%; up to 50% of women with first-trimester thyroid antibodies
Part of the Hashimoto spectrum (painless lymphocytic thyroiditis)
Hyperthyroid then hypothyroid phase in 22%, isolated hypothyroid phase in 48%, isolated thyrotoxicosis in 30%; permanent hypothyroidism in 20%–40%
Stagnaro-Green 2012; Caturegli et al. 2014
Painless (silent) sporadic thyroiditis
Painless transient thyroid dysfunction
Lymphocytic thyroiditis within the Hashimoto spectrum
Transient dysfunction; histologic differential of lithium-associated thyroiditis
Caturegli et al. 2014; Shimizu et al. 1997
Riedel thyroiditis (invasive fibrous thyroiditis)
Women in 81% (mean age 42 years); tobacco use in 76%; tracheal narrowing 48%, dysphagia 33%, vocal cord paralysis 29%
Storiform, keloid-like fibrosis extending beyond the capsule; occlusive phlebitis; lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells; no oncocytic change
Extracervical fibrosis in 38% (fibrosing mediastinitis, retroperitoneal, orbital, pancreatic); surgical complications in 39%; no disease-specific deaths
Fatourechi MM et al. 2011; Dahlgren et al. 2010; Falhammar et al. 2018; Uccella et al. 2023
Acute suppurative thyroiditis
Less than 1% of thyroid disease; mostly children aged 5–15 years; pyriform sinus fistula in 21% of one series; esophageal perforation by fish or chicken bones in adults
Bacterial abscess (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae); left lobe more often affected
Usually euthyroid; recurrence indicates a possible pyriform sinus fistula
Toschetti et al. 2025
Palpation thyroiditis
Found in more than 83% of surgically removed thyroids and reproduced by squeezing canine thyroids
Multifocal granulomatous folliculitis of single ruptured follicles
Little or no clinical importance
Carney et al. 1975
Radioiodine effect
Prior radioiodine for hyperthyroidism
Follicular atrophy, fibrosis, oncocytic metaplasia, random nuclear atypia
Hypothyroidism
Sande et al. 2023
Type 2 amiodarone-associated thyrotoxicosis
Amiodarone (37% iodine by weight) in a normal gland
Destructive histiocytic reaction around follicles with colloid release; no lymphocytes
Thyrotoxicosis; thyroidectomy when the drug cannot be stopped
Sande et al. 2023
Type 1 amiodarone-associated thyrotoxicosis
Amiodarone in a nodular gland or Hashimoto thyroiditis
Riedel thyroiditis and IgG4-related disease. Riedel thyroiditis is regarded as part of the IgG4-related disease spectrum (Dahlgren et al. 2010). Fibrosis extending beyond the capsule can involve the parathyroid glands and cause hypoparathyroidism (Falhammar et al. 2018), which occurred in three of 21 Mayo Clinic patients (Fatourechi MM et al. 2011).
Riedel thyroiditis versus the fibrous variant of Hashimoto thyroiditis. Extension of fibrosis outside the thyroid capsule was an inclusion criterion for Riedel thyroiditis in the Mayo Clinic series (Fatourechi MM et al. 2011). In IgG4 thyroiditis, which overlaps only in part with the fibrous variant, fibrosis is predominantly interfollicular and within the gland (Li et al. 2012). Oncocytic change is absent in Riedel thyroiditis, and its presence favors the fibrous variant of Hashimoto thyroiditis (Uccella et al. 2023).
Clinical and histologic comparison of the major forms of thyroiditis
Feature
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Painless and postpartum thyroiditis
Riedel thyroiditis
Acute suppurative thyroiditis
Pain
Painless
Painful in 96%
Painless
Pain in 24%
Painful with fever
Mechanism
Autoimmune (thyroid peroxidase and thyroglobulin antibodies)
Post-viral; HLA-B*35
Autoimmune
IgG4-related fibroinflammatory disease
Bacterial infection; pyriform sinus fistula in children
Key histology
Lymphoid follicles with germinal centers; oncocytic change; atrophy
Follicle-centered giant cells engulfing colloid
Lymphocytic thyroiditis
Storiform fibrosis beyond the capsule; occlusive phlebitis; no oncocytic change
Abscess
Function and complications
Hypothyroidism in most
Thyrotoxic phase, then transient hypothyroidism; permanent in 15%
Thyrotoxic and hypothyroid phases, alone or in sequence
Airway narrowing; hypoparathyroidism in 3 of 21 patients
Usually euthyroid; abscess and airway risk
Sources
Caturegli et al. 2014; Uccella et al. 2023
Fatourechi V et al. 2003; Toschetti et al. 2025; Prajapati and Hernandez-Prera 2019
Stagnaro-Green 2012; Caturegli et al. 2014
Fatourechi MM et al. 2011; Dahlgren et al. 2010; Falhammar et al. 2018; Uccella et al. 2023
Toschetti et al. 2025
Incidental findings in thyroid resections
Black thyroid. Minocycline causes a grossly black thyroid. Fine granular black pigment accumulates in colloid and in the apical cytoplasm of follicular cells. It is positive with Masson-Fontana and Schmorl stains, bleaches with potassium permanganate, and is negative with Prussian blue, PAS and Ziehl–Neelsen stains. Nodules can be pigmented or unpigmented independently of the background gland (Sande et al. 2023).
Amyloid goiter. Amyloid goiter is diffuse thyroid enlargement by amyloid that is Congo red positive with yellow-green birefringence. Most cases are secondary to chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis and familial Mediterranean fever. All three patients in one series were euthyroid. The usual presentation is thyroid enlargement, sometimes with compressive signs (Laamouri et al. 2025). Medullary thyroid carcinoma also contains amyloid (High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging).
Multifocal fibrosing thyroiditis. Multifocal fibrosing thyroiditis consists of multiple superficial scar-like lesions (mean 15.4 per gland; mean size 3.1 mm) with a paucicellular fibrotic center and a cellular periphery with reactive follicular atypia. Of 65 reported cases, 94% were women. It occurs mainly in glands removed for chronic lymphocytic thyroiditis, follicular nodular disease or Graves disease, coexists with papillary carcinoma in 38.5% and mimics papillary carcinoma on ultrasound, cytology and histology (Orsatti et al. 2022).
Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria
Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), divides follicular cell-derived thyroid neoplasms into benign tumors, low-risk neoplasms and malignant neoplasms (Baloch et al. 2022). Benign tumors are follicular adenoma, follicular adenoma with papillary architecture and oncocytic adenoma. Low-risk neoplasms are noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), thyroid tumors of uncertain malignant potential and hyalinizing trabecular tumor, all with ICD-O behavior code 1. Malignant encapsulated follicular-patterned carcinomas are follicular thyroid carcinoma (FTC), oncocytic carcinoma (OCA; formerly Hürthle cell carcinoma) and invasive encapsulated follicular variant papillary thyroid carcinoma (IEFVPTC) (Jung et al. 2022). The term "Hürthle cell" is discouraged as a misnomer (Baloch et al. 2022). The CAP Thyroid protocol, version 4.4.0.0 (March 2023), applies to malignant follicular cell-derived neoplasms. It is not required for thyroid tumors of uncertain malignant potential, hyalinizing trabecular tumor or NIFTP, and low-risk neoplasms are not required to be staged (CAP 2023).
FND was a new term with no 2017 equivalent; hyperfunctioning adenoma and follicular adenoma with papillary hyperplasia were variants of follicular adenoma; oncocytic adenoma was Hürthle cell adenoma
Jung et al. 2022
Low-risk follicular cell-derived neoplasms
NIFTP (subcentimeter and oncocytic subtypes); follicular tumor of uncertain malignant potential (FT-UMP); well-differentiated tumor of uncertain malignant potential (WDT-UMP); hyalinizing trabecular tumor
Subcentimeter and oncocytic NIFTP were not defined
Jung et al. 2022
Malignant follicular cell-derived neoplasms
FTC; IEFVPTC; PTC; OCA
IEFVPTC was a subtype of PTC; papillary microcarcinoma was a variant of PTC; OCA was Hürthle cell carcinoma
No high-grade category; DHGTC was a differentiated carcinoma with high-grade features
Jung et al. 2022
Anaplastic follicular cell-derived carcinoma
Anaplastic thyroid carcinoma, including the squamous cell carcinoma pattern
Squamous cell carcinoma of the thyroid was a separate entity
Jung et al. 2022
Thyroid C-cell-derived carcinoma
Medullary thyroid carcinoma
Grading by mitotic count, necrosis and Ki-67 introduced
Jung et al. 2022
Mixed medullary and follicular cell-derived carcinomas
Mixed medullary-follicular and mixed medullary-papillary carcinoma
Placed in a separate section
Baloch et al. 2022
Salivary gland-type carcinomas
Mucoepidermoid carcinoma; secretory carcinoma
Secretory carcinoma was formerly mammary analogue secretory carcinoma; sclerosing mucoepidermoid carcinoma with eosinophilia was a salivary gland-type carcinoma
Jung et al. 2022
Thyroid tumors of uncertain histogenesis
Sclerosing mucoepidermoid carcinoma with eosinophilia; cribriform-morular thyroid carcinoma
Cribriform-morular carcinoma was a variant of PTC
Jung et al. 2022
Thymic tumors within the thyroid
Thymoma family; intrathyroidal thymic carcinoma; spindle epithelial tumor with thymus-like elements
New grouping; diagnostic criteria unchanged
Jung et al. 2022
Embryonal thyroid neoplasms
Thyroblastoma (DICER1)
Renamed from malignant teratoma
Jung et al. 2022
Terminology. "Subtype" replaces "variant" for histologic subclasses, and "variant" is reserved for genetic alterations. Mitoses are counted per 2 mm² in a hotspot (previously per 10 high-power fields), and gene fusions are written with a double colon (previously a hyphen or slash) (Jung et al. 2022).
Non-thyroid chapters. Mesenchymal and stromal tumors, hematolymphoid tumors, germ cell tumors and metastases moved from the thyroid chapter to standalone chapters that cover all endocrine organs (Jung et al. 2022).
BRAF-like and RAS-like molecular groups of follicular cell-derived neoplasms
BRAF-like group. PTCs with many morphologic subtypes form the BRAF-like malignancies (Baloch et al. 2022). The BRAF V600E-like profile includes BRAF V600E and fusions of BRAF, RET and NTRK1/NTRK3, with papillary or infiltrative growth and florid nuclear atypia (Jung et al. 2022).
RAS-like group. IEFVPTC and FTC are the RAS-like malignancies (Baloch et al. 2022). The RAS-like profile includes NRAS, HRAS, KRAS, EIF1AX, EZH1, DICER1 and PTEN mutations, BRAF K601E and fusions involving PPARG and THADA. Encapsulated tumors with a predominant follicular pattern generally have a RAS-like profile (Jung et al. 2022).
Non-BRAF-like, non-RAS-like group. In a three-group scheme, PAX8::PPARG and mutations of EIF1AX, EZH1, IDH1, SOS1, SPOP, DICER1 and PTEN form a non-BRAF-like, non-RAS-like group (Jung et al. 2022).
Progression. BRAF-like and RAS-like carcinomas can acquire further alterations and progress to high-grade carcinoma (Jung et al. 2022).
Follicular adenoma
Definition. Follicular adenoma is a benign encapsulated follicular cell-derived neoplasm without capsular or vascular invasion and without the nuclear features of PTC. Separation from FTC depends on invasion of the capsule or vessels (CAP 2023).
Distinction from follicular nodular disease. FND can contain encapsulated cellular nodules that resemble follicular adenoma and cannot be separated from it on histologic features (Jung et al. 2022).
Genetics. In 88 follicular and Hürthle cell tumors, 48% of follicular adenomas had RAS mutations, 4% had PAX8::PPARG and 48% had neither (Nikiforova et al. 2003).
Follicular adenoma with papillary hyperplasia. A follicular adenoma with papillary growth that is not hyperfunctioning is classified as follicular adenoma with papillary hyperplasia within follicular adenoma (Jung et al. 2022).
Signet-ring cell change. In 7 thyroidectomies with signet ring cells, the tumors were 4 follicular adenomas, 2 NIFTPs and 1 secretory carcinoma with ETV6::NTRK3. One adenoma carried a PTEN mutation (Farhat et al. 2017).
Subtypes listed in WHO 2017. Hyperfunctioning adenoma, follicular adenoma with papillary hyperplasia, lipoadenoma, follicular adenoma with bizarre nuclei, signet-ring cell, clear cell, spindle cell and black follicular adenoma were variants of follicular adenoma in WHO 2017 (Bai et al. 2020).
Lipoadenoma (adenolipoma). Thyroid lipoadenoma has adipocytes intermixed between edematous follicles and is associated with PTEN hamartoma tumor syndrome. Thyroglobulin, TTF-1 and PAX8 confirm follicular origin and separate it from parathyroid lipoadenoma and lipid-rich follicular tumors (Cameselle-Teijeiro et al. 2020).
Follicular adenoma with papillary architecture (hyperfunctioning adenoma)
Definition and 2017 rule. Follicular adenoma with papillary architecture is a separate type in WHO 2022. It is generally an autonomous hyperfunctioning nodule with intrafollicular papillary growth. Previous rule (WHO 2017): hyperfunctioning (toxic) adenoma was a variant of follicular adenoma (Jung et al. 2022).
Genetics. These adenomas harbor activating mutations in TSHR, GNAS or EZH1, whereas conventional follicular adenomas usually harbor RAS mutations (Jung et al. 2022).
Mimic of PTC. The papillae have broad edematous cores and lack PTC-type nuclei (Jung et al. 2022).
Oncocytic adenoma and oncocytic carcinoma
Definition. Oncocytic adenoma and oncocytic carcinoma are follicular cell-derived neoplasms composed of ≥75% oncocytic cells that lack the nuclear features of PTC and lack high-grade features (necrosis and ≥5 mitoses per 2 mm²) (Baloch et al. 2022). The ≥75% thyroid threshold is the WHO 2022 definition as cited in ATA 2025 (Ringel et al. 2025). Capsular or vascular invasion separates the carcinoma from the adenoma. Oncocytic tumors with PTC nuclei are oncocytic PTCs (Baloch et al. 2022). Previous rule (WHO 2017): these tumors were named Hürthle cell adenoma and Hürthle cell carcinoma (Jung et al. 2022). WHO 2017 first recognized them as a distinct entity. Earlier classifications treated them as variants of follicular adenoma and FTC (Bai et al. 2020).
Oncocyte. An oncocyte is an enlarged polygonal cell with abundant granular eosinophilic cytoplasm, a round nucleus with even chromatin and a prominent nucleolus. Oncocytic carcinoma accounts for about 3% of differentiated thyroid carcinoma (DTC) and is now regarded as a third form of DTC (Ringel et al. 2025).
Invasion criteria. As in FTC, capsular or vascular invasion in an encapsulated oncocytic neoplasm establishes carcinoma. OCA is subtyped as minimally invasive, encapsulated angioinvasive or widely invasive (Ringel et al. 2025; CAP 2023).
Genetics. Whole-exome sequencing of Hürthle cell carcinomas showed recurrent mutations in DAXX, TP53, NRAS, NF1, CDKN1A, ARHGAP35 and the TERT promoter. Mitochondrial DNA carried recurrent homoplasmic mutations in complex I subunits. Widespread chromosomal loss produced near-haploid content in a large fraction of tumors and was maintained in metastases (Gopal et al. 2018). In 56 primary tumors, whole-chromosome duplications of chromosomes 5 and 7 and widespread loss of heterozygosity from haploidization and copy-neutral uniparental disomy were found (Ganly et al. 2018). Hürthle cell tumors infrequently carry RAS mutations or PAX8::PPARG (Nikiforova et al. 2003).
Clinical behavior. Oncocytic carcinomas are often not radioiodine avid despite thyroglobulin secretion and TSH receptor expression (Ringel et al. 2025). In 173 oncocytic carcinomas, minimally invasive tumors had no clinical recurrence or death. Recurrence was 17% in oncocytic carcinoma and 8% in FTC in a comparison of 126 and 252 patients (Ringel et al. 2025).
Infarction after FNA. Of 257 Hürthle cell tumors with matched FNA and resection, 8 showed extensive (≥80%) infarction or necrosis. Infarcted tumors were smaller than noninfarcted ones and carried the mitochondrial DNA common deletion less often (25% versus 72.7%) (Conti et al. 2017).
Oncocytic NIFTP and oncocytic PDTC. Oncocytic NIFTP requires ≥75% oncocytic cells (Jung et al. 2022; CAP 2023). Oncocytic poorly differentiated thyroid carcinoma is a CAP histologic type (CAP 2023).
Low-risk follicular cell-derived neoplasms
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features
Renaming in 2016. An international panel of 24 thyroid pathologists reviewed 109 noninvasive encapsulated follicular variant PTCs followed for 10 to 26 years and 101 invasive ones. All 109 patients with noninvasive tumors, 67 treated by lobectomy alone without radioactive iodine, were alive without disease at a median of 13 years. Adverse events occurred in 12 of 101 (12%) invasive tumors, including 5 distant metastases and 2 deaths. The noninvasive tumor was renamed NIFTP (Nikiforov et al. 2016).
Sampling. Complete submission of the tumor periphery is required in all encapsulated or well-demarcated nodules (CAP 2023).
Management. NIFTP, FT-UMP and hyalinizing trabecular tumor have a very low malignant potential, and completion thyroidectomy, lymphadenectomy or radioactive iodine are not advised routinely (Ringel et al. 2025).
Frequency. NIFTP comprised 2.2% and 2.6% of SEER-22 cases in 2018 and 2019 (CAP 2023) and 2.1%–9.6% of follicular cell-derived neoplasms in published series (Ringel et al. 2025).
Thyroid tumors of uncertain malignant potential
Definitions. Williams proposed WDT-UMP for an encapsulated tumor of well-differentiated follicular cells with well or partially developed PTC-type nuclei and questionable capsular or vascular invasion. The WHO 4th edition (2017) grid crossed PTC-type nuclei with invasion. A tumor without PTC-type nuclei and with questionable invasion is FT-UMP. A tumor with PTC-type nuclei and questionable invasion is WDT-UMP. A tumor with questionable PTC-type nuclei and definite invasion is well-differentiated carcinoma, not otherwise specified (Kakudo et al. 2018). WHO 2022 made no change to the diagnostic criteria of the low-risk neoplasms (Jung et al. 2022).
Observer variation. Eleven thyroid pathologists reviewing 20 encapsulated follicular neoplasms agreed poorly on questionable capsular invasion (κ = 0.186) and only fairly on a diagnosis of malignancy (κ = 0.545). Nine of 11 used FT-UMP, the term proposed in the WHO 2017 classification, for questionable invasion (Zhu et al. 2020).
Atypical follicular adenoma. "Atypical adenoma" is applied to a noninvasive follicular neoplasm with atypical features (indefinite capsular or vascular invasion, necrosis, solid growth or increased mitoses) and was used as a synonym of FT-UMP in a comparison of 31 atypical adenomas with 18 nonmetastatic and 38 metastatic FTCs. TERT promoter mutations were present in 10% of atypical adenomas, 25% of nonmetastatic FTCs and 50% of metastatic FTCs. The combination of solid growth with increased mitoses, necrosis and TERT promoter mutation occurred only in carcinomas (Cracolici et al. 2020).
Bizarre cells in atypical adenoma. In 2 atypical adenomas, the bizarre cells carried a TP53 codon 273 mutation that was absent from the bland follicular cells and from 6 typical adenomas and 6 FTCs (Tzen et al. 2003).
WDT-UMP outcome. In 30 WDT-UMPs, HBME-1, cytokeratin 19 and galectin-3 were positive in 40.0%, 33.3% and 36.7%. BRAF V600E was absent, CCDC6::RET (RET/PTC1) was found in 2 (6.7%), and none of 20 followed patients recurred at a mean of 80 months (Liu et al. 2011).
Hyalinizing trabecular tumor
Morphology. Hyalinizing trabecular tumor is encapsulated with trabecular growth and prominent intratrabecular and perivascular hyaline material that is PAS positive and Congo red negative. Tumor cells are polygonal to columnar with nuclear grooves and pseudoinclusions. Cytoplasmic "yellow bodies" are frequent, and mitoses and psammoma bodies are rare (Liu et al. 2017).
Immunohistochemistry. Tumor cells express thyroglobulin, TTF-1 and CD56 and are negative for calcitonin, cytokeratin 19 and HBME-1. The MIB-1 antibody gives membranous and cytoplasmic staining, whereas Ki-67 clone SP6 gives nuclear staining in <1% of cells (Liu et al. 2017).
Genetics.PAX8::GLIS3 was found in 13 of 14 (93%) and PAX8::GLIS1 in 1 of 14 (7%) hyalinizing trabecular tumors. The fusions upregulate extracellular matrix genes and cause collagen IV deposition, which accounts for the hyalinization. No PAX8::GLIS3 and one PAX8::GLIS1 were found in 220 PTCs. Among 10,165 indeterminate FNA samples, 8 (0.1%) carried PAX8::GLIS3, and all 5 resected fusion-positive nodules were hyalinizing trabecular tumors (Nikiforova et al. 2019).
Misdiagnosis as PTC. The shared nuclear features with PTC cause false-positive cytology (Nikiforova et al. 2019), and the tumor is often misdiagnosed on FNA and frozen section (Liu et al. 2017).
Follicular thyroid carcinoma
Definition. FTC is an encapsulated follicular-patterned carcinoma without the nuclear features of PTC, defined by capsular invasion, vascular invasion (limited or extensive) or wide invasion of the thyroid beyond the capsule (Ringel et al. 2025). FTC and IEFVPTC are the RAS-like follicular-patterned carcinomas, separated by subtle nuclear atypia that is subject to interobserver variability (CAP 2023).
Subtypes. WHO 2022 subtypes FTC, OCA and IEFVPTC as minimally invasive (capsular invasion only, irrespective of the number of foci), encapsulated angioinvasive (any number of involved vessels without widely invasive growth) and widely invasive (CAP 2023). Even a single focus of angioinvasion places a tumor in the encapsulated angioinvasive subtype (CAP 2023). Widely invasive tumors show grossly apparent invasion of thyroid or soft tissue, loss of encapsulation and multiple fronts of satellite invasion and are usually accompanied by extrathyroidal extension and extensive vascular invasion (CAP 2023). Extensive vascular invasion alone does not make a tumor widely invasive (Jung et al. 2022).
Previous rule (ATA 2015). FTCs were traditionally divided into minimally invasive (encapsulated with microscopic capsular or vascular invasion) and widely invasive. Newer schemes placed angioinvasive tumors in a separate category because capsular-only tumors have a mortality <5% and angioinvasive tumors 5%–30%, depending on the number of invaded vessels (Haugen et al. 2016).
Genetics. In conventional FTC, 49% had RAS mutations, 36% PAX8::PPARG and 3% both. PAX8::PPARG-positive carcinomas occurred in younger patients, were smaller and were almost always overtly invasive. RAS-mutant carcinomas were minimally or overtly invasive (Nikiforova et al. 2003). Other drivers are EIF1AX and PIK3CA mutations and PTEN loss. DICER1 mutations are prevalent in FTC. BRAF V600E and RET fusions are typically absent (Ringel et al. 2025).
TERT promoter.TERT promoter mutations were found in 17.1% of FTCs, 7.5% of PTCs, 29.0% of PDTCs and 33.3% of anaplastic carcinomas. In FTC they were associated with disease-specific mortality (P < .001) (Melo et al. 2014).
Spread. FTC spreads mainly by the hematogenous route and PTC mainly by lymphatics (CAP 2023). Among 30 patients with distant metastases from thyroid carcinoma (19 papillary, 3 follicular, 3 Hürthle cell and 5 with focal anaplasia), sites were lung in 26, bone in 11 and brain in 1 (Clark et al. 2005).
Size. FTC larger than 3.5 cm is associated with a worse prognosis (CAP 2023).
Ki-67. A Ki-67 labeling index above 5% may be a risk factor in FTC, and routine Ki-67 in differentiated carcinoma requires further validation (CAP 2023).
High-grade features. All encapsulated tumors are examined for high-grade features and dedifferentiation. FTC with ≥5 mitoses per 2 mm² or tumor necrosis is classified as a high-grade follicular cell-derived carcinoma (CAP 2023; Jung et al. 2022).
Capsular and vascular invasion criteria in encapsulated follicular-patterned thyroid tumors
Criterion
Counts as invasion
Does not count, or mimics
Source
Capsular invasion
No consensus definition; some authorities require complete transgression of the capsule and others do not
Changes from a previous biopsy can confound the interpretation
CAP 2023
Location of invaded vessels
Vessels in the capsule or outside the capsule
Vessels within the tumor nodule parenchyma
Haugen et al. 2016; CAP 2023
Rigid (unequivocal) vascular invasion
Tumor through a vessel wall with fibrin thrombus; tumor juxtaposed to the vessel wall with thrombus; tumor fragments intermingled with organized thrombus and adherent to the wall
Free-floating irregular fragments (artifactual displacement); tumor bulging into and indenting a vessel wall; endothelialized tumor floating in an intracapsular vessel (tangential section)
CAP 2023
Contentious vascular invasion
Endothelialized deposit juxtaposed to the vessel wall without thrombus is equivocal
The same deposit can represent organization of a tumor thrombus
CAP 2023
Traditional (2015) definition
Direct extension into the lumen, or an intraluminal aggregate attached to the wall and covered by endothelium
Rigid criteria add fibrin thrombus attached to the tumor cells
Haugen et al. 2016
Lymphatic invasion
Tumor in lymphatic spaces; psammoma bodies alone in lymphatics are reported as lymphatic invasion
Lymphatic and blood vessel invasion are distinguished; "lymphovascular invasion" is discouraged in endocrine neoplasms
CAP 2023
Ancillary stains. CD31 (vascular endothelium) and podoplanin (D2-40, lymphatic endothelium) separate capillary-sized blood vessels from lymphatics. CD61 highlights platelets admixed with tumor cells at sites of angioinvasion (CAP 2023).
Deeper levels. Endothelialized tumor in an intracapsular vessel prompts deeper levels, at least 3, to exclude definitive vascular invasion (CAP 2023). Multiple levels from individual blocks also assist in assessing capsular invasion (CAP 2023).
Evidence for the rigid criteria. Among 4000 carcinomas of follicular epithelial derivation, tumor through a vessel wall with adherent thrombus was found in 118 (3%). Of 98 with follow-up, 35% developed distant metastases, including about one-third of angioinvasive well-differentiated carcinomas and one-half of angioinvasive poorly differentiated carcinomas at a mean of 5.3 years (Mete and Asa 2011). Metastasizing angioinvasive carcinomas in that series mostly had a single focus and never more than 2 foci of vascular invasion (CAP 2023).
Other endocrine organs. WHO 2022 endorsed the rigid criteria for parathyroid carcinoma and adrenal cortical carcinoma, and validation in follicular cell-derived carcinomas is still recommended (CAP 2023).
Chan criteria. Capsular invasion is full-thickness penetration of the capsule, with or without a "mushroom" of protruding tumor or a newly formed thin fibrous covering over the protruding tumor. Blood vessel invasion is an endovascular tumor plug protruding into the lumen, covered by endothelium or associated with fibrin, with or without attachment to the wall. Intratumoral and subcapsular vessels do not qualify. The ICCR endorses these criteria (Mansour et al. 2025).
Reproducibility. In an e-learning study of 69 challenging encapsulated follicular-patterned lesions, among the 211 pathologists who scored every lesion, interobserver agreement across five categories (certain or doubtful capsular invasion, certain or doubtful vascular invasion, no invasion) was slight before training (combined κ = 0.199). Agreement for certain vascular invasion against the other four categories rose from κ = 0.330 to 0.423 after a training lecture and was maintained at 3 months (Mansour et al. 2025).
Polar sections. Adding vertical cuts at the upper and lower poles to transverse serial sectioning nearly doubled the odds of detecting capsular invasion (odds ratio 1.91). Capsular or vascular invasion was found in the added polar cuts in 23% of tumors sampled this way, and detection of vascular invasion did not change (Oh et al. 2019).
Capsular invasion alone. Among 65 FTCs followed for a median of 11 years, none of the 20 tumors with capsular invasion alone produced distant metastasis or cancer death. Tumors with vascular invasion had 10-year rates of 19% for distant metastasis and 28% for cause-specific mortality (van Heerden et al. 1992).
Number of invaded vessels
CAP 4.4.0.0. Historically, fewer than 4 vessels was focal and 4 or more was extensive angioinvasion. WHO 2022 questioned the validity of this cutoff, and the CAP protocol asks for the extent of angioinvasion as the number of vessels involved (CAP 2023). Jung et al. 2022 describe WHO 2022 as dividing encapsulated angioinvasive tumors into limited (<4 foci) and extensive (4 or more foci) vascular invasion.
ATA 2025. Vascular invasion, particularly extensive vascular invasion in FTC or OCA, is associated with an increased risk of distant metastasis and may warrant completion thyroidectomy (Ringel et al. 2025). In 276 low-grade encapsulated DTCs, recurrence was 1% with focal (<4 vessels) and 26% with extensive vascular invasion. In 523 FTCs, the hazard ratio for distant metastasis was 2.5 with <4 vessels and 8.03 with ≥4 vessels. In a meta-analysis of the FTC subgroup, extensive (≥4 foci) vascular invasion raised the odds of distant recurrence (OR 26.38) (Ringel et al. 2025).
Previous rule (ATA 2015). The number of invaded blood vessels (fewer than 4, or 4 or more) was to be stated in the pathology report. FTC with extensive vascular invasion was ATA high risk (the ATA 2015 risk table wording is ">4 foci of vascular invasion") because new distant metastases develop in up to 30%–55%. Encapsulated minimally invasive FTC with a small number of foci confined to intracapsular vessels had a recurrence rate of about 0%–5%, and FTC with capsular invasion only had 0%–7% (Haugen et al. 2016).
Encapsulated follicular-patterned thyroid lesions
Lesion
PTC-type nuclei
Capsular invasion
Vascular invasion
Usual molecular class
Source
Follicular adenoma
Absent
Absent
Absent
RAS; PAX8::PPARG in 4%
Nikiforova et al. 2003; Jung et al. 2022
Follicular adenoma with papillary architecture
Absent; intrafollicular papillae with edematous cores
Absent
Absent
TSHR, GNAS or EZH1
Jung et al. 2022
Oncocytic adenoma
Absent; ≥75% oncocytic cells
Absent
Absent
RAS and PAX8::PPARG infrequent in Hürthle cell tumors
Follicular lesions. In a meta-analysis of 46 studies of frozen section for nodules with Bethesda IV cytology, sensitivity was 43% and specificity 100%, and routine use was discouraged (Grisales and Sanabria 2020). For follicular lesions, FNA was more sensitive and frozen section more specific with a higher positive predictive value. For nonfollicular lesions the two methods performed almost identically (Peng and Wang 2008).
Frozen section in classic PTC. Frozen section is most helpful when the diagnosis is classic PTC and has low impact for follicular variant PTC and FTC. It can confirm malignancy during lobectomy and allow conversion to total thyroidectomy (Haugen et al. 2016).
Parathyroid tissue. A devascularized or removed parathyroid gland is autotransplanted into muscle after frozen section of a portion confirms benign parathyroid tissue (Ringel et al. 2025).
Familial and syndromic follicular cell-derived thyroid neoplasia
Familial non-medullary thyroid carcinoma (FNMTC) is syndromic when DTC is one of a constellation of tumors and non-syndromic when DTC is the single or prevailing inherited malignancy (Ringel et al. 2025). WHO 2022 describes syndromic and non-syndromic familial thyroid disease in its familial tumor syndrome chapter (Nosé et al. 2022).
Related page: Papillary thyroid carcinoma (familial PTC and the two groups of familial non-medullary thyroid carcinoma)
Premature aging, cataracts, diabetes mellitus, other cancers
Ringel et al. 2025
Cowden syndrome thyroid pattern. In 2723 Cowden and Cowden-like patients, all 6 diagnosed with thyroid cancer before age 18 years carried pathogenic PTEN mutations (Ngeow et al. 2011).
Oncocytic carcinoma. OCA was formerly included with FTC and is likely associated with the same hereditary predispositions (Ringel et al. 2025).
Germline testing. ATA 2025 conditionally recommends germline testing when DTC occurs with features of PTEN hamartoma tumor syndrome, and consideration of DICER1 testing in families with pediatric DTC. A pathologic diagnosis of cribriform-morular thyroid carcinoma is a conditional indication for APC testing, and histologic subtypes associated with familial syndromes (cribriform-morular carcinoma with familial adenomatous polyposis, PTEN hamartoma tumor syndrome-associated FTC or PTC) are identified and reported as a good practice statement (Ringel et al. 2025).
High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging
Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), groups high-grade follicular cell-derived carcinomas without anaplastic histology into one tumor type with two subtypes: poorly differentiated thyroid carcinoma (PDTC) and the new differentiated high-grade thyroid carcinoma (DHGTC). Both show increased mitotic activity and tumor necrosis and behave similarly. Anaplastic thyroid carcinoma (ATC) remains the most undifferentiated form. Medullary thyroid carcinoma (MTC), derived from C cells, keeps a separate section with a new grading system, and mixed medullary and follicular cell-derived carcinomas have their own section (Baloch et al. 2022). The CAP Thyroid protocol, version 4.4.0.0 (March 2023), applies to all malignant follicular cell-derived carcinomas, MTC, mixed carcinomas, salivary gland-type carcinomas, thymic tumors within the thyroid, thyroblastoma and tumors of uncertain cytogenesis. It does not apply to lymphoma, sarcoma, struma ovarii-derived carcinoma or metastases to the thyroid (CAP 2023).
WHO 2022 changes for high-grade, medullary and rare thyroid tumors
Entity
WHO 5th edition (2022)
Previous rule, WHO 4th edition (2017)
Source
High-grade follicular cell-derived carcinoma
New tumor type "follicular-derived carcinomas, high-grade" with two subtypes, PDTC and DHGTC
No combined high-grade tumor type
Jung et al. 2022
DHGTC
New subtype: PTC, FTC or oncocytic carcinoma with ≥5 mitoses per 2 mm² and/or tumor necrosis
Differentiated thyroid carcinoma (PTC, FTC or oncocytic carcinoma) with high-grade features, without a separate name
Jung et al. 2022
PDTC
Diagnostic criteria unchanged (Turin)
Turin criteria
Jung et al. 2022
MTC
Grading by mitotic count, tumor necrosis and Ki-67 index (high grade versus low grade)
No grading system
Jung et al. 2022; Xu et al. 2022
Cribriform-morular thyroid carcinoma (CMTC)
Thyroid tumor of uncertain histogenesis
Cribriform-morular variant of PTC
Jung et al. 2022
Sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE)
Thyroid tumor of uncertain histogenesis
Grouped with the salivary gland-type carcinomas
Jung et al. 2022
Thyroblastoma
New name for an embryonal tumor with DICER1 mutation
Malignant teratoma (carcinosarcoma with DICER1 mutation)
Jung et al. 2022
Grading by least differentiated component. Tumors with mixed histologic patterns are classified by the least differentiated component and the highest grade. A PDTC or DHGTC diagnosis requires the absence of an anaplastic component (Jung et al. 2022).
Counting method. Mitoses are counted in the region with the highest activity (hotspot) and expressed per 2 mm², roughly 10 high-power fields (Jung et al. 2022).
AJCC grade. The CAP protocol does not endorse the generic four-tier AJCC grade for thyroid carcinomas (CAP 2023).
The Turin consensus (83 tumors from Europe, Japan and the United States, reviewed by 12 thyroid pathologists) defines PDTC by all of the following (Volante et al. 2007):
A solid, trabecular or insular growth pattern.
Absence of the conventional nuclear features of papillary carcinoma.
At least one of convoluted nuclei, mitotic activity ≥3 per 10 high-power fields or tumor necrosis.
2022 expression of the mitotic criterion. The WHO 5th edition expresses the PDTC threshold as ≥3 mitoses per 2 mm². An FTC with solid or trabecular areas and ≥3 mitoses per 2 mm² in those areas is classified as PDTC (Jung et al. 2022).
Historical names and subtypes. PDTC was historically called insular or trabecular carcinoma. The CAP protocol lists PDTC NOS and oncocytic PDTC (CAP 2023).
Extent needed. A PDTC component of as little as 10% of a differentiated carcinoma confers aggressive behavior (CAP 2023).
Encapsulation. Encapsulated PDTCs without capsular or vascular invasion on adequate sampling appear to have a more favorable prognosis than unencapsulated tumors (CAP 2023).
Ki-67. Ki-67 is not required for the diagnosis. Most PDTCs have a Ki-67 index of 10%–30%, and ATCs tend to be higher (CAP 2023; Jung et al. 2022).
CMTC exception. High-grade features in cribriform-morular thyroid carcinoma do not make it a PDTC (CAP 2023).
Differentiated high-grade thyroid carcinoma
Definition. DHGTC is a PTC, FTC, oncocytic carcinoma or invasive encapsulated follicular variant PTC with ≥5 mitoses per 2 mm² and/or tumor necrosis, without solid, trabecular or insular growth meeting PDTC criteria and without anaplastic histology (Jung et al. 2022; CAP 2023).
Follicular carcinoma rule. An FTC without solid or trabecular growth and with ≥5 mitoses per 2 mm² is classified as DHGTC (Jung et al. 2022).
NIFTP-like tumors with mitoses. A noninvasive tumor with NIFTP features and ≥5 mitoses per 2 mm² is classified as DHGTC (noninvasive high-grade follicular variant PTC) (Jung et al. 2022).
CAP reporting. The CAP protocol reports the parent tumor with a high-grade prefix, for example high-grade tall cell PTC or high-grade widely invasive FTC, or DHGTC NOS (CAP 2023).
Behavior. DHGTCs present at more advanced stage and have lower radioactive iodine avidity than well-differentiated carcinomas. Their overall prognosis is similar to PDTC defined by the Turin criteria (Jung et al. 2022; Juhlin et al. 2023).
Outcome in a large series. In 364 high-grade non-anaplastic carcinomas (200 Turin PDTC and 164 high-grade tumors not meeting Turin criteria), disease-specific survival at 3, 5, 10 and 20 years was 89%, 76%, 60% and 35%. Survival was similar in the two groups. Turin PDTC had more radioactive iodine avidity, more RAS mutations, fewer BRAF V600E mutations and a higher propensity for distant metastasis. Older age, male sex, extensive necrosis and lack of encapsulation predicted death from disease (Xu et al. 2022b).
PTC with high-grade features. In 15 PTCs with high-grade features compared with 47 PDTCs, the PTCs had more pT4 disease (53% versus 13%), more nodal metastases (73% versus 38%), worse disease-specific survival and more BRAF V600E mutations (42% versus 3%) (Wong et al. 2021).
Comparison of PDTC, DHGTC and ATC
Feature
Poorly differentiated thyroid carcinoma
Differentiated high-grade thyroid carcinoma
Anaplastic thyroid carcinoma
Source
Architecture
Solid, trabecular or insular
Retains the architecture of PTC, FTC or oncocytic carcinoma
Undifferentiated: epithelioid, spindle, giant cell, pleomorphic, small cell, squamous, rhabdoid, angiomatoid or paucicellular patterns
Volante et al. 2007; Jung et al. 2022
Cytology
No conventional PTC nuclei; convoluted nuclei count as a criterion
PTC nuclei may be present
Spindled, pleomorphic, squamoid or rhabdoid cells
Volante et al. 2007; Jung et al. 2022; CAP 2023
Mitoses and necrosis
≥3 mitoses per 2 mm², necrosis or convoluted nuclei
≥5 mitoses per 2 mm² and/or necrosis
No mitotic or necrosis threshold; defined by undifferentiated histology
pT categories of follicular cell-derived carcinoma
pT categories of follicular cell-derived carcinoma
Same pT categories; always stage IV (IVA, IVB or IVC)
CAP 2023; Perrier et al. 2018
Molecular pathology of poorly differentiated and anaplastic carcinoma
Progression model. Sequencing of 341 cancer genes in 117 PDTCs and ATCs supports origin of both from well-differentiated tumors through accumulation of additional alterations (Landa et al. 2016).
Driver frequencies.BRAF V600E was present in 33% of PDTCs and 45% of ATCs. NRAS, HRAS or KRAS mutations occurred in 28% of PDTCs and 24% of ATCs and were mutually exclusive with BRAF mutation and gene fusions (Landa et al. 2016).
RAS versus BRAF by definition.RAS mutations characterized PDTC defined by the Turin criteria, and BRAF mutations characterized PDTC defined by the Memorial Sloan Kettering criteria (Landa et al. 2016).
TP53.TP53 mutations were found in 73% of ATCs and 8% of PDTCs and distinguish the two tumors (Landa et al. 2016).
TERT promoter.TERT promoter mutation frequency rose from 9% in PTC to 40% in PDTC and 73% in ATC, and these mutations were clonal in advanced cancers (Landa et al. 2016).
Other alterations.EIF1AX mutations occurred in 11% of PDTCs and 9% of ATCs and co-occurred with RAS. Mutations in PI3K/AKT/mTOR effectors, SWI/SNF subunits and histone methyltransferases were more frequent in ATC (Landa et al. 2016).
High-grade non-anaplastic carcinoma. Across 364 tumors, BRAF, RAS, TERT, TP53 and PTEN alterations were present in 28%, 40%, 55%, 11% and 10%. TP53, PTEN and TERT alterations predicted unfavorable outcome, and BRAF V600E with TERT promoter mutation increased the risk of distant metastasis (Xu et al. 2022b).
Anaplastic thyroid carcinoma
Morphology. ATC is the most extreme form of tumor progression and is often lethal. It shows epithelioid, spindle cell, giant cell, pleomorphic, small cell, squamous cell, rhabdoid, angiomatoid or paucicellular patterns, and the WHO does not define subtypes by the predominant pattern (Jung et al. 2022; CAP 2023).
Squamous cell carcinoma pattern. Tumors with squamous cell carcinoma morphology are a pattern of ATC in the 5th edition (CAP 2023). Previous rule (WHO 2017): primary squamous cell carcinoma of the thyroid was a separate entity (Jung et al. 2022). This pattern has a higher BRAF V600E rate and more frequent PAX8 expression than other ATCs (Jung et al. 2022). PAX8 was a sensitive marker of thyroid origin in primary squamous cell carcinoma of the thyroid (Lam 2020).
Squamous differentiation in other tumors. Squamous differentiation also occurs in PTC, FTC, PDTC, MTC, mucoepidermoid carcinoma and intrathyroidal thymic carcinoma. Intrathyroidal thymic carcinoma has a 10-year survival above 80% and is separated from ATC with a squamous pattern (Jung et al. 2022).
PAX8. PAX8 was retained in 76% of ATCs and was negative in head and neck squamous cell carcinomas (Bishop et al. 2011). ATC usually lacks morphologic and immunohistochemical thyroid differentiation, which makes PAX8 the most useful marker of follicular cell origin (Bishop et al. 2011).
Diagnosis of exclusion. An ATC negative for both TTF-1 and PAX8 is a diagnosis of exclusion after other high-grade malignancies are ruled out, and immunohistochemistry is required in the workup (CAP 2023).
Mandatory BRAF testing. Reflex BRAF V600E mutation-specific VE1 immunohistochemistry and/or BRAF mutation analysis is required in every ATC because BRAF and MEK inhibitors are active against BRAF V600E-driven tumors (CAP 2023). Dabrafenib plus trametinib gave a confirmed response rate of 69% (11 of 16) in BRAF V600E-mutated ATC, with an estimated 12-month overall survival of 80% (Subbiah et al. 2018).
Minor anaplastic component. One series found no survival difference between tumors with a minor ATC component and conventional ATC (CAP 2023). Tumors with only focal anaplastic areas and no extrathyroidal extension are still reported separately, and the CAP protocol lists "ATC, focal or minor component without extrathyroidal extension" and "ATC, major component" (CAP 2023).
Angiomatoid pattern versus angiosarcoma. Thyroid angiosarcoma expresses CD31, ERG and factor VIII and often keratin. Absence of thyroid differentiation markers, including PAX8, separates angiosarcoma from angiomatoid ATC (Arcovito and Franchi 2026).
Medullary thyroid carcinoma: clinical and morphologic features
Clinical presentation. Sporadic MTC occurs in the fourth to sixth decades. Of patients presenting with a palpable nodule, 70% have cervical nodal metastases and 10% have distant metastases. Central and lateral nodal metastases occur in 14% and 11% of T1 tumors and in 86% and 93% of T4 tumors (Wells et al. 2015). Microcarcinomas under 1.0 cm still show a 20% rate of regional spread and a 5% rate of distant metastasis (CAP 2023).
Gross. MTC is firm and white, tan or red. Sporadic MTC is usually solitary and unilateral. Hereditary MTC is usually multicentric and bilateral (Wells et al. 2015).
Microscopy. Round, polyhedral or spindle cells form sheets or nests with peripheral palisading in a vascular stroma. Amyloid is present in more than half of MTCs and is composed of full-length calcitonin (Wells et al. 2015).
Morphologic mimics. MTC can resemble PTC, FTC, paraganglioma, lymphoma or sarcoma, and some tumors show oncocytic change (Wells et al. 2015).
Subtypes. WHO 2017 listed papillary, follicular (tubular or glandular), spindle cell, giant cell, clear cell, oncocytic, melanotic, squamous, amphicrine, paraganglioma-like, angiosarcoma-like and small cell variants of MTC (Bai et al. 2020). The 2022 WHO calls these patterns subtypes (Jung et al. 2022). PAX8 reactivity with some antibody clones can lead to misclassification of a papillary MTC as a follicular cell-derived neoplasm (Cameselle-Teijeiro et al. 2020).
Survival by stage. Ten-year survival for stages I, II, III and IV is 100%, 93%, 71% and 21%. On multivariate analysis, only age and stage are independent prognostic factors in historical series (Wells et al. 2015).
Marker
Result in MTC
Comment
Source
Calcitonin
Positive; intensity and extent vary
Absence makes the diagnosis doubtful; reduced in undifferentiated tumors
Wells et al. 2015
CEA (monoclonal)
Almost always strongly positive
Retained when calcitonin staining is weak
Wells et al. 2015; CAP 2023
Chromogranin A, synaptophysin, INSM1
Positive
Neuroendocrine markers used to confirm nodal metastases
Wells et al. 2015; CAP 2023
TTF-1 (NKX2-1), keratins 7 and 18
Positive
TTF-1 is also used to confirm follicular cell-derived carcinoma
Wells et al. 2015; CAP 2023
Thyroglobulin
Negative
Its absence is part of the recommended panel
Wells et al. 2015
PAX8
Clone-dependent
Reactivity occurs unless C-terminus-specific monoclonal antibodies are used; monoclonal clone MRQ-50 was negative in 45 MTCs
CAP 2023
Recommended panel. A thyroid tumor with any feature of MTC is assessed for calcitonin, chromogranin and CEA and for the absence of thyroglobulin (ATA grade B recommendation) (Wells et al. 2015).
C-cell hyperplasia and the hereditary precursor of medullary carcinoma
Hereditary precursor. In hereditary MTC, C-cell hyperplasia (CCH) precedes carcinoma and is best shown by calcitonin immunohistochemistry. Because it is multicentric and probably clonal, the terms C-cell carcinoma in situ or C-cell neoplasia are considered more appropriate (Wells et al. 2015).
Criteria. Most pathologists diagnose CCH when there are more than seven C cells per cluster, complete follicles surrounded by C cells and C cells beyond their normal location at the junction of the upper third and lower two-thirds of the lateral lobes. Atypical C cells that breach the basement membrane, or a desmoplastic stromal response, indicate invasion (Wells et al. 2015).
Secondary (physiologic) CCH. CCH associated with hyperparathyroidism, chronic lymphocytic thyroiditis, renal insufficiency and aging is not premalignant (Wells et al. 2015).
Specificity. In 118 completion thyroidectomies without MTC or MEN2 risk factors, criteria for CCH were met in 4.2% to 30.5% depending on the definition, so CCH is not a specific marker of hereditary MTC (Fuchs et al. 2019).
Genetic triage. Patients with presumed sporadic MTC who have CCH or multifocal disease are evaluated for germline RET mutation (Wells et al. 2015).
Medullary thyroid carcinoma: molecular pathology and hereditary disease
Germline RET. Germline RET mutations are present in virtually all patients with MEN2A and MEN2B (Wells et al. 2015).
Hidden hereditary disease. Between 1% and 7% of patients with presumed sporadic MTC have hereditary disease. Every patient with a cytologic or histologic diagnosis of MTC has a physical examination, serum calcitonin and CEA and germline RET testing, and pheochromocytoma and hyperparathyroidism are excluded in hereditary cases (Wells et al. 2015).
Somatic alterations. About half of sporadic MTCs carry somatic RET mutations, and 18%–80% of tumors without somatic RET mutations carry somatic RAS mutations. Somatic RET M918T predicts an aggressive course (Wells et al. 2015).
Somatic testing. Routine testing of sporadic MTC for somatic RAS or RET M918T is not standard practice (Wells et al. 2015).
Serum markers. Calcitonin and CEA are the clinically useful tumor markers. Rare advanced MTCs secrete neither, which indicates dedifferentiation or misdiagnosis and carries a poor prognosis (Wells et al. 2015).
International Medullary Thyroid Carcinoma Grading System
The International Medullary Thyroid Carcinoma Grading System (IMTCGS) was developed from 327 MTCs at five centers in the United States, Europe and Australia. It unified the earlier Memorial Sloan Kettering two-tier and Sydney three-tier schemes (Xu et al. 2022a). The WHO 5th edition endorses the IMTCGS as a prognostic variable for MTC. Previous rule (WHO 2017): MTC had no grading system (CAP 2023; Jung et al. 2022).
Grade
Mitotic count
Ki-67 index
Tumor necrosis
Frequency
10-year disease-specific survival
Source
Low grade
<5 per 2 mm²
<5%
Absent
75.2% (246 of 327)
97%
Xu et al. 2022a
High grade (any one feature)
≥5 per 2 mm²
≥5%
Present
24.8% (81 of 327)
53%
Xu et al. 2022a
Methods. Mitoses and Ki-67 are assessed in hotspots, mitoses per 2 mm² and Ki-67 on 500–2,000 tumor cells. Necrosis is tumor necrosis with degenerating cytoplasm and karyorrhectic debris regardless of extent. Infarct-like necrosis with fibroblastic reaction, hemorrhage or an FNA tract is excluded (Xu et al. 2022a).
Independent prognostic value. High grade independently predicted worse overall survival (hazard ratio 10.8), disease-specific survival (8.5), distant metastasis-free survival (2.3) and locoregional recurrence-free survival (1.9) in the Results section; the abstract gives 11.5, 8.5, 2.5 and 2.1 (Xu et al. 2022a).
Necrosis alone. Ten-year disease-specific survival was 95% without and 34% with tumor necrosis (Xu et al. 2022a).
Associations. High-grade MTCs were larger, more often in men and stage IV, and more often showed vascular invasion, microscopic extrathyroidal extension and positive margins (Xu et al. 2022a).
Reporting. The exact mitotic count and Ki-67 index are documented with the grade (Xu et al. 2022a). Ki-67 is required in every MTC and in the MTC component of mixed carcinomas, by manual count or image analysis. Visual estimation is not allowed (CAP 2023).
Mixed medullary and follicular cell-derived thyroid carcinoma
Classification. The 2022 WHO has a separate section for mixed tumors composed of C cells and any follicular cell-derived malignancy, with mixed medullary-follicular and mixed medullary-papillary carcinoma (Baloch et al. 2022; Jung et al. 2022).
Dual origin. Microdissection of 12 mixed medullary-follicular carcinomas showed different mutations, allelic losses and clonal composition in the two components, so they do not derive from a single progenitor cell. The follicular structures were often oligoclonal or polyclonal and hyperplastic (Volante et al. 1999).
Invasion in mixed tumors. In mixed-type thyroid carcinoma, only the neuroendocrine tumor cells escape the follicular basement membrane and invade, with a migratory phenotype resembling C-cell precursors (Lobo et al. 2026).
Collision. Coexisting PTC or FTC and MTC is considered a collision of neoplastic C cells and follicular cells. Simultaneous MTC and PTC occurred in 2.6% of 1,019 PTCs and in 3.6% of 727 MTCs in one German series (Wells et al. 2015).
Reporting. Each component of a mixed carcinoma is documented in its own synoptic report (CAP 2023).
Primary thyroid lymphoma
Types. Diffuse large B-cell lymphoma (DLBCL) was the most frequent primary thyroid lymphoma in SEER (68% of 1,408). Most (88%) were stage I–II, and median survival was 9.3 years. Age ≥80 years, advanced stage, no radiation or surgery and DLBCL or follicular histology predicted worse survival (Graff-Baker et al. 2009).
Hashimoto thyroiditis. In 829 patients with chronic lymphocytic thyroiditis, the relative risk of thyroid lymphoma was 67 (Holm et al. 1985).
Extranodal marginal zone (MALT) lymphoma. In 18 thyroid MALT lymphomas, prominent lymphoepithelial lesions including "MALT ball" lesions were present, plasmacytic differentiation occurred in 15 (extensive in 12), 14 were IgG positive and IRTA1-positive cells were present in all tested cases. IRTA1 is also present in Hashimoto thyroiditis, with a less extensive and perifollicular pattern (Carlsen et al. 2023).
Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (extranodal marginal zone lymphoma)
Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (diffuse large B-cell lymphoma)
Rare primary thyroid tumors
Tumor
WHO 2022 section
Morphology
Immunohistochemistry and genetics
Behavior and distinction
Source
Mucoepidermoid carcinoma
Salivary gland-type carcinoma
Epidermoid and mucous cells
Thyroglobulin, PAX8, keratin 19, p63 and S100 positive; TTF-1 weak; CRTC1::MAML2 or CRTC3::MAML2 fusion
Separated from SMECE by the MAML2 fusion and thyroglobulin expression
Papillary growth and nuclear irregularity that mimic PTC
Thyroglobulin and TTF-1 negative; PAX8 negative or weak; GATA3, mammaglobin, GCDFP-15 and S100 positive; ETV6::NTRK3 fusion, a target of TRK inhibitors
13 reported cases; advanced presentation, tumor-related mortality about 30%
Jung et al. 2022; Chu et al. 2024
Sclerosing mucoepidermoid carcinoma with eosinophilia
Uncertain histogenesis
Epidermoid and mucous cells in sclerotic stroma with eosinophils and lymphocytes, always with chronic lymphocytic thyroiditis
p63 and keratin 19 positive; thyroglobulin, TTF-1 (or weak focal) and PAX8 negative; MAML2 fusion absent
Age and distant metastasis are possible risk factors
Jung et al. 2022; Han and Xu 2025
Cribriform-morular thyroid carcinoma
Uncertain histogenesis
Cribriform growth with morulae and little or no colloid; mean age 33 years, almost all female
Nuclear and cytoplasmic β-catenin; TTF-1 positive in the cribriform component; thyroglobulin negative; PAX8 absent or focal; morulae keratin 5 and CD5 positive; APC or CTNNB1 alteration; estrogen and progesterone receptor positive
Germline APC mutations in 12 tumors of the subset tested; association with familial adenomatous polyposis, sometimes before polyps are known; ATA 2025 conditionally recommends germline APC testing after a pathologic diagnosis of CMTC
Boyraz et al. 2021; Jung et al. 2022; CAP 2023; Ringel et al. 2025
Intrathyroidal thymic carcinoma
Thymic tumor within the thyroid
Squamous features that mimic ATC with a squamous pattern or metastatic squamous cell carcinoma
p63, high-molecular-weight keratin, CEA and CD5 positive (CD5 in 80%); TTF-1 negative; polyclonal PAX8 positive in 40% and monoclonal PAX8 negative
10-year survival above 80%
Reimann et al. 2006; Suzuki et al. 2018; Jung et al. 2022
Spindle epithelial tumor with thymus-like elements (SETTLE)
Thymic tumor within the thyroid
Biphasic spindle cell and glandular tumor with low mitotic activity, no necrosis and no pleomorphism; median age 13.5 years
High-molecular-weight keratin in 88% and keratin 7 in 88%; SS18::SSX fusion absent (separates it from synovial sarcoma)
Low-grade malignancy with late lymph node and lung metastases
Folpe et al. 2009
Thyroblastoma
Embryonal thyroid neoplasm
Primitive small cells, TTF-1 and PAX8-positive primitive follicles or tubules and immature mesenchymal stroma
Somatic DICER1 hotspot mutations; SALL4 in the small cell or stromal component
Highly aggressive
Agaimy et al. 2020; Jung et al. 2022
Angiosarcoma
Mesenchymal (standalone chapter)
Large epithelioid pleomorphic cells with vascular spaces, hemosiderin and necrosis, often in long-standing goiter (Alpine regions)
CD31, ERG and factor VIII positive; keratin often positive; thyroid markers including PAX8 negative
Aggressive; 20% of thyroid mesenchymal tumors
Arcovito and Franchi 2026
Solid cell nests. Shared expression of p63, CEA and high-molecular-weight keratin supports a solid cell nest origin for intrathyroidal thymic carcinoma and SMECE (Reimann et al. 2006; Jung et al. 2022).
Monoclonal PAX8 in thymic carcinoma. All PDTCs and 92.9% of thyroid squamous cell carcinomas were positive for polyclonal and monoclonal PAX8, and no intrathyroidal thymic carcinoma was positive for monoclonal PAX8 (Suzuki et al. 2018).
Frequency and primaries. Metastases account for 0.02%–1.4% of resected thyroid specimens (Nixon et al. 2011).
Institutional series. Of 1,939 thyroid malignancies, 31 (1.6%) were metastatic epithelial neoplasms. Clear cell renal cell carcinoma (36%), non-small cell lung carcinoma (19%), esophageal carcinoma (16%), head and neck carcinoma (16%) and melanoma (10%) were the primaries. The interval from the primary tumor was longest for clear cell renal cell carcinoma, and resection was associated with longer survival (25 versus 3.8 months) (Stergianos et al. 2021).
Renal cell carcinoma. Clear cell renal cell carcinoma is the most frequent metastasizing tumor in clinical series, followed by lung and breast carcinoma. Metastatic clear cell renal cell carcinoma is positive for PAX8 and carbonic anhydrase IX (CAIX) and negative for TTF-1 and thyroglobulin. Most patients have a history of goiter, the metastasis can be the first sign of the renal tumor (Queipo et al. 2019).
AJCC 8th edition staging of anaplastic and medullary thyroid carcinoma
ATC and MTC use the AJCC 8th edition T and N definitions of differentiated thyroid carcinoma (Papillary thyroid carcinoma). Age is not used for MTC stage groups (CAP 2023).
Stage
Anaplastic thyroid carcinoma (AJCC 8th edition)
Medullary thyroid carcinoma (AJCC 7th and 8th editions)
Source
I
No ATC is assigned stage I; every ATC is stage IV
T1 N0 M0
Perrier et al. 2018; Mathiesen et al. 2019
II
No ATC is assigned stage II
T2–T3 N0 M0
Mathiesen et al. 2019
III
No ATC is assigned stage III
T1–T3 N1a M0
Mathiesen et al. 2019
IVA
T1–T3a N0/NX M0 (intrathyroidal tumor)
T4a any N M0; T1–T3 N1b M0
Perrier et al. 2018; Wells et al. 2015
IVB
T1–T3a N1 M0; T3b any N M0; T4 any N M0
T4b any N M0
Perrier et al. 2018; Wells et al. 2015
IVC
Any T, any N, M1
Any T, any N, M1
Perrier et al. 2018; Wells et al. 2015
ATC T category.Previous rule (AJCC 7th edition): every ATC was T4, with intrathyroidal ATC T4a and ATC with gross extrathyroidal extension T4b. The 8th edition applies the differentiated carcinoma T definitions to ATC and keeps the stage groups: intrathyroidal IVA, nodal disease or gross extrathyroidal extension IVB and distant metastasis IVC (Perrier et al. 2018).
Distant metastasis in older patients with DTC versus ATC. In the 8th edition, distant metastasis in a patient aged 55 years or older with differentiated carcinoma is stage IVB, while distant metastasis in ATC remains stage IVC (Perrier et al. 2018).
Level VII nodes.Previous rule (AJCC 7th edition, as applied to MTC): superior mediastinal (level VII) nodes were N1b; the 8th edition classifies them as N1a (Wells et al. 2015; CAP 2023).
Minimal extrathyroidal extension.Previous rule (AJCC 7th edition, as applied to MTC): T3 included any tumor with minimal extrathyroidal extension (Wells et al. 2015). In the 8th edition, minimal extrathyroidal extension no longer changes the T category (CAP 2023).
Limits of TNM in MTC. TNM does not include age gradations, postoperative calcitonin or the number of involved nodes, and the ATA task force proposed nodal groups of 0, 1–10, 11–20 and >20 (Wells et al. 2015). A proposed regrouping gave better survival separation of stage I versus II and III versus IV in a Danish national cohort of 191 patients (Mathiesen et al. 2019).
CAP Thyroid 4.4.0.0 reporting elements for non-papillary carcinomas
Element
Responses and rules
Source
Separate reports
MTC uses a separate synoptic report, and each component of a mixed medullary and follicular cell-derived carcinoma is documented separately
CAP 2023
Histologic type
FTC and oncocytic carcinoma as minimally invasive, encapsulated angioinvasive or widely invasive; high-grade FTC, invasive encapsulated follicular variant PTC, PTC or oncocytic carcinoma, or DHGTC NOS; PDTC NOS or oncocytic PDTC; ATC NOS, focal or minor component without extrathyroidal extension, or major component; MTC; mixed carcinomas; salivary gland-type, thymic, uncertain cytogenesis and embryonal tumors
CAP 2023
Mitotic rate
<3, ≥3 to <5, or ≥5 mitoses per 2 mm², with the count optional; perineural invasion optional
CAP 2023
Ki-67 labeling index
Required in every MTC and the MTC component of mixed carcinomas; manual count or automated image analysis
CAP 2023
Tumor necrosis
Not identified or present
CAP 2023
Ancillary studies
Reflex BRAF V600E (VE1 immunohistochemistry and/or mutation analysis) in every ATC; molecular results on the CAP Thyroid Biomarker template
Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes
Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), classifies parathyroid proliferations as parathyroid adenoma, multiglandular parathyroid disease, atypical parathyroid tumor and parathyroid carcinoma, with secondary hyperplasia kept for glands stimulated by chronic kidney disease (Erickson et al. 2022; Uljanovs et al. 2022). Primary hyperparathyroidism is caused by a single adenoma in 80%–85% of patients, by disease of multiple glands in 10%–15% and by carcinoma in less than 1% in most series and up to 5% in others (Duan et al. 2015; Uljanovs et al. 2022). About 95% of hyperparathyroidism is sporadic and about 5% is hereditary (Duan et al. 2015). The 2022 classification adds the parafibromin-deficient parathyroid neoplasm and emphasizes morphologic and immunohistochemical clues to germline MEN1, CDKN1B, MAX and CDC73 disease (Erickson et al. 2022). No CAP cancer protocol exists for the parathyroid. The International Collaboration on Cancer Reporting (ICCR) dataset covers parathyroid carcinoma and atypical parathyroid neoplasm (Williams et al. 2021).
Parathyroid embryology, anatomy and normal histology
Origin. In the sixth gestational week, the inferior parathyroid glands develop from the dorsal part of the third pharyngeal pouch, whose ventral part forms the thymus. The superior parathyroid glands develop from the dorsal part of the fourth pharyngeal pouch, whose ventral part forms the ultimobranchial body. The inferior glands migrate caudally with the thymus (Uludağ et al. 2019).
Number. In 503 autopsies, 84% had four glands, 13% had supernumerary glands (most often a fifth gland in the thymus) and 3% had only three glands found. Glands on the two sides were symmetric in about 80% (Akerström et al. 1984). A supernumerary gland weighs at least 5 mg; smaller extra glands are rudimentary or accessory glands (Uludağ et al. 2019).
Size and position. A normal gland measures about 5 × 3 × 1 mm and weighs 35–40 mg (range 10–78 mg). Superior glands lie at the cricothyroid junction on the posterolateral upper and middle thyroid. Inferior glands lie within 1 cm of the lower thyroid pole or in the upper thymus or thyrothymic ligament (Akerström et al. 1984; Uludağ et al. 2019).
Ectopic glands. Ectopic glands occur in 2%–43% of anatomic series and in up to 16% of patients with primary and 14% with secondary hyperparathyroidism. Ectopic inferior glands are found most often in the anterior mediastinum with the thymus or thyroid; ectopic superior glands are found most often in the tracheoesophageal groove and retroesophageal region (Noussios et al. 2012). In a meta-analysis, 31.4% of ectopic cervical glands were retroesophageal or paraesophageal, 20.3% intrathyroidal, 17.7% in the carotid sheath and 17% in the thyrothymic ligament. Most mediastinal glands were in the thymus (Uludağ et al. 2019).
Intrathyroidal glands. Intrathyroidal parathyroid glands are completely surrounded by thyroid tissue and occur in 0.2%–3.2% of autopsy and surgical series. Inferior glands are intrathyroidal more often than superior glands (Uludağ et al. 2019). Intrathyroidal parathyroid glands account for about 2% of primary hyperparathyroidism (Juhlin and Mete 2026).
Congenital and acquired ectopy. Congenital ectopy, from abnormal embryologic migration, affects mainly the inferior glands. Acquired ectopy, from migration of an enlarged gland, affects mainly the superior glands, which can descend along the paraesophageal and retroesophageal route into the posterior mediastinum (Uludağ et al. 2019).
Stromal fat. In 90 autopsied patients without parathyroid disease, stromal fat averaged 17%, almost one-third of glands had less than 10% fat and fat did not correlate with age, serum calcium or gland weight (Dufour and Wilkerson 1982). In 100 normal glands measured by image analysis, fat averaged 38% and correlated with age and body constitution with wide variation (Obara et al. 1990). Stromal fat percentage alone therefore does not separate a normal from an abnormal gland (Dufour and Wilkerson 1982; Obara et al. 1990).
Intraoperative assessment and immunohistochemical identification of parathyroid tissue
Frozen section and gland number. Frozen section does not reliably separate a single adenoma from involvement of several glands, and intraoperative PTH monitoring is more reliable for that question (Juhlin and Erickson 2021). The pathologist confirms that each excised nodule is parathyroid tissue and reports its weight and size (Duan et al. 2015).
Frozen section discrepancies. Among 1,844 head and neck frozen sections, 5 of 23 major interpretive errors concerned the distinction of parathyroid from thyroid tissue. Three microfollicular lesions were called thyroid or parathyroid when the reverse was true on permanent sections and needed immunohistochemistry, and two involved scant parathyroid tissue at the edge of the slide that was not identified (Albright et al. 2026).
Fat stains. Oil red O on frozen sections showed less intracellular lipid in hyperfunctioning chief cells than in suppressed parathyroid tissue and helped separate adenoma from hyperplasia (Ljungberg and Tibblin 1979). Sudan IV gave contradictory results in 2 of 13 hyperfunctioning glands and 11 of 73 normal glands, so neutral lipid stains are interpreted with caution (Dufour and Durkowski 1982).
Parathyroid versus thyroid. PTH and GATA3 are retained in parathyroid tumors, including water-clear cell adenoma and lipoadenoma (Juhlin and Mete 2026). TTF-1 and thyroglobulin are negative in parathyroid cells, and PTH is absent from thyroid tissue (Uljanovs et al. 2022). Monoclonal C-terminus-specific PAX8 does not stain parathyroid tissue, whereas polyclonal PAX8 can stain parathyroid tumors, so the PAX8 clone is documented (Juhlin and Mete 2026).
Neuroendocrine markers. Chromogranin A is positive in 98% of parathyroid lesions, synaptophysin in 11%–100% and INSM1 in none. CD56 is negative in parathyroid tissue and favors a nonparathyroid origin in a cervical neoplasm (Uljanovs et al. 2022).
Parathyroid versus medullary thyroid carcinoma. Medullary thyroid carcinoma is positive for chromogranin A, calcitonin and CEA, usually positive for TTF-1 and negative for PTH (Juhlin and Erickson 2021; Uljanovs et al. 2022). Calcitonin can be positive in rare parathyroid tumors, so PTH and TTF-1 form the distinguishing panel (Juhlin and Erickson 2021).
Parathyroid versus paraganglioma. Paraganglioma has zellballen with S100-positive sustentacular cells and lacks keratins (Uljanovs et al. 2022).
Marker
Parathyroid tissue and tumors
Medullary thyroid carcinoma
Source
PTH
Positive (almost always)
Negative
Uljanovs et al. 2022; Juhlin and Erickson 2021
TTF-1
Negative
Positive in up to 80%
Uljanovs et al. 2022
Thyroglobulin
Negative
Negative
Uljanovs et al. 2022
Chromogranin A
Positive in 98%
Positive
Uljanovs et al. 2022
Calcitonin
Rarely positive
Positive in 80%
Uljanovs et al. 2022; Juhlin and Erickson 2021
PAX8
Negative with monoclonal C-terminus antibody; positive with polyclonal antibody
Positive in 75%; clone dependent
Uljanovs et al. 2022; Juhlin and Mete 2026
WHO 2022 classification of parathyroid proliferations
Multiglandular parathyroid disease. The 2022 classification no longer supports "hyperplasia" for multiglandular disease in primary hyperparathyroidism, because affected glands are usually composed of multiple clonal neoplastic proliferations. It classifies this disease (multiple parathyroid adenomas) as germline susceptibility-driven multiglandular parathyroid neoplasia (Erickson et al. 2022). Previous rule (WHO 4th edition, 2017): multiglandular disease in primary hyperparathyroidism was primary parathyroid hyperplasia (Hernandez-Prera et al. 2025; Uljanovs et al. 2022).
Hyperplasia. "Parathyroid hyperplasia" is now used mainly for secondary hyperplasia, most often caused by chronic renal failure (Erickson et al. 2022).
Atypical parathyroid tumor. The 2022 classification replaces "atypical parathyroid adenoma" with "atypical parathyroid tumor," a parathyroid neoplasm of uncertain malignant potential (Erickson et al. 2022; Gokozan and Scognamiglio 2023).
Parafibromin-deficient parathyroid neoplasm. A parathyroid neoplasm with complete absence of nuclear parafibromin immunoreactivity is designated parafibromin-deficient. Nucleolar loss alone is abnormal and needs molecular testing to confirm its significance (Erickson et al. 2022).
Lesion (WHO 2022)
Former term
Setting
Glands
Defining histology
Behavior
Source
Parathyroid adenoma
Parathyroid adenoma
Primary hyperparathyroidism (80%–85%)
One
Circumscribed chief, oncocytic, transitional or water-clear cell proliferation with reduced stromal fat; rim of residual gland in about half
Clonal nodules in several glands; increased parenchyma-to-fat ratio
Clonal neoplasia
Erickson et al. 2022; Uljanovs et al. 2022
Secondary parathyroid hyperplasia
Secondary parathyroid hyperplasia
Chronic kidney disease
Several
Diffuse hyperplasia, then nodular hyperplasia with fibrosis and irregular contours
Hyperplasia that can mimic carcinoma
Duan et al. 2015; Palumbo et al. 2021; Juhlin and Mete 2026
Atypical parathyroid tumor
Atypical parathyroid adenoma
Primary hyperparathyroidism
One
Worrisome features without unequivocal invasion or metastasis
Uncertain malignant potential
Erickson et al. 2022; Juhlin and Mete 2026
Parathyroid carcinoma
Parathyroid carcinoma
Primary hyperparathyroidism (less than 1%); hyperparathyroidism-jaw tumor syndrome
One
Angioinvasion, lymphatic or perineural invasion, invasion of adjacent structures or metastasis
Malignant
Erickson et al. 2022; Juhlin and Erickson 2021
Parathyroid adenoma
Clinical correlation. Adenomas of 40–100 mg are associated with mild or asymptomatic disease. Adenomas larger than 1 cm are associated with higher calcium and PTH and a greater risk of skeletal involvement (Juhlin and Mete 2026).
Histology. An adenoma is a circumscribed, noninvasive proliferation of chief cells in micro-acinar or palisading formations, with transitional, oncocytic or water-clear cells. Stromal fat is reduced or absent. Scattered hyperchromatic, atypical or multinucleated cells can occur (Juhlin and Erickson 2021; Juhlin and Mete 2026).
Rim of residual gland. A rim of compressed nontumorous parathyroid tissue is present in more than half of adenomas when the gland is sectioned through the vascular hilum (Juhlin and Mete 2026). It is seen more often in small adenomas. A rim does not exclude multiglandular disease, which shows an apparent rim in up to 10% (Juhlin and Erickson 2021).
Proliferation and biomarkers. Adenomas have a Ki-67 labeling index below 5% and ≤5 mitoses per 10 mm². Parafibromin, APC and BCL2 are retained, and galectin-3 and PGP9.5 are negative (Juhlin and Mete 2026).
Somatic genetics. About 25%–40% of sporadic adenomas show loss of heterozygosity at the MEN1 locus on 11q13, and half of these carry an inactivating MEN1 mutation of the other allele (Juhlin and Erickson 2021). The pericentric 11p inversion that places CCND1 under control of the PTH gene promoter occurs in 5%–8% of adenomas, whereas cyclin D1 protein is overexpressed in about 40% (Uljanovs et al. 2022). Somatic CDC73 mutations occur in up to 6% of adenomas (Uljanovs et al. 2022).
Larger tumors; calcium and PTH can be lower than in conventional adenomas of similar size
Martiradonna et al. 2026; Juhlin and Erickson 2021
Water-clear cell adenoma
Composed entirely of water-clear cells, which have vacuolated cytoplasm, probably from glycogen accumulation, and hyperchromatic nuclei
Higher calcium than lipoadenoma (12.1 versus 11.3 mg/dL); ultrasound positive in 97%
Uljanovs et al. 2022; Martiradonna et al. 2026
Cystic adenoma
Predominant cystic growth pattern
Parafibromin loss occurs in a subset of sporadic cystic adenomas; cystic tumors raise the possibility of CDC73 disease
Juhlin and Erickson 2021
Lipoadenoma
Mature adipose tissue forms more than 50% of the glandular volume
Possible association with arterial hypertension
Martiradonna et al. 2026
Rare subtypes and localization. Sestamibi scintigraphy was positive in 61%–67% of lipoadenomas, oncocytic adenomas and water-clear cell adenomas (Martiradonna et al. 2026).
Multiglandular parathyroid disease and secondary and tertiary hyperparathyroidism
Multiglandular disease in primary hyperparathyroidism. Multiple adenomas are diagnosed when each nodule meets the features of adenoma (Uljanovs et al. 2022). Up to 10% of patients with primary multiglandular disease have MEN1 (Juhlin and Erickson 2021).
Supernumerary glands. Supernumerary and accessory glands can enlarge under continuous stimulation in MEN1 and secondary hyperparathyroidism (Uludağ et al. 2019). Wide excision of perithyroidal fat and thymectomy are recommended in uremic hyperparathyroidism and MEN syndromes because of supernumerary glands in the thymus (Akerström et al. 1984).
Secondary hyperparathyroidism. Secondary hyperparathyroidism usually presents with diffuse parathyroid hyperplasia (Duan et al. 2015). In chronic kidney disease, hyperphosphatemia, calcitriol deficiency and hypocalcemia stimulate PTH secretion. Hyperphosphatemia directly stimulates the parathyroid cell and produces nodular hyperplasia (Palumbo et al. 2021).
Carcinoma mimics in secondary disease. Long-standing secondary hyperparathyroidism produces nodular hyperplasia with irregular contours, nodules protruding through a thickened capsule, broad fibrous bands and more than 5 mitoses per 10 mm². Similar findings occur in multiglandular adenomas of MEN1 and with chronic lithium therapy (Juhlin and Mete 2026).
Tertiary hyperparathyroidism. Tertiary hyperparathyroidism is excess PTH secretion after long-standing secondary hyperparathyroidism. Some authorities reserve the term for secondary disease that persists after successful renal transplantation (Palumbo et al. 2021). It reflects the emergence of autonomous PTH-producing neoplasms from secondary hyperplasia (Duan et al. 2015). No carcinoma associated with tertiary hyperparathyroidism showed parafibromin loss in one series (Uljanovs et al. 2022).
Atypical parathyroid tumor
An atypical parathyroid tumor (formerly atypical parathyroid adenoma) is a noninvasive parathyroid neoplasm with worrisome features that does not meet the criteria for carcinoma after adequate sampling (Erickson et al. 2022; Uljanovs et al. 2022).
Worrisome feature of atypical parathyroid tumor
Qualification
Source
Trabecular or sheet-like architecture
Not diagnostic of malignancy alone
Uljanovs et al. 2022
Band-like fibrosis
Without prior FNA; secondary and tertiary hyperparathyroidism also produce fibrous bands
Uljanovs et al. 2022
Cytologic atypia with enlarged nucleoli or macronucleoli
Not diagnostic of malignancy alone
Uljanovs et al. 2022; Juhlin and Mete 2026
Increased mitotic activity
More than 5 mitoses per 10 mm² in a noninvasive tumor without prior manipulation
Juhlin and Mete 2026
Atypical mitoses
Not diagnostic of malignancy alone
Uljanovs et al. 2022
Coagulative necrosis
Without prior FNA
Uljanovs et al. 2022
Adherence to surrounding tissues
Without frank invasion of those tissues
Uljanovs et al. 2022
Tumor cells within the capsule
Without full-thickness capsular penetration
Uljanovs et al. 2022
Workup. Additional levels search for invasion, and a biomarker panel (parafibromin, RB, p27, APC, galectin-3, PGP9.5 and Ki-67) refines the risk. Diffuse loss of parafibromin or APC and PGP9.5 reactivity raise the suspicion of malignancy. Intact parafibromin and APC with negative PGP9.5 support a benign process (Juhlin and Mete 2026).
Behavior. Most atypical parathyroid tumors are indolent after complete excision, and a small subset recurs or metastasizes (Juhlin and Mete 2026; Juhlin and Erickson 2021). Atypical parathyroid tumors with parafibromin deficiency are at high risk of recurrence (Juhlin and Mete 2026).
Clinical correlation. Preoperative cytology, multiglandular disease, MEN1 or prior manipulation often explains fibrosis or mitoses in a parathyroid tumor (Juhlin and Mete 2026).
Parathyroid carcinoma: clinical features, diagnostic criteria and reporting
Frequency and demographics. Parathyroid carcinoma causes less than 1% of primary hyperparathyroidism in Western series, and surgical cohorts report 0.3%–5.2% (Uljanovs et al. 2022). The population incidence is 3.5–5.7 per 10 million (Uljanovs et al. 2022). The carcinoma affects women and men about equally or with a slight male predominance and presents most often at 45–60 years (Juhlin and Erickson 2021; Juhlin and Mete 2026).
Clinical clues. A firm palpable neck mass, a gland larger than 3 cm, serum calcium above 3.0 mmol/L (12 mg/dL), PTH several times the upper reference limit and intraoperative adhesion or invasion raise suspicion. None is diagnostic alone (Juhlin and Mete 2026). Adenomas can also adhere firmly to the thyroid (Juhlin and Erickson 2021).
Spread and outcome. In 609 SEER cases, lymph node metastases were present in 25.2% and distant metastases in 2.2% (Uljanovs et al. 2022). Ten-year survival is about 50%–70%, and death often results from hypercalcemia (Juhlin and Erickson 2021).
WHO 2022 diagnostic criteria for parathyroid carcinoma
The histologic diagnosis requires one of the following (Erickson et al. 2022):
Criterion
Definition and exclusions
Source
Angioinvasion (vascular invasion)
Tumor invading through a vessel wall with associated thrombus, or intravascular tumor cells admixed with thrombus, in a vessel in the capsule or outside the tumor; tumor cells in an intratumoral vessel or displaced during grossing do not qualify
Erickson et al. 2022; Uljanovs et al. 2022
Lymphatic invasion
Retraction artifact excluded; endothelial immunostains are recommended
Erickson et al. 2022; Uljanovs et al. 2022
Perineural (intraneural) invasion
Tumor around or within a nerve
Erickson et al. 2022; Juhlin and Mete 2026
Local invasion into adjacent structures
Soft tissue, thyroid, esophagus or skeletal muscle; tumor within its capsule and intrathyroidal parathyroid location do not qualify
Erickson et al. 2022; Uljanovs et al. 2022
Metastasis
Histologically or cytologically documented regional or distant metastasis
Erickson et al. 2022
Nondiagnostic features. Broad fibrous bands, coagulative necrosis, solid growth, macronucleoli and increased mitoses are common in carcinoma and are not diagnostic alone. The triad of coagulative necrosis, macronucleoli and more than 5 mitoses per 10 mm² (originally 5 per 50 high-power fields) raises suspicion for carcinoma but lacks absolute specificity (Juhlin and Mete 2026).
Capsule. Most parathyroid tumors are unencapsulated. Tumor extension into a capsule does not establish malignancy, and the capsular invasion criteria of encapsulated follicular thyroid tumors do not apply to parathyroid tumors (Juhlin and Mete 2026).
Vascular invasion search. Vascular invasion is sought at the interface of tumor and nontumorous parenchyma and beyond the tumor periphery. CD61 highlights the platelet and fibrin response of true vascular invasion, and CD31 or ERG confirm an endothelial lining (Juhlin and Mete 2026).
Proliferation. Mitotic count per 10 mm² and the Ki-67 labeling index are documented in parathyroid carcinoma (Erickson et al. 2022). Mean Ki-67 in carcinoma ranges from 6.1% to 13.9%, compared with 1.9%–4.3% in adenomas, and a 5% cutoff helps separate them without being a WHO diagnostic criterion (Uljanovs et al. 2022). Hotspot Ki-67 averaged 11.8% in carcinoma and 3.5% in adenoma in one series (Uljanovs et al. 2022).
Biomarker panel. Loss of parafibromin, RB, p27, BCL2, MDM2 and APC and overexpression of galectin-3, PGP9.5 and p53 support malignancy (Juhlin and Mete 2026). p27 was expressed in 80% of adenomas, 43% of atypical adenomas and 18% of carcinomas at a 30% cutoff (Uljanovs et al. 2022). Cyclin D1 does not separate benign from malignant parathyroid tumors (Uljanovs et al. 2022).
Molecular findings. Somatic CDC73 mutations are present in 60%–90.9% of carcinomas (Uljanovs et al. 2022). TERT promoter mutations are rare. Carcinomas show hypermethylation of CDKN2A, CDKN2B, WT1 and SFRP genes, and APC promoter methylation can explain APC loss without mutation (Juhlin and Mete 2026). Actionable alterations were found in about 54% of advanced carcinomas in one series (Juhlin and Mete 2026). Somatic MEN1 mutations are very infrequent in carcinoma (Juhlin and Erickson 2021).
Submission. Parathyroidectomy specimens with atypical features are submitted completely and examined at multiple levels with ancillary biomarkers (Erickson et al. 2022; Juhlin and Mete 2026).
Reporting dataset. The ICCR dataset has 16 core elements: clinical information, operative procedure, specimens submitted, tumor site, parathyroid weight, size, classification, grade for carcinoma (incorporating necrosis, mitotic count, perineural invasion and lymphovascular invasion), extent of local, regional and distant disease and pathologic stage. Ancillary studies are noncore elements (Williams et al. 2021).
Staging. The AJCC 8th edition stages parathyroid carcinoma (Williams et al. 2021; Akirov et al. 2019). The categories are summarized in the table below. No prognostic stage groups were defined because data on tumor characteristics and prognosis are limited (Akirov et al. 2019; Silva et al. 2026).
AJCC 8th category
Definition
Source
pTis
Atypical parathyroid neoplasm of uncertain malignant potential
Silva et al. 2026
pT1
Tumor confined to the parathyroid gland with extension limited to soft tissue
Akirov et al. 2019; Silva et al. 2026
pT2
Direct invasion into the thyroid gland
Akirov et al. 2019; Silva et al. 2026
pT3
Direct invasion into the recurrent laryngeal nerve, esophagus, trachea, skeletal muscle, adjacent lymph nodes or thymus
Akirov et al. 2019
pT4
Direct invasion into a major blood vessel or the spine
Akirov et al. 2019; Silva et al. 2026
pN1a
Metastasis to level VI or VII lymph nodes
Akirov et al. 2019
pN1b
Metastasis to levels I, II, III, IV or V or retropharyngeal lymph nodes
Akirov et al. 2019
M1
Distant metastasis
Akirov et al. 2019; Silva et al. 2026
Parafibromin, CDC73 and the parafibromin-deficient parathyroid neoplasm
Gene and protein.CDC73 (formerly HRPT2, chromosome 1q31.2) encodes parafibromin, a 531-amino-acid nuclear tumor suppressor in the PAF transcriptional regulatory complex (Carpten et al. 2002; Bradley et al. 2005; Juhlin and Erickson 2021). Most germline and somatic mutations are truncating or affect nuclear localization, so mutant parafibromin fails to accumulate in the nucleus (Juhlin and Mete 2026).
Immunohistochemistry. Normal parathyroid nuclei always express parafibromin. Loss is reported in 0%–3.7% of multiglandular disease, 0%–17.6% of adenomas and 33.3%–100% of carcinomas (Uljanovs et al. 2022). Endothelial cells serve as the internal positive control. Diffuse nuclear loss prompts germline CDC73 testing, as does primary hyperparathyroidism at age 45 years or younger (Juhlin and Mete 2026).
Parafibromin deficiency and malignancy. Parafibromin deficiency alone does not establish malignancy because germline or somatic CDC73-driven adenomas can be parafibromin deficient (Juhlin and Mete 2026). In 43 parafibromin-negative tumors from 40 patients, 37.2% met the WHO 2017 criteria for carcinoma and 1 of 27 noninvasive tumors later metastasized (Gill et al. 2019).
Morphology of parafibromin-deficient tumors. Parafibromin-negative tumors show extensive sheet-like growth with little acinar architecture, eosinophilic cytoplasm, nuclear enlargement with coarse chromatin, perinuclear cytoplasmic clearing, prominent arborizing vessels and frequently a thick capsule. Microcystic change was present in 48.8%. Patients were younger (mean 36 versus 63 years) and tumors were heavier (mean 3.04 versus 0.62 g) than parafibromin-positive tumors (Gill et al. 2019).
Germline frequency. About 20%–30% of apparently sporadic parathyroid carcinomas are associated with a germline CDC73 mutation (Uljanovs et al. 2022).
Mimics of invasion and parathyromatosis
Prior manipulation. FNA, PTH washout and ethanol injection cause capsular defects, fibrosis, pigment-laden macrophages along the needle tract and displaced parathyroid cells that mimic invasion (Juhlin and Mete 2026).
Mechanical artifact. Crush artifact and tumor cells displaced into vessels during handling mimic vascular invasion. Intraluminal deposits without continuity with the tumor and without a fibrin reaction suggest contamination (Juhlin and Mete 2026).
Peliosis. Blood-filled spaces without an endothelial lining mimic vascular invasion and are separated by CD31 or ERG staining (Juhlin and Mete 2026).
Intrathyroidal parathyroid tumors. Expansile growth in the thyroid, especially after FNA, can mimic thyroid invasion (pT2, AJCC 8th edition). Vascular or perineural invasion and biomarker aberrations establish malignancy in this setting (Juhlin and Mete 2026).
Parathyromatosis. Parathyromatosis is multiple small nodules of hyperfunctioning parathyroid tissue in the neck or mediastinum, related mostly to prior parathyroidectomy and rarely to an embryologic remnant (Gheorghe et al. 2025). It results from seeding during surgery, biopsy or rupture of a cystic lesion. The nests are small, uniform and well circumscribed, without atypia, increased or atypical mitoses or desmoplasia (Juhlin and Mete 2026). Parathyroid carcinoma shows more coarse chromatin, infiltrative growth and metastasis, whereas parathyromatosis shows circumscribed expansile nests in soft tissue without tissue destruction (Juhlin and Mete 2026). In 22 reported patients, 21 had prior parathyroidectomy for primary (14) or secondary (7) hyperparathyroidism, and recurrent hyperparathyroidism was recognized 1–17 years after surgery (Gheorghe et al. 2025).
Parathyroid cysts
Frequency and types. Parathyroid cysts form less than 0.5% of parathyroid lesions and 1%–5% of neck masses. In 359 reported cases, 61.6% were nonfunctioning, the mean diameter was 4.88 cm and the commonest sites were the left thyroid lobe (31.6%) and superior mediastinum (19.3%) (Papavramidis et al. 2018).
Fluid. PTH was elevated in the cyst fluid in 97% of tested cysts. Fluid was clear and watery in 77.3%. Nonfunctioning cysts more often had clear fluid and functioning cysts more often had brown fluid (Papavramidis et al. 2018).
Histology. The cyst wall contained parathyroid tissue in 98.9%, with thyroid or thymic tissue in a few cases and fibrosis or hemorrhage in some (Papavramidis et al. 2018).
Cystic tumors and CDC73. Somatic CDC73 mutations were found in 3 of 48 parathyroid adenomas with cystic features (Carpten et al. 2002), and a cystic tumor raises the possibility of hyperparathyroidism-jaw tumor syndrome (Juhlin and Erickson 2021).
Hereditary hyperparathyroidism
Frequency. MEN1 is the most common syndrome, with a prevalence of 1 per 40,000 (Juhlin and Erickson 2021).
Morphologic clues to germline disease. The 2022 classification describes morphologic and immunohistochemical harbingers of MEN1-, CDKN1B-, MAX- and CDC73-related disease (Erickson et al. 2022). MEN1-related tumors are often multiglandular and asymmetric, lack a rim of normal parathyroid tissue and show compact sheet-like chief cells with fibrosis. No histologic feature separates an MEN1-related adenoma from a sporadic adenoma with certainty (Juhlin and Erickson 2021). Parafibromin-deficient morphology and cystic change point to CDC73 disease (Gill et al. 2019; Juhlin and Erickson 2021).
Menin and p27 immunohistochemistry. Menin loss is characteristic of MEN1 and reduced p27 of MEN4. Both stains are technically difficult, and p27 loss also occurs in sporadic carcinoma (Uljanovs et al. 2022). Menin immunohistochemistry is not suitable for routine screening because somatic MEN1 loss is common in sporadic adenomas (Juhlin and Erickson 2021).
Primary hyperparathyroidism in about 90%, penetrance 95% by age 50 years; multiglandular, synchronous or metachronous, often asymmetric; carcinoma exceedingly rare
Pancreatic islet, duodenal, pituitary, adrenal cortical and carcinoid tumors
Thakker et al. 2012; Juhlin and Erickson 2021
MEN2A
RET (activating); autosomal dominant
Primary hyperparathyroidism in 15%–30%; mild, one to four glands enlarged; carcinoma exceedingly rare
Medullary thyroid carcinoma and pheochromocytoma
Wells et al. 2015; Juhlin and Erickson 2021
MEN4
CDKN1B (p27Kip1); heterozygous germline variants
Parathyroid adenomas, the most common feature; reduced p27 expression
Pituitary adenomas
Lee and Pellegata 2013; Uljanovs et al. 2022
MEN5 (MAX-related)
MAX (loss of function)
Multiglandular parathyroid adenomas in one proband
Pheochromocytoma, pituitary tumors, ganglioneuroma and neuroblastoma
Neonatal severe hyperparathyroidism with homozygous inactivating CASR
Pollak et al. 1996; Juhlin and Erickson 2021
Other genes. Germline inactivating variants in CDKN1A, CDKN2B or CDKN2C occur in rare MEN1-like families (Juhlin and Erickson 2021). Familial hypocalciuric hypercalcemia types 2 and 3 (GNA11 and AP2S1) and FHH testing are taught in Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate; type 3 is the more severe variant (Hannan et al. 2016). Familial hypercalciuric hypercalcemia is a separate hereditary cause (Duan et al. 2015).
HPT-JT uterine disease. Menorrhagia in the second to fourth decades with uterine tumors at hysterectomy affected women in 13 of 33 kindreds and reduced maternal transmission (Bradley et al. 2005). Reported uterine lesions include leiomyoma, adenomyosis, endometrial hyperplasia, adenofibroma and adenosarcoma (Uljanovs et al. 2022).
HPT-JT renal lesions. Renal cysts, hamartomas, Wilms tumor, papillary renal cell carcinoma and metanephric adenoma are reported (Uljanovs et al. 2022).
Multiple endocrine neoplasia syndromes
The 2022 classification newly defines MAFA-related familial insulinomatosis, MEN4 and MEN5 as familial endocrine syndromes and adds new pathologic findings in DICER1 syndrome (Nosé et al. 2022). Previous rule (WHO 4th edition, 2017): these three syndromes were not defined as separate familial syndromes (Nosé et al. 2022).
Syndrome
Gene
Endocrine, neuroendocrine and other tumors and features
Source
MEN1
MEN1
Parathyroid; duodenal and pancreatic neuroendocrine tumors, most often gastrinoma, insulinoma or glucagonoma; pituitary tumors; adrenal cortical lesions (20%–45%); thymic neuroendocrine tumors (3.1%–8.2%) (Piórek et al. 2025) and other carcinoid tumors (Thakker et al. 2012); meningioma, facial angiofibroma, collagenoma and lipoma
Thakker et al. 2012; Juhlin and Erickson 2021; Piórek et al. 2025
MEN2A
RET
Medullary thyroid carcinoma (more than 90%), pheochromocytoma (about 50%), parathyroid (15%–30%); cutaneous lichen amyloidosis, almost only with codon 634 variants; Hirschsprung disease in about 7%
Parathyroid and pituitary adenomas (MEN1-like spectrum)
Lee and Pellegata 2013
MEN5
MAX
Pheochromocytoma (bilateral and metastatic), pituitary tumors, ganglioneuroma, neuroblastoma and possibly parathyroid adenoma; chondrosarcoma and lung adenocarcinoma in one proband
Seabrook et al. 2021
MAFA-related familial insulinomatosis
MAFA p.Ser64Phe
Multiple insulin-secreting pancreatic neuroendocrine tumors; diabetes mellitus; congenital cataract or glaucoma in some carriers
Iacovazzo et al. 2018
MEN1 thymic tumors. About 25% of thymic neuroendocrine tumors arise in MEN1, and thymic atypical carcinoids show the strongest association (Piórek et al. 2025).
MEN2B inheritance. At least 75% of patients with MEN2B have de novo RET variants and phenotypically normal parents (Wells et al. 2015). In 6 children with sporadic MEN2B and the de novo p.M918T variant, all had medullary thyroid carcinoma and 4 had nodal metastases at diagnosis (Liu et al. 2026).
MAFA. Insulinomatosis presented more often in females (8 of 10) and diabetes more often in males (12 of 16) (Iacovazzo et al. 2018).
RET risk categories in MEN2 (ATA 2015)
ATA risk category
RET variants
Prophylactic thyroidectomy
Pheochromocytoma
Hyperparathyroidism
Source
Highest (ATA-HST)
M918T (MEN2B)
In the first year of life
About 50%
None
Wells et al. 2015
High (ATA-H)
C634 and A883F
At or before age 5 years, guided by serum calcitonin
About 50%
20%–30% with C634; none with A883F
Wells et al. 2015
Moderate (ATA-MOD)
All other codons
Timed by the first elevated serum calcitonin
About 10% (G533C, K666E, L790F, V804L, V804M, S891A); about 10% to 20%–30% (codons 609, 611, 618, 620, 630); about 50% (D631Y); none reported (E768D, R912P)
About 10% (codons 609, 611, 618, 620, 630, V804L, V804M, S891A); none reported for the others
Wells et al. 2015
Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases
Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), divides adrenal cortical proliferations into diffuse adrenal cortical hyperplasia, adrenal cortical nodular disease, adrenal cortical adenoma and adrenal cortical carcinoma (ACC). It adds separate chapters on adrenal ectopia, adrenal cysts and myelolipoma (Mete et al. 2022). Previous rule (4th edition, 2017): tumors of the adrenal cortex were classified as cortical carcinoma, cortical adenoma, sex cord-stromal tumors, adenomatoid tumor, mesenchymal and stromal tumors (myelolipoma and schwannoma), hematological tumors and secondary tumors, with schwannoma and hematological tumors newly listed (Lam 2017). The CAP Adrenal protocol, version 4.3.1.0 (March 2023), applies to ACC in all age groups. It does not apply to adrenal medullary tumors, adrenal cortical neoplasms of uncertain malignant potential, sarcomas or lymphomas (CAP 2023).
Adrenal development, anatomy and ectopic adrenal tissue
Embryology. The adrenal medulla derives from neural crest cells and the cortex from intermediate mesoderm. The fetal zone accounts for most prenatal growth of the gland, a definitive zone appears between the capsule and the fetal zone by the 8th week of gestation, and fetal zone cells undergo apoptosis and involute immediately after birth (Xing et al. 2015).
Zonation. The zona glomerulosa and zona fasciculata mature under angiotensin II and ACTH. The zona reticularis begins to form between the fasciculata and the medulla at 6–8 years of age in girls and 7–9 years in boys and produces the androgen precursors DHEA and androstenedione (Xing et al. 2015). Aldosterone synthase (CYP11B2) is expressed in the zona glomerulosa, and CYP11B1 marks zona fasciculata-type cells (Mete et al. 2022).
Gross anatomy. The cortex is lipid-rich and bright yellow, and the medulla is gray-white. The short right central vein drains into the inferior vena cava and the left central vein into the left renal vein. Regional lymph nodes are the aortic (para-aortic and peri-aortic) and retroperitoneal (perinephric and periadrenal) nodes (CAP 2023).
Adrenal weight. In 20 sudden-death controls at autopsy, the two adrenal glands together weighed 7.84 ± 1.63 g, against 10.38 ± 2.74 g in 100 suicides aged 15–60 years. Gland weight correlated with height and showed no significant relation to age or body weight (Chaurasia et al. 2023). In an autopsy series spanning infancy to more than 100 years, adrenal weight fell with age in men, and no age-related change was found in women (Nonaka et al. 2020). In 106 infant deaths, the median combined adrenal weight was 0.056% of body weight (5th–95th percentile 0.025%–0.23%), and adrenal weight alone was insufficient to diagnose adrenal insufficiency (Morrison et al. 2017).
Adrenal ectopia (2022 chapter). Adrenal ectopia is benign adrenal cortical tissue outside the orthotopic gland, most often found incidentally along the developmental tract in the kidney, spermatic cord, rete testis, epididymis and paraovarian or parasalpingeal tissue. Ectopic rests are small yellow subcentimeter nodules of bland eosinophilic or clear cells that express SF1. Adrenal cortical choristoma is cortical tissue in a site that embryogenesis does not explain, including corticotroph pituitary neuroendocrine tumors. "Adrenal rest tumor" is reserved for nodular proliferations in the gonads. Rests can mimic metastasis and can give rise to adenomas in the liver or gastric wall (Mete et al. 2022).
Congenital adrenal hyperplasia and testicular adrenal rest tumors
Genetics. Congenital adrenal hyperplasia (CAH) is autosomal recessive. CYP21A2 (21-hydroxylase) is mutated in 95%–99% of patients. Loss of cortisol removes feedback inhibition, raises ACTH and causes bilateral hyperplasia with androgen excess and virilization. Other enzyme defects are tabulated in Endocrine Function Tests: Thyroid, Adrenal and Pituitary (Mete et al. 2022).
Adrenal morphology. Glands and adrenal rests in CAH show diffuse compact cell (lipid-depleted) cortical hyperplasia. A resected CAH gland can show a multinodular cortex of zona reticularis-like cells with chronic lymphocytic infiltrates and multifocal myelolipomas (Mete et al. 2022).
Tumors in CAH. Adrenal cortical tumors develop in about 24% of patients with genetically confirmed CAH, and almost 40% may have adrenal myelolipoma (Mete et al. 2022). CAH was present in 10% of 440 reported myelolipomas (Decmann et al. 2018).
Testicular adrenal rest tumors. Prolonged ACTH stimulation can cause a hyperplasia-to-neoplasia sequence in gonadal rests. CYP11B1 and CYP21A2 immunohistochemistry, abundant DLK1 and absent INSL3 separate testicular adrenal rest tumors from Leydig cell tumors (Mete et al. 2022).
Adrenal cortical hyperplasia and nodular disease in the WHO 2022 classification
The 2022 classification restricts "adrenal cortical hyperplasia" to bilateral diffuse hyperplasia dependent on ACTH or CRH and to diffuse compact cell hyperplasia in CAH. Bilateral micronodular and macronodular disease are classified among benign adrenal cortical tumors because each nodule is an independent clonal proliferation, usually on a germline background (Mete et al. 2022).
Multiple pigmented micronodules <1 cm (often 2–5 mm) of eosinophilic CYP11B1-positive cells with internodular cortical atrophy; mainly children and young adults, mostly female
Carney complex (c-PPNAD) or isolated (i-PPNAD); germline PRKAR1A most often, then PRKACA and the CNC2 locus
Massive bilateral enlargement by nodules >1 cm of lipid-rich clear cells with occasional eosinophilic cells; adults; hypercortisolism in >90%
Germline ARMC5 in 25%–55% with a somatic second hit in each nodule; also MEN1, FH, APC, GNAS, PDE8B, PDE11A; aberrant G-protein-coupled receptor expression
Frequency. Bilateral micronodular and macronodular disease together account for about 2% of patients with endogenous hypercortisolism. Patients with ARMC5 variants have larger glands and more severe hypercortisolism (Mete et al. 2022).
Molecular clusters of benign cortisol excess. Pan-genomic analysis separates PPNAD and cortisol-producing adenomas with protein kinase A activation, adenomas with mild autonomous cortisol secretion and Wnt activation, and ARMC5-related macronodular disease with an ovarian-type gene expression signature (Mete et al. 2022).
Primary aldosteronism: HISTALDO classification and CYP11B2 immunohistochemistry
The 2022 classification endorses the HISTALDO nomenclature and CYP11B2 immunohistochemistry on all adrenalectomy specimens from patients with primary aldosteronism. Not every radiologic nodule produces aldosterone, and microscopic clonal lesions may be invisible on imaging (Mete et al. 2022).
Subcapsular zona glomerulosa-like cells, often a few millimeters, hard to identify on H&E
Gradient from the outer to the inner front
Mete et al. 2022
Multiple APN or APM (formerly "micronodular hyperplasia")
Synchronous multifocal APN and/or APM
Discrete positive nodules without a continuous glomerulosa layer
Mete et al. 2022
Aldosterone-producing diffuse hyperplasia (APDH)
Broad, uninterrupted strip of zona glomerulosa
More than 50% of glomerulosa cells positive
Mete et al. 2022
Classic versus non-classic histology. A solitary APA or APN is classic histology. APDH and multifocal APN or APM are non-classic. Biochemical recurrence from bilateral disease occurred in about 42% of patients with non-classic histology and in less than 5% with classic histology. APDH is the most common cause of bilateral idiopathic primary aldosteronism (Mete et al. 2022).
Paradoxical zona glomerulosa hyperplasia. The non-lesional cortex beside an APA or APN often shows glomerulosa hyperplasia that is negative for CYP11B2 and is non-functional (Mete et al. 2022).
Genotype and morphology. Somatic ion channel mutations (KCNJ5, CACNA1D, CACNA1H, ATP1A1, ATP2B3) cause constitutive depolarization. They were first reported in about half of APAs and are found in 90%–96% when CYP11B2 positivity is required. KCNJ5 accounts for about 40% of APAs, favors younger women and clear zona fasciculata-like cells, and gives a canary-yellow cut surface. KCNJ5 wild-type tumors are more frequent in older men and are smaller and compact-celled. About 5% of sporadic APAs carry CTNNB1 mutations (Mete et al. 2022).
Spironolactone bodies. Spironolactone causes eosinophilic, concentrically laminated cytoplasmic inclusions in the tumor and the adjacent zona glomerulosa that stain with Luxol fast blue. Eplerenone does not produce them (Mete et al. 2022).
Familial hyperaldosteronism. Type I is caused by a germline CYP11B1/CYP11B2 chimeric gene, type II by CLCN2, type III by KCNJ5 and type IV by CACNA1H. Germline CACNA1D variants cause primary aldosteronism with seizures and neurologic abnormalities (PASNA syndrome) (Mete et al. 2022).
Adrenal insufficiency and adrenalitis in pathology specimens
Autoimmune adrenalitis causes 80%–90% of primary adrenal insufficiency in the United States and Europe. Tuberculosis was the most common cause 100 years ago, and bacterial, fungal (histoplasmosis), viral and protozoal (Plasmodium falciparum) infections can still involve the adrenals in immunocompetent and immunocompromised patients (Murray 2026). Bilateral infiltrative disease belongs in the differential diagnosis of new primary adrenal insufficiency, especially when autoimmune testing is negative; in a Mayo Clinic series, all 7 such patients had bilateral adrenal masses diagnosed histologically (Herndon et al. 2018).
Cause of primary adrenal insufficiency
Pathologic findings
Source
Autoimmune adrenalitis
Small or unidentifiable glands at autopsy; cortical destruction by CD4 and CD8 T cells directed against 21-hydroxylase; 21-hydroxylase antibodies occur only in the autoimmune form, and tuberculosis, metastasis and other infiltrative causes enlarge the glands
Kemp et al. 2016; Capalbo et al. 2024
Adrenal tuberculosis
Granulomatous inflammation in 73%, caseous necrosis in 51% and Langhans giant cells in 25% of 55 cases with pathology; calcification in 50% on imaging
Ye et al. 2026
Histoplasmosis and cryptococcosis
Bilateral adrenal masses; diagnosis by adrenal biopsy
Herndon et al. 2018
Bilateral metastases and lymphoma
Lung and breast adenocarcinoma and diffuse large B-cell lymphoma in a biopsy series of bilateral infiltrative disease; 5 of 464 patients with adrenal metastases presented with adrenal insufficiency
Acute insufficiency when hemorrhage destroys more than 90% of the cortex
Aloini et al. 2023
X-linked adrenoleukodystrophy (ABCD1)
Very long-chain fatty acids accumulate in the zona fasciculata and zona reticularis with relative sparing of the zona glomerulosa; electron microscopy shows lamellar (striated) lipid inclusions of cholesterol esters and gangliosides esterified with very long-chain fatty acids in adrenocortical cells, also present in Leydig cells; lesions begin in fetal adrenal tissue; adrenal insufficiency develops in 80%–86% of males, peaking at 3–10 years, usually without mineralocorticoid deficiency
Kemp et al. 2026
Histology of autoimmune adrenalitis. A lymphoplasmacytic infiltrate accompanies destruction of the adrenal cortex, and insufficiency becomes clinically apparent only when about 90% of the cortex is destroyed. Focal lymphocytic adrenalitis is a common incidental finding in the elderly; it lacks the diffuse inflammation of autoimmune adrenalitis and causes no adrenal dysfunction (Uccella et al. 2023).
APS-1. Autoimmune polyendocrine syndrome type 1 (APECED) is caused by AIRE abnormalities. Its triad is mucocutaneous candidiasis (82.5%), usually the first manifestation, hypoparathyroidism (84.2%) and primary adrenal insufficiency (72.2%) (Uccella et al. 2023).
Geographic variation. In a Chinese referral series of 131 patients, infection caused 58.1% of adult primary adrenal insufficiency (tuberculosis in 93.0% of these) and autoimmune adrenalitis 19.0%. Genetic defects caused 52.6% of cases in adolescents, half of them NR0B1 (DAX1) deficiency (Wang et al. 2020).
Adrenal hemorrhage and Waterhouse–Friderichsen syndrome
Unilateral versus bilateral. Adrenal hemorrhage is most often unilateral and caused by abdominal trauma. Bilateral hemorrhage accounts for 10% of cases and follows systemic conditions: surgery, sepsis, bleeding diathesis, coagulopathy, systemic lupus erythematosus, antiphospholipid syndrome, anticoagulant therapy and pregnancy (Aloini et al. 2023).
Mechanism. Three adrenal arteries divide into capillaries at the zona reticularis, which drain into a single central vein. Vasoconstriction or thrombosis of the adrenal vein raises capillary pressure and causes bleeding. Heparin-induced thrombocytopenia is a frequent cause of adrenal vein thrombosis in heparin-associated hemorrhage, and antiphospholipid syndrome is one of the most common reported risk factors (Aloini et al. 2023).
Neonatal adrenal hemorrhage. Neonatal adrenal hemorrhage is more common in term infants and after perinatal asphyxia. It presents with prolonged jaundice, an abdominal mass, anemia, scrotal discoloration or swelling, hypotonia, lethargy or hypertension, or is found incidentally. The right gland is involved in about 70% of cases, ultrasound establishes the diagnosis and follow-up, and the hemorrhage usually resolves within 3 weeks to 6 months (Tognato et al. 2020).
Waterhouse–Friderichsen syndrome. Waterhouse–Friderichsen syndrome, first described in 1911, is massive thrombotic adrenal hemorrhage in meningococcal sepsis. Many other bacteria and viruses can cause it. Mortality reaches nearly 15% even with prompt treatment, and adrenal insufficiency after sepsis is often irreversible (Aloini et al. 2023).
Forensic autopsy pattern. In 86 autopsy-confirmed fatal cases, bilateral adrenal hemorrhage occurred within a systemic septic pattern of multiorgan congestion, hemorrhage and changes of disseminated intravascular coagulation. Culture and molecular results were often discordant (Camatti et al. 2026).
Adrenal cortical adenoma
Function. Adrenal cortical adenomas may be non-functional or may secrete cortisol or aldosterone, with overt or subclinical syndromes. Some patients have concurrent primary aldosteronism and Cushing syndrome. Cortisol-secreting adenomas are the most frequent cause of ACTH-independent Cushing syndrome. Sex steroid-secreting adenomas are exceptional in adults, and virilization or feminization raises the possibility of carcinoma (Mete et al. 2022).
Gross findings. Most adenomas are homogeneous, well delineated and yellow. Oncocytic adenomas are mahogany brown, and black adenomas contain lipofuscin. Size and weight above 5 cm and 100 g, an irregular border or a heterogeneous cut surface with necrosis, hemorrhage, fibrosis or a gelatinous appearance warrant extensive sampling or complete submission (Mete et al. 2022).
Atrophy of the adjacent cortex. In the absence of exogenous glucocorticoid, atrophy of the non-tumorous cortex (thickness <2 mm with a reduced or absent zona reticularis) is a hallmark of autonomous cortisol secretion. Intermittent loss of the zona reticularis can be the first sign in mild autonomous cortisol secretion. A subset of black adenomas shows mild autonomous cortisol secretion (Mete et al. 2022). Mild autonomous cortisol secretion is defined as serum cortisol >1.8 µg/dL (>50 nmol/L) after a 1-mg overnight dexamethasone test without clinical signs of overt Cushing syndrome (Fassnacht et al. 2023).
Histology. Adenomas contain lipid-rich clear cells mixed with compact eosinophilic cells. Vascular invasion, local invasion, necrosis unrelated to manipulation, any atypical mitotic figure, more than 5 mitoses per 10 mm² and marked reticulin loss are absent. Focal random nuclear atypia of Fuhrman grade 3 or 4 (endocrine atypia), infarct-type necrosis from involution and myelolipomatous change occur in adenomas (Mete et al. 2022).
Weight and size. Adrenal cortical neoplasms weighing less than 50 g are often benign, and adult carcinomas usually weigh more than 100 g. One study found that tumors larger than 6.5 cm are likely malignant (CAP 2023).
Oncocytic neoplasms. "Oncocytoma" is no longer a recommended term for oncocytic adrenal cortical neoplasms. Diffuse growth and macronucleoli are intrinsic to these tumors, so the Weiss system overestimates their malignancy, and other algorithms are used. Cortical origin is confirmed in all non-functional lesions and in oncocytic tumors because oncocytic adenomas are mistaken for pheochromocytoma on the basis of synaptophysin. Oncocytic cortical neoplasms are chromogranin A-negative and SF1-positive (Mete et al. 2022).
Molecular findings. Cortisol-producing adenomas carry PRKACA, PRKAR1A, GNAS or PRKACB mutations that activate protein kinase A. CTNNB1 mutations occur in non-functional adenomas and adenomas with mild autonomous cortisol secretion. Adenomas have few chromosomal alterations and global DNA hypermethylation (Mete et al. 2022).
Syndromes. Adenomas are unusual manifestations of Li–Fraumeni syndrome, MEN1, familial adenomatous polyposis, Beckwith–Wiedemann syndrome and Carney complex (Mete et al. 2022).
Adrenal cortical carcinoma: clinical features, subtypes and angioinvasion
Presentation. About half of adult ACCs present with hormone excess, usually glucocorticoids alone or with sex steroids, and 10%–15% are incidental. Virilization or feminization is highly worrisome for malignancy. Aldosterone-producing ACC is rare (Mete et al. 2022).
Hereditary ACC. About 10% of ACCs arise in a hereditary setting. Li–Fraumeni syndrome is found in 50%–80% of children and 3%–5% of adults with ACC, and about 3% of adults have Lynch syndrome. Lynch syndrome, MEN1, Beckwith–Wiedemann syndrome, Carney complex and NF1 are also overrepresented, and genetic counseling may be considered for all patients (Mete et al. 2022).
Angioinvasion (emphasized in 2022). Vascular invasion is assessed at the tumor–capsule interface or beyond the capsule. Microscopic angioinvasion is tumor invading through a vessel wall to form a thrombus/fibrin–tumor complex, or intravascular tumor admixed with platelet thrombus or fibrin. CD61 immunohistochemistry highlights platelets at sites of angioinvasion (Mete et al. 2022). In an adult series, microscopic angioinvasion was the best prognostic parameter, predicting adverse outcome in all ACCs and within low-grade ACCs. The WHO 5th edition requires lymphatic and vascular invasion to be reported separately and does not endorse the term "lymphovascular invasion" (CAP 2023).
Molecular pathology. ACCs carry mutually exclusive Wnt pathway (activating CTNNB1, inactivating ZNRF3) and p53 pathway (TP53 in 20%, RB1, MDM2, CDKN2A) alterations, with DAXX, ATRX, MEN1 and PRKAR1A in subsets. Loss of the maternal 11p15 allele with paternal duplication downregulates H19 and upregulates IGF2. ACCs are globally hypomethylated. Pan-genomic studies separate low-, intermediate- and high-risk clusters; high-risk tumors have Wnt/p53 mutations, a CpG island methylator (CIMP-high) phenotype and whole-genome doubling, and G0S2 hypermethylation is a surrogate for CIMP-high disease (Mete et al. 2022).
ACC subtype (WHO 2022)
Definition and features
Assessment system
Source
Conventional
Eosinophilic or clear cortical cells; thick fibrous bands, necrosis and prominent mitoses
Weiss, modified Weiss, reticulin algorithm, Helsinki
Mete et al. 2022; Lam 2021
Oncocytic
Oncocytic cells in more than 90% of the tumor; tan-brown cut surface; most common subtype; alpha-inhibin in about half and melan-A in slightly more than one third; chromogranin A negative; median survival 60 months in pooled cases
Lin–Weiss–Bisceglia, reticulin algorithm, Helsinki
Mete et al. 2022; Lam 2021
Myxoid
Prominent extracellular mucin; Weiss parameters hard to assess; tumors with a Weiss score of 1 have caused death
Resembles sarcomatoid carcinoma of other organs and often retains cortical differentiation; distinguished from sarcoma when no other ACC component is present
Separation from sarcoma by adrenal cortical differentiation
Mete et al. 2022
Previous rule (4th edition, 2017): oncocytic, myxoid and sarcomatoid ACC were listed as variants, myxoid ACC being formally labeled a variant for the first time in 2017 (Lam 2021). The 2017 classification adopted a system for separating oncocytoma from oncocytic cortical carcinoma (Lam 2017). The 2022 classification calls them subtypes and drops the term "oncocytoma" (Mete et al. 2022).
Weiss and modified Weiss criteria for adrenal cortical carcinoma
Histologic parameter
Weiss score
Modified Weiss score
Source
High nuclear grade (Fuhrman grade 3 or 4)
1
Not scored
Mete et al. 2022
Mitotic count >5 per 10 mm² (50 high-power fields)
1
2
Mete et al. 2022
Atypical mitoses
1
1
Mete et al. 2022
Necrosis
1
1
Mete et al. 2022
Diffuse architecture in >30% of tumor volume
1
Not scored
Mete et al. 2022
Clear cells ≤25% of tumor volume
1
2
Mete et al. 2022
Capsular invasion
1
1
Mete et al. 2022
Venous invasion
1
Not scored
Mete et al. 2022
Sinusoidal (lymphatic) invasion
1
Not scored
Mete et al. 2022
Maximum score and threshold for carcinoma
9; ≥3
7; ≥3
Mete et al. 2022; CAP 2023
Original Weiss series. In 43 adrenocortical tumors, none of the 24 tumors with two or fewer criteria metastasized or recurred, and all but one of the 19 tumors with four or more recurred or metastasized. Mitotic activity, atypical mitoses and venous invasion correlated best with malignancy, and no single criterion sufficed (Weiss 1984).
Modified Weiss system. In 49 tumors, three or more Weiss criteria had 100% sensitivity and 96% specificity for malignancy, with excellent interobserver agreement (r = 0.94). The modified system keeps the five most reliable criteria, doubles the weight of mitotic rate and clear cells, and correlates with the Weiss score (r = 0.98) (Aubert et al. 2002).
Weiss score in oncocytic and pediatric tumors. Diffuse growth, high nuclear grade and ≤25% clear cells are intrinsic to oncocytic neoplasms, so the Weiss score is not used for them (Lam 2021). Weiss criteria overdiagnose pediatric tumors that behave benignly (Mete et al. 2022).
Reticulin algorithm, Lin–Weiss–Bisceglia system and Helsinki score
System
Criteria
Diagnosis
Validation
Source
Reticulin algorithm
Altered reticulin framework (Gordon–Sweet silver stain) plus one of: >5 mitoses per 10 mm², tumor necrosis or angioinvasion
Carcinoma when altered reticulin is combined with one parameter
245 tumors: 27% of Weiss-classified tumors reclassified as adenoma; complete agreement among 8 pathologists in 75% (κ = 0.702), 86% after training
One major criterion: oncocytic ACC. One or more minor criteria only: oncocytic neoplasm of uncertain malignant potential. None: oncocytic adenoma
Proposed from 10 tumors and a literature review
Bisceglia et al. 2004; Mete et al. 2022
Helsinki score
3 × (mitoses >5 per 10 mm²) + 5 × (necrosis) + Ki-67 index (%) from the most proliferative area by image analysis
>8.5: carcinoma; >17: adverse prognosis
177 adults: 100% sensitivity and 99.4% specificity for metastatic ACC, versus 90.2% specificity for Weiss and 96.9% for modified Weiss
Pennanen et al. 2015; Mete et al. 2022
Reticulin pattern. Most ACCs show quantitative loss of the reticulin framework. Qualitative change (a mesh-like pericellular pattern) alone is not a feature of carcinoma because it occurs focally in adenomas with a preserved framework. Hemorrhage, degeneration and biopsy sites disrupt reticulin in benign tumors (Mete et al. 2022).
Oncocytic sampling. The Lin–Weiss–Bisceglia system applies only when more than 90% of an extensively sampled tumor is oncocytic. Mixed tumors are assessed with conventional criteria (Mete et al. 2022).
Systems by subtype (WHO 5th edition). Conventional adult ACC is diagnosed with a Weiss score ≥3, modified Weiss score ≥3, Helsinki score >8.5 or the reticulin algorithm. Oncocytic ACC is diagnosed with any Lin–Weiss–Bisceglia major criterion, a Helsinki score >8.5 or the reticulin algorithm. Pediatric ACC is diagnosed with a Wieneke score ≥4 (CAP 2023).
Mitotic grade, Ki-67 and immunohistochemistry of adrenal cortical carcinoma
Mitotic grade. The 2022 classification adopts the mitotic grade introduced by Weiss and colleagues: low grade ≤20 mitoses per 10 mm² and high grade >20 mitoses per 10 mm². Its prognostic value is validated in adults and not yet in children. Two series found that a cut-off of 10 mitoses per 10 mm² performed better (Mete et al. 2022). The CAP protocol requires mitotic grade for adult patients only and recommends documenting it in children (CAP 2023).
Counting method. The original method counted 10 high-power fields on each of 5 sections of high mitotic density (50 fields). Counting 10 mm² in hot spots across several slides is acceptable, and phosphohistone H3 immunohistochemistry helps in low-grade tumors (Mete et al. 2022).
Ki-67. Most ACCs have a Ki-67 index above 5%. Prognostic tiers used in large series are <10%, 10%–19% and ≥20%, or <20%, 20%–50% and >50%; pediatric series support 15%. Ki-67-based grading is not endorsed because proliferation is continuous. The numeric mitotic count and Ki-67 index are reported for every ACC, hot spots are counted manually or by image analysis, visual estimation is not used and the method is documented (Mete et al. 2022).
Clinical use. The European Society of Endocrinology guideline suggests expert pathology review with the Weiss score and Ki-67 index for every suspected ACC, and adjuvant mitotane after radical surgery for patients at high risk of recurrence (ENSAT stage III, R1 resection or Ki-67 >10%) (Fassnacht et al. 2018).
Marker
Result in adrenal cortical carcinoma
Interpretation
Source
SF1
Nuclear
Most reliable marker of cortical origin; also positive in gonadotroph pituitary neuroendocrine tumors, steroid cell tumor and Leydig cell tumor
Mete et al. 2022
Melan-A, alpha-inhibin, calretinin, synaptophysin
Variable
Non-specific; panel use only. Synaptophysin and alpha-inhibin also stain pheochromocytoma, especially pseudohypoxia-pathway tumors
Mete et al. 2022; CAP 2023
Chromogranin A
Negative
Separates oncocytic cortical neoplasms from pheochromocytoma
Mete et al. 2022; Lam 2021
IGF2
Paranuclear (juxtanuclear) granular dots in about 80% of adult ACCs
Best ancillary marker of malignancy, independent of grade and oncocytic morphology
Mete et al. 2022
p53 and β-catenin
Overexpression or global loss of p53; nuclear β-catenin
Enriched in high-grade ACC and poor-prognosis molecular clusters; CAP recommends both on every ACC
Mete et al. 2022; CAP 2023
ATRX and DAXX
Global loss
Prognostic
Mete et al. 2022
MLH1, PMS2, MSH2, MSH6
Loss
Screens for Lynch syndrome and informs immunotherapy trials
Mete et al. 2022
CYP11B1 and CYP11B2
Zona fasciculata-type and aldosterone synthase expression
Functional immunohistochemistry of cortisol- and aldosterone-producing lesions
Mete et al. 2022
SDHB, APC, menin and p27
Loss
Raise SDH-deficient paraganglioma syndrome, familial adenomatous polyposis, MEN1 and MEN4
Mete et al. 2022
Staging and reporting of adrenal cortical carcinoma (AJCC 8th edition and CAP Adrenal 4.3.1.0)
Category
AJCC 8th edition definition
Source
pT1
Tumor ≤5 cm, no extra-adrenal invasion
CAP 2023
pT2
Tumor >5 cm, no extra-adrenal invasion
CAP 2023
pT3
Tumor of any size with local invasion, not invading adjacent organs
CAP 2023
pT4
Tumor of any size invading adjacent organs (kidney, diaphragm, pancreas, spleen or liver) or large blood vessels (renal vein or vena cava)
CAP 2023
pN1
Metastasis in regional (aortic or retroperitoneal) lymph nodes
CAP 2023
Stage I
T1 N0 M0
Lam 2021
Stage II
T2 N0 M0
Lam 2021
Stage III
T1–T2 N1 M0, or T3–T4 any N M0
Lam 2021
Stage IV
Any T, any N, M1
Lam 2021
Change from the 7th edition. The AJCC 8th edition adopted the ENSAT staging. T4 N0 M0 and T3–T4 N1 M0 tumors, which were stage IV in the 7th edition, are stage III, and tumor thrombus in the renal vein or vena cava, formerly M1, is T4. Only distant metastasis is stage IV (Lam 2021).
Weight. The adrenal gland weight is reported because the tumor is not dissected free and weighed separately (CAP 2023).
Metastatic sites. ACC metastasizes most often to liver, lung and retroperitoneum. Scalp metastasis can mimic angiosarcoma (CAP 2023).
CAP 4.3.1.0 element
Responses and rules
Source
Histologic subtype
Conventional, oncocytic, myxoid or sarcomatoid
CAP 2023
Mitotic tumor grade
Low grade ≤20 or high grade >20 mitoses per 10 mm²; required for adults
CAP 2023
Tumor size and adrenal gland weight
Greatest dimension in centimeters; gland weight in grams
CAP 2023
Direct extension
Confined to cortex; into or through capsule; peri-adrenal fat; kidney, pancreas, liver, spleen, diaphragm, stomach or large vessels
CAP 2023
Lymphatic and vascular invasion
Large vessel invasion of renal vein or vena cava (including clinical or gross); microscopic angioinvasion; lymphatic invasion
CAP 2023
Margins, lymph nodes and pTNM
Closest margin; nodes examined and involved; AJCC 8th edition pT, pN and pM
CAP 2023
Ki-67 labeling index
Percentage; required
CAP 2023
Biomarkers confirming cortical origin
Required for all non-functional tumors; SF1 named as the most reliable marker
CAP 2023
p53, β-catenin and reticulin (optional)
Abnormal or wild-type p53; nuclear or membranous β-catenin; reticulin result
CAP 2023
Pediatric adrenal cortical tumors and the Wieneke criteria
Epidemiology. Pediatric ACC has an annual incidence of 0.2–0.3 per million (about 25 patients per year in the United States) with peaks before 5 years and in adolescence. It is 15 times more frequent in southern Brazil because of the TP53 p.R337H founder variant (Mete et al. 2022).
Presentation and genetics. Androgen excess is the presenting feature in up to 80% of children and causes virilization in boys and girls; cortisol excess is less common. Germline TP53 variants are present in up to 80% of pediatric ACCs, in high-incidence regions and elsewhere. p53 loss leads to 11p15 loss of heterozygosity and IGF2 overexpression, and Beckwith–Wiedemann syndrome (11p15) also predisposes. Somatic ATRX and CTNNB1 mutations may indicate a poor outcome (Mete et al. 2022).
Behavior of pediatric tumors. In 83 pediatric adrenal cortical neoplasms (2–20 cm, mean 8.8 cm), only 31% of histologically malignant tumors behaved malignantly. Vena cava invasion, necrosis and >15 mitoses per 20 high-power fields independently predicted malignant behavior (Wieneke et al. 2003). The mean weight of pediatric ACC was 631 g (range 24–2260 g) (CAP 2023).
Ki-67 in children. A Ki-67 index below 10% is associated with benign disease and above 15% with a higher risk of malignancy or poor outcome (Mete et al. 2022).
Prognostic factors. Meta-analyses confirm age, stage, tumor weight >200 g, extra-adrenal extension, incomplete resection, metastatic disease and cortisol secretion. Metastases favor brain, liver, lungs and bone (Mete et al. 2022).
Children's Oncology Group stage. Stage I is complete excision with negative margins, tumor weight <200 g and no metastasis; stage II is the same with weight >200 g; stage III is microscopic or gross incomplete resection or inoperable tumor; stage IV is hematogenous metastasis at presentation (Mete et al. 2022). Sources disagree on the stage I/II weight limit. The WHO 2022 overview tabulates COG stage I as <200 g and stage II as >200 g (Mete et al. 2022), whereas Lam describes the International Pediatric Adrenocortical Tumor Registry system validated by the COG with stage I ≤100 g or ≤200 cm³ and stage II >100 g or >200 cm³ (Lam 2021).
Adrenal myelolipoma
Definition. Adrenal myelolipoma is a benign neoplasm of mature adipose tissue and extramedullary hematopoiesis. It is the second most common primary adrenal incidentaloma after cortical adenoma and has a separate chapter in the 2022 classification (Decmann et al. 2018; Mete et al. 2022).
Clinical profile. In 440 reported and institutional cases, the mean age was 51 years with no sex difference and the mean size was 10.2 cm. CAH was associated with 10% of cases, and cortisol or aldosterone hypersecretion with 7.5%. CT and MRI usually establish the diagnosis, and an unambiguous asymptomatic, hormonally inactive myelolipoma does not require surgery (Decmann et al. 2018).
Differential diagnosis of myelolipoma. The histologic differential diagnosis is extramedullary hematopoiesis and well-differentiated or dedifferentiated liposarcoma. Both myelolipoma and extramedullary hematopoiesis contain trilineage hematopoietic cells, and myelolipoma forms a well-circumscribed mass in which mature fat and hematopoietic tissue are intimately admixed. In atypical lipomatous tumors, MDM2 amplification by FISH is more reliable than MDM2 immunohistochemistry (Hanaoka et al. 2026).
Myelolipomatous change. Foci of fat and hematopoiesis are often found in cortical adenomas, especially involuted adenomas with infarction and fibrocalcification (Mete et al. 2022).
Adrenal cysts and pseudocysts
Adrenal cysts are benign circumscribed fluid-containing masses with an incidence of 0.06%. They account for up to 4% of adrenal masses, show a slight female predominance and averaged 7.9 cm in one review. Most grossly cystic adrenal glands are cortical neoplasms or pheochromocytomas with cystic hemorrhagic degeneration, so the cyst wall is sampled extensively (Mete et al. 2022).
Cyst type
Wall and contents
Pathogenesis and frequency
Immunohistochemistry
Source
Pseudocyst
No lining; thick fibrous wall with fibrinohemorrhagic contents
Most common (up to 80%); follows hemorrhage or trauma, including COVID-19-related hemorrhage
Not required
Mete et al. 2022
Endothelial (vascular) cyst
Single layer of flat endothelium, occasional intraluminal protrusions; often lymphatic
Dilated and thrombosed blood or lymphatic vessels
CD31, ERG, D2-40
Mete et al. 2022
Epithelial (mesothelial) cyst
Flat or cuboidal mesothelial cells without atypia
Mesothelial remnants
Calretinin, WT1
Mete et al. 2022
Parasitic cyst
Clear fluid, single or multiple spaces, fibrocalcific wall with PAS-positive laminated membranes
Echinococcus infection
PAS stain
Mete et al. 2022
Pseudocyst and carcinoma. An adrenal pseudocyst can simulate a cystic primary neoplasm or ACC. Cystic change also occurs in adenoma, ACC, pheochromocytoma, hemangioma, lymphangioma, angiosarcoma, renal cell carcinoma, teratoma and metastases (Mete et al. 2022).
Metastases and other non-cortical lesions of the adrenal gland
Collision tumors. An adrenal collision tumor is two histologically distinct tumors coexisting in the same gland. Most are incidental. The mixed composition makes the CT washout protocol unreliable and can mimic malignancy, and the standard incidentaloma pathway identifies both a functional and a malignant component (Botros and Estafanous 2026).
Confirmation of cortical origin. Non-functional adrenal masses require confirmation of adrenal cortical origin because metastases and other non-cortical tumors mimic cortical neoplasms (CAP 2023; Mete et al. 2022).
Lesion
Diagnostic features
Source
Adenomatoid tumor
Mesothelial neoplasm; 39 earlier adrenal cases in the English literature; angiomatoid, cystic and solid patterns infiltrating cortex or medulla, thread-like bridging strands and signet-ring-like cells; AE1/AE3, CK7, D2-40, calretinin and WT1 positive; Ki-67 1%–2%
Guan et al. 2021
Schwannoma
Fewer than 50 adrenal cases reported; can be FDG-avid on PET/CT and clinically indeterminate
Fackelmayer et al. 2023
Hemangioma
Thick- and thin-walled vessels with cortical elements at the periphery
Toklu et al. 2022
Weiss, modified Weiss and Helsinki score calculator for adrenal cortical neoplasms
Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms
Definition and classification. Paragangliomas are non-epithelial neuroendocrine neoplasms of the adrenal medulla and extra-adrenal paraganglia that secrete mainly catecholamines. They are sympathetic or parasympathetic, and "pheochromocytoma" is reserved for the intra-adrenal paraganglioma, the classical sympathetic form. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), renames cauda equina paraganglioma as cauda equina neuroendocrine tumor and gangliocytic paraganglioma as composite gangliocytoma/neuroma and neuroendocrine tumor (CoGNET), and it includes the AJCC 8th edition staging of pheochromocytoma and extra-adrenal sympathetic paraganglioma (Mete et al. 2022). Previous rule (4th edition, 2017): the chapter on the adrenal medulla and extra-adrenal paraganglia comprised pheochromocytoma, head and neck and sympathetic paraganglioma, neuroblastic tumors (newly included), composite pheochromocytoma and composite paraganglioma (in separate sections), and "metastatic pheochromocytoma/paraganglioma" replaced "malignant pheochromocytoma/paraganglioma" (Lam 2017). The CAP Paraganglioma and Pheochromocytoma protocol, version 1.0.0.0, is a new protocol posted in March 2025 and required for accreditation from December 2025. It covers pheochromocytoma, extra-adrenal paragangliomas of all sites and composite tumors, and excludes neuroblastic tumors, peripheral nerve sheath tumors and cauda equina neuroendocrine tumor (CAP 2025a).
Normal medulla. Chromaffin cells derive from neural crest cells that migrate into the developing adrenal and coalesce after birth (Xing et al. 2015). Adrenal glucocorticoids induce phenylethanolamine N-methyltransferase (PNMT), so epinephrine is the dominant catecholamine of the postnatal medulla (Xing et al. 2015). The medulla is normally present only in the head and body of the gland, with minimal extension into the alae and none in the tail (CAP 2025a).
Adrenal medullary hyperplasia. Diffuse, non-nodular expansion of the medulla to more than one third of the gland thickness, or medulla in an abnormal location such as the tail, is adrenal medullary hyperplasia. It is a precursor of inherited pheochromocytoma with pathogenic RET (most common), MAX, TMEM127 and NF1 variants. The non-tumorous gland is submitted entirely, and its status is a required element for every adrenalectomy (CAP 2025a).
Micro-pheochromocytoma. Any distinct nodular chromaffin proliferation in the medulla, whatever its size, is a micro-pheochromocytoma (CAP 2025a). In MEN2A, intra-adrenal adrenaline-producing nodules smaller than 1 cm were formerly called adrenomedullary hyperplasia and are now recognized as micro-pheochromocytomas because they share the molecular alterations of the main tumor (Kimura 2026).
Cortical hyperplasia from ectopic hormone. Diffuse compact cell cortical hyperplasia beside a pheochromocytoma raises the possibility of ectopic ACTH or CRH production by the tumor (CAP 2025a).
Pheochromocytoma and paraganglioma: clinical features and morphology
Incidence and heredity. Pheochromocytoma and paraganglioma (PPGL) occur in about 1–2 per 100,000 people per year (Casey and Lussey-Lepoutre 2026). At least 40% of adult PPGLs are hereditary, caused by germline variants of at least 23 genes (CAP 2025a).
Function. Pheochromocytomas and most sympathetic paragangliomas cause symptoms of catecholamine excess, while only a small proportion of parasympathetic paragangliomas are symptomatic. Functional status is defined biochemically by the O-methylated metabolites metanephrine, normetanephrine and 3-methoxytyramine (CAP 2025a).
Architecture. The basic pattern resembles the adrenal medulla: nests (zellballen) of chief cells surrounded by S100-positive sustentacular cells and a rich vascular network (Kimura 2026).
Genotype–phenotype morphology.VHL-related tumors often have a thick vascular capsule, hyalinized vascular and myxoid stroma, small round cells among small vessels, clear or amphophilic cytoplasm and no hyaline globules. SDHx-related tumors show cytoplasmic vacuoles or oncocytic change. Expanded large confluent nests with central comedo necrosis occur in a subset of metastatic tumors (CAP 2025a).
Pigmented tumors. Abundant cytoplasmic neuromelanin produces the rare "black" PPGL, seen in dopamine-producing tumors (Kimura 2026).
Feature
Sympathetic tumors (pheochromocytoma and thoracoabdominal paraganglioma)
Parasympathetic tumors (most head and neck paragangliomas)
Source
Sites
Adrenal medulla; extra-adrenal sympathetic paraganglia of the thorax, abdomen and pelvis
Carotid body, jugulotympanic, vagal, laryngeal and aorticopulmonary paraganglia
Kimura 2026; Casey and Lussey-Lepoutre 2026
Secretion
Norepinephrine, epinephrine or dopamine; RET-, NF1-, TMEM127- and MAX-related tumors are associated with epinephrine production
Usually non-secretory or dopamine only; acetylcholine causes no syndrome
Casey and Lussey-Lepoutre 2026; Kimura 2026; CAP 2025a
Cytology
Polygonal chromaffin cells with amphophilic to basophilic cytoplasm
Chief cells with clearer cytoplasm
CAP 2025a
Catecholamine enzymes
Tyrosine hydroxylase and dopamine β-hydroxylase positive
Tyrosine hydroxylase and chromogranin A absent to reduced; choline acetyltransferase positive
Immunohistochemistry of pheochromocytoma and paraganglioma
Marker
Result
Interpretation
Source
Keratins (AE1/AE3, low molecular weight)
Negative
Testing is recommended for every neuroendocrine neoplasm; keratin (K8/K18) expression distinguishes epithelial NET and NEC from PPGL (Bellizzi 2020). CK7, CK20 and CK5/6 are not used for this purpose
CAP 2025a; Kimura 2026
Chromogranin A, synaptophysin, INSM1
Positive
General neuroendocrine markers; chromogranin A may be reduced in parasympathetic tumors
Mete et al. 2022; CAP 2025a
GATA3
Positive
Confirms paraganglionic origin in a keratin-negative NEN; also expressed by gonadotroph pituitary tumors
CAP 2025a
Tyrosine hydroxylase
Positive in most functional tumors
Rate-limiting enzyme converting L-tyrosine to L-DOPA; can be negative in non-functional tumors
Mete et al. 2022; Kimura 2026
Dopamine β-hydroxylase
Positive in norepinephrine-producing cells
Positive even in tyrosine hydroxylase-negative sympathetic tumors and well preserved after fixation
Mete et al. 2022; Kimura 2026
PNMT
Positive in epinephrine-producing tumors
Identifies epinephrine synthesis
Mete et al. 2022
PHOX2B
Positive
Supports paraganglionic origin and highlights ganglioneuronal elements of composite tumors
CAP 2025a
S100 and SOX10
Sustentacular cell network
Not specific for PPGL; reduced network is an adverse risk factor and helps separate multifocal primaries from metastases
CAP 2025a
SDHB
Global loss of granular cytoplasmic staining
SDH deficiency from any SDHx alteration
CAP 2025a
SDHA
Loss
Germline SDHA variant
Korpershoek et al. 2011
Alpha-inhibin
Positive
Pseudohypoxia pathway tumors (SDHx, VHL) and noradrenergic immature secretory phenotype
CAP 2025a
CAIX
Membranous
VHL-related tumors
CAP 2025a
FH and 2SC
FH loss with 2-succinocysteine positivity
FH-related tumors
CAP 2025a
Menin
Loss
MEN1-related tumors
CAP 2025a
MAX
Nuclear loss
MAX-related tumors; experience is conflicting, and gene analysis follows a negative result
CAP 2025a; Kimura 2026
ATRX and Ki-67
ATRX loss; Ki-67 often >3%
Adverse parameters in risk stratification
CAP 2025a
Germline testing. Immunohistochemistry raises the possibility of heritable disease, and germline genetic testing is offered to all patients with PPGL (CAP 2025a).
SDHB pitfalls. SDHB loss also occurs with SDHC promoter methylation and occasionally with VHL or NF1 mutations, so an SDHB-negative tumor proceeds to gene analysis (Kimura 2026).
Metastatic potential and risk stratification of pheochromocytoma and paraganglioma
No benign or malignant categories. Since the 4th edition, paragangliomas have not been classified as benign or malignant because any tumor can metastasize and no feature reliably predicts metastasis. Some tumors are lethal through local invasion of critical structures (Mete et al. 2022). PPGLs are regarded as malignant non-epithelial neuroendocrine neoplasms, and "metastatic paraganglioma or pheochromocytoma" is used for metastatic disease (CAP 2025a).
Definition of metastasis. Metastases are paragangliomas in sites where paraganglia do not normally exist. Lymph node and bone are the only reliable sites of unequivocal metastasis. Primary paragangliomas occur in lung, liver, prostate, kidney, bladder, heart and mesentery, so a tumor in lung or liver is not proof of metastasis, especially in a germline carrier with multifocal disease (CAP 2025a; Mete et al. 2022). Metastases tend to lack a sustentacular cell network (CAP 2025a).
Scoring systems. The WHO 2022 classification reviews the scoring systems and neither endorses nor discourages their use (Mete et al. 2022). The CAP protocol notes that higher scores can overestimate the risk of metastasis in some subgroups (CAP 2025a).
Proliferation. No formal WHO grade exists for PPGL. Ki-67 is counted in hot spots of at least 500 cells by manual count of a printed image or by image analysis, and visual estimation is not acceptable. Mitoses are reported per 2 mm² after counting at least 10 mm² (CAP 2025a). Historically, metastatic PPGLs were described as having Ki-67 >3% but usually <10%; a high Ki-67 index is not rare in metastatic PPGL and does not argue against the diagnosis (Kimura 2026).
Clinical and molecular risk factors. Extra-adrenal location, size above 5 cm, local invasion and germline SDHx variants, especially SDHB, increase the risk of metastasis. MAML3 fusions, ATRX mutations with alternative lengthening of telomeres, and TERT activation by promoter mutation, rearrangement or hypermethylation are associated with metastatic disease (Casey and Lussey-Lepoutre 2026).
PASS parameter
Points
Source
Large nests or diffuse growth
2
Thompson 2002
Focal or confluent necrosis
2
Thompson 2002
High cellularity
2
Thompson 2002
Tumor cell spindling
2
Thompson 2002
Cellular monotony
2
Thompson 2002
Mitoses >3 per 10 high-power fields
2
Thompson 2002
Atypical mitotic figures
2
Thompson 2002
Extension into periadrenal adipose tissue
2
Thompson 2002
Vascular invasion
1
Thompson 2002
Capsular invasion
1
Thompson 2002
Profound nuclear pleomorphism
1
Thompson 2002
Nuclear hyperchromasia
1
Thompson 2002
Interpretation
≥4: potential for aggressive behavior; <4: benign behavior in the original series
Thompson 2002
GAPP parameter
Finding and points
Source
Histologic pattern
Zellballen 0; large irregular nests 1; pseudorosettes (even focal) 1
Kimura 2026
Cellularity
Low (<150 cells per unit) 0; moderate (150–250) 1; high (>250) 2
Kimura 2026
Comedo-type necrosis
Absent 0; present 2
Kimura 2026
Capsular or vascular invasion
Absent 0; present 1
Kimura 2026
Ki-67 labeling index
<1% 0; 1%–3% 1; >3% 2
Kimura 2026
Catecholamine type
Epinephrine type 0; norepinephrine type 1; non-functional 0
Kimura 2026
Grade
0–2 well differentiated; 3–6 moderately differentiated; 7–10 poorly differentiated
Kimura et al. 2014
PASS performance. PASS was built from 50 histologically benign and 50 malignant adrenal pheochromocytomas (Thompson 2002). Its strength is a high negative predictive value, and its clinical use is limited by interobserver variation (Casey and Lussey-Lepoutre 2026).
GAPP performance. In 163 tumors including 40 metastatic tumors, mean GAPP scores were 2.08 in non-metastatic and 5.33 in metastatic tumors. Five-year survival was 100%, 66.8% and 22.4% for well, moderately and poorly differentiated tumors. SDHB was negative in 13 moderately or poorly differentiated tumors, and 10 of the 13 metastasized (Kimura et al. 2014). A modified GAPP adds SDHB immunohistochemistry (Casey and Lussey-Lepoutre 2026).
COPPS. The Composite Pheochromocytoma/paraganglioma Prognostic Score combines size >7 cm, necrosis, vascular invasion and loss of S100 and/or SDHB staining. A score of 3 or more predicted metastasis with 100% sensitivity and 95% specificity in the initial series (Casey and Lussey-Lepoutre 2026).
Hereditary pheochromocytoma and paraganglioma
Another 30%–40% of apparently sporadic tumors carry somatic drivers (Casey and Lussey-Lepoutre 2026). Up to 80% of pediatric PPGLs are hereditary (Casey and Lussey-Lepoutre 2026), compared with at least 40% of adult PPGLs (CAP 2025a), and germline testing is recommended for every child (Casey and Lussey-Lepoutre 2026). The SDHx genes account for about half of hereditary paragangliomas (Casey and Lussey-Lepoutre 2026).
Mixed adrenergic and noradrenergic; bilateral or multiple pheochromocytomas
Nuclear MAX loss in 9 of 13 pheochromocytomas in one series
Kimura 2026; CAP 2025a
FH
Hereditary leiomyomatosis and renal cell cancer
Pseudohypoxia cluster
FH loss, 2SC positive
CAP 2025a
EPAS1 (HIF2A)
Pseudohypoxia cluster; somatic or germline
Noradrenergic
Not part of the CAP molecular immunohistochemistry panel
Casey and Lussey-Lepoutre 2026
Associated tumors. Hereditary PPGL syndromes are associated with gastrointestinal stromal tumors, renal cell carcinomas and pituitary neuroendocrine tumors (CAP 2025a). Paragangliomas in unusual sites such as the duodenum and colorectum have shown SDHB loss with confirmed SDHB mutation (Kimura 2026).
Multifocality. Multiple pheochromocytomas, a pheochromocytoma with an extra-adrenal paraganglioma, or multifocal extra-adrenal paragangliomas prompt genetic testing and are recorded in the synoptic report (CAP 2025a).
Composite pheochromocytoma and paraganglioma
Definition. A composite PPGL combines a typical PPGL with a developmentally related component: ganglioneuroma (mature or maturing), ganglioneuroblastoma (nodular or intermixed), neuroblastoma (undifferentiated, poorly differentiated or differentiating) or malignant peripheral nerve sheath tumor. The 2022 classification proposes a minimum of 5% for each element, which requires thorough sampling (CAP 2025a).
Diagnosis. Scattered ganglion-like cells or degenerated neuropil-like stroma do not make a tumor composite. Neuroblastic elements are classified with INPC criteria, and their extent and mitosis-karyorrhexis index can be documented. PHOX2B and S100 or SOX10 highlight ganglioneuronal elements and Schwannian stroma (CAP 2025a).
Genetics. Composite PPGLs occur with pathogenic RET, MAX and NF1 variants (CAP 2025a). Composite pheochromocytoma in NF1 contains ganglioneuroma with many ganglion cells and nerve bundles (Kimura 2026).
Renamed entities and paraganglioma at specific sites
Cauda equina neuroendocrine tumor. The tumor formerly called cauda equina paraganglioma is an epithelial neuroendocrine tumor in the 2022 classification and is not reported with the PPGL protocol (Mete et al. 2022; CAP 2025a).
CoGNET. Duodenal gangliocytic paraganglioma is renamed composite gangliocytoma/neuroma and neuroendocrine tumor because its neuronal and glial elements are integral and its neuroendocrine component is epithelial. Middle ear and spinal tumors have also been reclassified as epithelial NETs (Rindi et al. 2022; Mete et al. 2022).
Head and neck paraganglioma. Head and neck paragangliomas are classified by site as carotid body, jugulotympanic, vagal, laryngeal and aorticopulmonary paragangliomas (Kimura 2026).
Staging and reporting of pheochromocytoma and paraganglioma (AJCC 8th edition and CAP 1.0.0.0)
The AJCC 8th edition stages pheochromocytoma and extra-adrenal sympathetic paraganglioma by size, location and invasion of the primary tumor, regional nodes and the site of distant metastasis. Bone-only metastasis carries longer survival than lung or liver metastasis. No TNM classification exists for parasympathetic and composite tumors, and the CAP authors encourage applying the same template for uniform data collection (CAP 2025a).
Category
Definition
Source
T1
Pheochromocytoma <5 cm, no extra-adrenal invasion
CAP 2025a
T2
Pheochromocytoma ≥5 cm, or sympathetic paraganglioma of any size, no extra-adrenal invasion
CAP 2025a
T3
Tumor of any size invading surrounding organs or tissues (liver, pancreas, spleen, kidneys)
CAP 2025a
N1
Regional lymph node metastasis
CAP 2025a
M1a / M1b / M1c
Bone only / distant lymph nodes, liver or lung only / bone plus multiple other sites
CAP 2025a
Stage 1
T1 N0 M0
CAP 2025a
Stage 2
T2 N0 M0
CAP 2025a
Stage 3
T1–T2 N1 M0, or T3 any N M0
CAP 2025a
Stage 4
Any T, any N, M1
CAP 2025a
CAP 1.0.0.0 element
Responses and rules
Source
Functional status
Metanephrine/adrenaline, normetanephrine/noradrenaline, 3-methoxytyramine/dopamine, non-functional or not tested
CAP 2025a
Tumor number, location and size
Unifocal or multifocal; intra-adrenal or extra-adrenal site; size of the dominant and second tumors
CAP 2025a
Histologic type
Paraganglioma; pheochromocytoma; micro-pheochromocytoma; composite paraganglioma or pheochromocytoma with the composite element named
CAP 2025a
Necrosis, angioinvasion and lymphatic invasion
Each reported separately; angioinvasion requires tumor through a vessel wall with tumor–thrombus complex or intravascular tumor admixed with thrombus; CD61 highlights platelets
Neuroblastic tumors: neuroblastoma, ganglioneuroblastoma and ganglioneuroma
Sites and presentation. More than 70% of neuroblastomas arise in the abdomen, in the adrenal gland or paravertebral sympathetic chain, and the posterior mediastinum is the second most common site. Cervical tumors may cause Horner syndrome, and any neuroblastoma can extend through the spinal foramina as a dumbbell mass (CAP 2025b). About 90% take up MIBG (CAP 2025b).
Paraneoplastic syndromes. Opsoclonus-myoclonus ataxia syndrome occurs with 2%–4% of neuroblastic tumors, and these tumors nearly always contain extensive lymphoid infiltrates with follicles. VIP-secreting tumors cause watery diarrhea and are usually differentiating neuroblastoma or ganglioneuroblastoma with a better prognosis. ROHHAD syndrome is usually associated with ganglioneuroma (CAP 2025b).
Urinary catecholamines. VMA and HVA are increased and support the diagnosis, but they are no longer part of the International Neuroblastoma Response Criteria (CAP 2025b).
INPC category
Schwannian stroma and composition
Source
Neuroblastoma (Schwannian stroma-poor)
Neuroblastic nests separated by delicate septa; Schwannian stroma <50%
Ganglioneuromatous component >50% with randomly distributed microscopic nests of neuroblasts in various stages of differentiation within neuropil; no macroscopic hemorrhagic nodules
CAP 2025b
Ganglioneuroma (Schwannian stroma-dominant), maturing or mature
Schwannian stroma with individual or clustered maturing and mature ganglion cells; no neuroblasts with naked neuritic processes
CAP 2025b
Ganglioneuroblastoma, nodular (composite)
One or more grossly visible, often hemorrhagic neuroblastoma nodules in a ganglioneuroblastoma, intermixed, or ganglioneuroma background
CAP 2025b
Neuroblastoma subtype
Definition
Source
Undifferentiated
No neuropil and no differentiation; diagnosis relies on immunohistochemistry or molecular studies; may show a starry-sky pattern
CAP 2025b
Poorly differentiated
Neuropil present; <5% of cells are differentiating neuroblasts
CAP 2025b
Differentiating
>5% differentiating neuroblasts (enlarged vesicular nucleus with a single prominent nucleolus and eosinophilic or amphophilic cytoplasm twice the nuclear diameter)
CAP 2025b
Mitosis-karyorrhexis index (MKI)
Mitotic and karyorrhectic cells per 5000 neuroblastic cells
Source
Low
<100 (<2%)
CAP 2025b
Intermediate
100–200 (2%–4%)
CAP 2025b
High
>200 (>4%)
CAP 2025b
Age
Favorable histology
Unfavorable histology
Source
Any age
Ganglioneuroma; ganglioneuroblastoma, intermixed
Undifferentiated neuroblastoma (any MKI); any neuroblastoma with high MKI
CAP 2025b
<18 months
Poorly differentiated or differentiating neuroblastoma with low or intermediate MKI
Undifferentiated or high MKI
CAP 2025b
18 months to <5 years
Differentiating neuroblastoma with low MKI
Poorly differentiated neuroblastoma (any MKI); differentiating neuroblastoma with intermediate or high MKI
CAP 2025b
≥5 years
None among neuroblastomas
Neuroblastoma of any subtype and any MKI
CAP 2025b
Nodular ganglioneuroblastoma
Nodule meets favorable criteria for age
Nodule meets unfavorable criteria for age; the least favorable nodule decides
CAP 2025b
Basis of INPC. The International Neuroblastoma Pathology Classification is an age-linked system modeled on the Shimada classification, using neuroblast differentiation, MKI and Schwannian stroma (Shimada et al. 1999). The original INPC classified all nodular ganglioneuroblastomas as unfavorable, and the 2003 revision divides them into favorable and unfavorable subsets by grading the nodules (CAP 2025b).
Treated tumors. INPC does not apply after chemotherapy. Treated tumors show maturation toward ganglioneuroma, necrosis with hemorrhage, calcification and fibrosis, or no effect. Once assigned before treatment, the favorable or unfavorable designation never changes (CAP 2025b).
Sampling. At least one section per centimeter is taken, every nodule and hemorrhagic focus is sampled, and at least 1 g of viable tumor is kept for MYCN, ploidy and segmental chromosomal studies (CAP 2025b).
Immunohistochemistry. PHOX2B is the most sensitive and specific marker of neuroblastoma, though it also stains all peripheral neuroblastic tumors and PPGLs. It separates neuroblastoma from Ewing sarcoma and alveolar rhabdomyosarcoma and detects marrow metastases. PGP9.5, CD56, NB84, synaptophysin and neuron-specific enolase are less specific, Schwann cells express S100, and undifferentiated cells occasionally express vimentin (CAP 2025b).
Molecular finding
Significance
Source
MYCN amplification (2p)
Most prognostically relevant alteration; high risk; undifferentiated or poorly differentiated tumors with high MKI; double minutes or homogeneously staining regions; amplified when MYCN signals exceed chromosome 2 signals at least threefold by FISH (CAP); the INRG consensus uses a >4-fold increase over the 2q reference probe and calls lesser increases 2p24 gain (Ambros et al. 2009)
CAP 2025b; Ambros et al. 2009
Genotype–phenotype discordance
MYCN-amplified tumors with favorable histology lack active N-myc and bull's-eye nucleoli; non-amplified tumors with unfavorable histology often express C-myc
High risk; whole-chromosome changes indicate lower risk
CAP 2025b
ALK
Kinase-domain mutations in 8%–10% and amplification in about 2%; germline in familial neuroblastoma; ALK immunohistochemistry does not predict mutation
CAP 2025b
DNA index
Hyperdiploid (near-triploid) tumors favorable; near-diploid or tetraploid unfavorable; effect limited to patients younger than 1 year
CAP 2025b
ATRX, TERT
ATRX mutations in 2%–3% overall but most high-stage tumors of older children and adolescents; TERT rearrangements in high-risk tumors; MYCN, ATRX and TERT groups barely overlap
CAP 2025b
PHOX2B
Germline mutations frequent in familial neuroblastoma, rare in sporadic tumors
CAP 2025b
Staging and risk. The International Neuroblastoma Risk Group Staging System uses pretreatment imaging, age and clinical extent: L1 (localized without image-defined risk factors and confined to one compartment), L2 (locoregional with one or more image-defined risk factors), M (distant metastasis) and MS (metastases confined to skin, liver and/or bone marrow in children younger than 18 months). Pretreatment risk groups combine INRGSS stage, age, histologic category, MYCN status, 11q aberration and ploidy. The pathologist is not required to report stage (CAP 2025b). L1 and L2 are separated by the absence or presence of one or more of 20 image-defined risk factors, and 5-year event-free survival was 90% for L1 versus 78% for L2 in 661 European patients (Monclair et al. 2009).
CAP Neuroblastoma 5.0.0.1 element (resection)
Responses
Source
Treatment history and age group
No preoperative therapy or therapy given; <18 months, 18 months to <5 years, ≥5 years
CAP 2025b
Tumor site and size
Adrenal or periadrenal, retroperitoneal, thoracic paraspinal, cervical or other
CAP 2025b
Histologic type
Neuroblastoma; ganglioneuroblastoma, nodular (with number of nodules) or intermixed; ganglioneuroma, maturing or mature; unclassifiable; treated neuroblastic tumor
CAP 2025b
Differentiation and MKI
Reported for untreated neuroblastic components
CAP 2025b
INPC
Favorable or unfavorable with the defining combination; not applicable after chemotherapy
CAP 2025b
Lymph nodes and distant sites
Nodes examined and involved
CAP 2025b
MYCN status and molecular studies
Required for all tumors except ganglioneuroma and post-therapy resections; segmental chromosomal aberrations and method optional
CAP 2025b
Common classification framework for neuroendocrine neoplasms
The IARC–WHO common framework uses "neuroendocrine neoplasm" (NEN) for all neoplasms with predominant neuroendocrine differentiation. Epithelial NENs form two families: well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Paragangliomas, the non-epithelial NENs, form a third family (Rindi et al. 2018). The WHO 2022 endocrine classification consolidates this nomenclature (Rindi et al. 2022).
Family
Epithelial
Grade
Defining features
Source
Neuroendocrine tumor (NET)
Yes
G1, G2 or G3 by mitotic count and Ki-67 at most sites
Well differentiated; keratin positive
Rindi et al. 2018; Rindi et al. 2022; Kimura 2026
Neuroendocrine carcinoma (NEC)
Yes
High grade by definition; not formally graded
Poorly differentiated; small cell or large cell type; TP53 and RB1 alterations; may be mixed with adenocarcinoma or squamous carcinoma
Rindi et al. 2018
Paraganglioma (including pheochromocytoma)
No
No formal grade
Keratin negative; GATA3 and catecholamine enzymes positive; sustentacular cells
Rindi et al. 2018; Mete et al. 2022
Grading parameters. Mitoses are counted per mm², ideally in up to 10 mm² and expressed per 2 mm² in lung and pancreas. Ki-67 is counted in hot spots of at least 0.4 mm² with a validated antibody (MIB1). Necrosis is recorded as punctate or geographic. Reports state the site-specific WHO term first and the uniform framework term in brackets (Rindi et al. 2018).
G3 NET versus NEC. Somatostatin receptor expression and molecular immunohistochemistry separate them (Rindi et al. 2022).
Biomarkers. INSM1, synaptophysin, chromogranins and somatostatin receptors confirm neuroendocrine differentiation. Transcription factors identify the site of origin of a metastasis of unknown primary, and hormones, enzymes and keratins support functional and structural correlation. Mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN) and amphicrine tumors are defined in the 2022 classification (Rindi et al. 2022).
Site of origin of metastatic NET. A first-round panel assigns metastatic well-differentiated NETs to presumed midgut origin (CDX2-positive, ISL1- and PAX6-negative) or a pancreatic pattern (ISL1 and/or PAX6 positive), which is also typical of rectal and duodenal NETs. SATB2 is strongly positive in 96% of rectal NETs. OTP is the preferred bronchopulmonary marker and is about twice as sensitive as TTF-1 (30%–40%). ISL1 is also expressed by medullary thyroid carcinoma and PPGL (Bellizzi 2020).
Site
Site-specific rule within the framework
Source
Lung and thymus
Typical carcinoid is NET G1 and atypical carcinoid NET G2; small cell carcinoma and large cell neuroendocrine carcinoma are NECs; G3 atypical carcinoid is not a validated pulmonary entity
Rindi et al. 2018
Pancreas
NET G1–G3 and NEC; G3 NETs at least as frequent as NECs
Rindi et al. 2018
Pituitary
Pituitary neuroendocrine tumors are NETs classified by cell lineage; NECs do not occur
Adenomas, atypical tumors and carcinomas are parathyroid NETs; NECs are extremely unusual
Rindi et al. 2018
Adrenal medulla and paraganglia
Paragangliomas; NECs do not occur
Rindi et al. 2018
Digestive tract
Most high-grade NENs are NECs with TP53 and RB1 mutations
Rindi et al. 2018
Pituitary and Sellar Region Pathology: Pituitary Neuroendocrine Tumors, Hypophysitis, Craniopharyngioma, Rathke Cleft Cyst and Posterior Pituitary Tumors
Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), separates anterior lobe (adenohypophyseal), posterior lobe (neurohypophyseal) and hypothalamic tumors. Anterior lobe tumors are pituitary neuroendocrine tumors (PitNETs; formerly pituitary adenomas), pituitary blastoma and the two types of craniopharyngioma. Routine immunohistochemistry for PIT1, TPIT, SF1, GATA3 and ERα is endorsed, the null cell tumor is reserved for PitNETs without lineage differentiation, and "metastatic PitNET" replaces "pituitary carcinoma" to avoid confusion with neuroendocrine carcinoma (Asa et al. 2022). The pituitary classification first appeared in the 5th edition CNS volume (2021) and was revised in the endocrine volume (2022) (Lopes 2025). Previous rule (4th edition, 2017): pituitary adenomas were classified by adenohypophyseal cell lineage with pituitary transcription factors, the concept of "a hormone-producing pituitary adenoma" was abandoned, null cell adenoma required negativity for transcription factors and hormones, "atypical pituitary adenoma" was no longer recommended, and routine electron microscopy was not required (Mete and Lopes 2017). The CAP Pituitary Neuroendocrine Tumor (PitNET) protocol, version 1.0.0.0, is a new protocol posted in March 2025. It is recommended for clinical care and is not required for accreditation, and no TNM staging exists for sellar tumors (CAP 2025).
Normal pituitary: anatomy, histology and transcription factor lineages
Adenohypophysis. Hormone-producing cells form acini outlined by an intact reticulin network. Folliculostellate cells are GFAP- and S100-positive sustentacular cells that surround the acini (Hacioglu et al. 2025).
Neurohypophysis. Pituicytes of the posterior lobe include major, dark, oncocytic, granular and ependymal types on electron microscopy, and they are the proposed normal counterpart of TTF-1-positive posterior pituitary tumors (Roncaroli and Giannini 2025).
Vascular vulnerability. The location of hormone-secreting cells relative to the vasculature explains why GH and prolactin secretion are lost first after ischemic necrosis, followed by FSH and LH, and then TSH and ACTH (Karaca et al. 2016).
Transcription factor lineage
Cell types
Hormones
Cofactors
Source
PIT1
Somatotroph, lactotroph, thyrotroph
GH, prolactin, TSH
ERα in lactotrophs (predicts dopamine agonist sensitivity); GATA3 in thyrotrophs
CAP 2025; Pandit et al. 2026
TPIT
Corticotroph
ACTH (PAS-positive)
None
CAP 2025
SF1
Gonadotroph
FSH, LH, alpha-subunit
GATA3 and ERα
CAP 2025
Pituitary neuroendocrine tumors: WHO 2022 types and subtypes
TPIT, diffuse strong PAS and ACTH, diffuse cytoplasmic keratin
Densely granulated corticotroph adenoma
CAP 2025; Nasi-Kordhishti et al. 2025
TPIT
Sparsely granulated corticotroph tumor
TPIT, weak and focal PAS and ACTH, diffuse cytoplasmic keratin
Sparsely granulated corticotroph adenoma
CAP 2025; Nasi-Kordhishti et al. 2025
TPIT
Crooke cell tumor
TPIT, peripheral and perinuclear PAS and ACTH, ring-like keratin
Crooke cell adenoma
CAP 2025; Nasi-Kordhishti et al. 2025
SF1
Gonadotroph tumor
SF1, GATA3, ERα, FSH, LH, alpha-subunit
Gonadotroph adenoma
CAP 2025
None
Null cell tumor
No transcription factor or hormone; diagnosis of exclusion
Null cell adenoma
CAP 2025; Mete and Lopes 2017
Multiple
Multilineage PitNET (plurihormonal tumor)
Multiple lineages in one cell population
Plurihormonal adenoma or adenoma with unusual immunohistochemical combination
CAP 2025; Nasi-Kordhishti et al. 2025
Multiple synchronous PitNETs. About 1% of patients have two or more synchronous PitNETs, usually in one specimen. An unusual immunoprofile can reflect two discrete tumors, and each is subtyped separately (CAP 2025; Asa et al. 2022).
Silent corticotroph tumors. Biochemically non-functional densely and sparsely granulated corticotroph tumors were called silent corticotroph tumors types I and II. "Silent" is used only as a clinical designation (CAP 2025).
Shift from hormone-based classification. In 921 tumors, 35.3% were PIT1-positive, 11.9% TPIT-positive and 51.8% SF1-positive, and 0.7% lacked every transcription factor, ERα and GATA3. SF1 reclassified 377 of 397 (95%) 2004 null cell adenomas as gonadotroph tumors. Applying the 2022 criteria changed the overall distribution little; the main change was the division of plurihormonal PIT1-positive tumors into mature (11) and immature (6) types (Nasi-Kordhishti et al. 2025).
Keratin patterns. Low-molecular-weight keratin (CAM5.2 or CK18) is required for PIT1-lineage, TPIT-lineage and null cell tumors. Sparsely granulated somatotroph tumors are defined by fibrous bodies (CAP 2025).
Null cell tumor. A null cell tumor is diagnosed only after excluding other neuroendocrine neoplasms, including keratin-negative sellar paraganglioma and metastatic neuroendocrine neoplasms (CAP 2025).
p27 in corticotroph tumors. Glucocorticoid excess suppresses p27, so loss of nuclear p27 reflects a functioning corticotroph tumor, and clinically silent corticotroph tumors usually retain p27 (CAP 2025).
Molecular correlates.GNAS gain-of-function mutations are found in up to 40% of somatotroph tumors, mainly densely granulated tumors, which are smaller and respond better to somatostatin analogs. Sparsely granulated somatotroph tumors express less SSTR2 and respond poorly to first-generation somatostatin analogs. Germline AIP variants are linked to large, aggressive sparsely granulated somatotroph tumors in young patients (Pandit et al. 2026). USP8 mutations underlie densely granulated corticotroph tumors, and MEN1 mutations are not cell-type specific (Rindi et al. 2018).
Outcome by lineage. After complete resection, recurrence-free survival was 98.3% at 5 years and 89.9% at 10 years. Corticotroph tumors had the highest 10-year recurrence risk (38.3%) (Nasi-Kordhishti et al. 2025).
High-risk, aggressive and metastatic pituitary neuroendocrine tumors
Concept
WHO 2022
Previous rule
Source
High-risk subtypes
Sparsely granulated somatotroph, lactotroph tumor in men, silent corticotroph, Crooke cell, immature PIT1-lineage and acidophil stem cell tumors
Nasi-Kordhishti et al. 2025; Pandit et al. 2026; Casar-Borota et al. 2025; Mete and Lopes 2017
Proliferation-based category
No grade; mitotic count and Ki-67 documented without cut-offs
2004: "atypical adenoma" (Ki-67 ≥3%, extensive p53, increased mitoses), abandoned in 2017 for low predictive value
Casar-Borota et al. 2025; Nasi-Kordhishti et al. 2025; Mete and Lopes 2017
Tumor with distant spread
Metastatic PitNET: metastasis to lymph nodes and distant sites, or discontinuous spread through the central nervous system
Pituitary carcinoma
Casar-Borota et al. 2025; Asa et al. 2022
p53 immunohistochemistry
Removed as a criterion suggestive of aggressiveness
Part of the 2004 atypical adenoma definition
Casar-Borota et al. 2025; Nasi-Kordhishti et al. 2025
Aggressive PitNET. The European Society of Endocrinology defines a clinically aggressive PitNET as a radiologically invasive tumor with unusually rapid growth, or clinically relevant growth or recurrence despite optimal standard therapy (Villa et al. 2025). Functioning corticotroph tumors make up 40%–50% of aggressive tumors, and silent corticotroph and PIT1-lineage tumors are overrepresented among non-functioning ones (Casar-Borota et al. 2025).
Proliferation. Ki-67 >10% was found in 41% of aggressive tumors and 61% of carcinomas in the second ESE survey, and in less than 3% of non-aggressive PitNETs. Ki-67 was ≤3% at first surgery in 15% of 150 aggressive and metastatic tumors, so Ki-67 alone does not predict metastasis (Casar-Borota et al. 2025). PitNETs are not graded by Ki-67 or mitoses because cell type is more informative; Ki-67 is counted from a printed image or by image analysis in hot spots of at least 500 cells, and mitoses are reported per 2 mm² (CAP 2025).
Molecular findings.TP53 and ATRX mutations occur in aggressive tumors and carcinomas, especially corticotroph tumors (Casar-Borota et al. 2025). ATRX loss and p53 alterations are optional CAP elements (CAP 2025).
Invasion. Invasion of the cavernous or sphenoid sinus occurs in up to 40% of resections and is assessed by MRI with the Knosp system. Knosp grades cavernous sinus invasion on coronal MRI against the intracavernous internal carotid artery: 0, medial to the medial tangent; 1, up to the intercarotid line; 2, up to the lateral tangent; 3, lateral to the lateral tangent; 4, complete encasement of the artery. Grades 3 and 4 are invasive. The revised system divides grade 3 into 3A (superior cavernous sinus compartment) and 3B (inferior compartment); in 228 tumors, surgical cure was 56.0% for 3A and 30.0% for 3B, a difference that was not significant (Araujo-Castro et al. 2021). The five-tiered Trouillas classification combines invasion (grade 1 non-invasive, grade 2 invasive) with proliferation (b, at least two of Ki-67 ≥3%, mitoses >2 per 10 high-power fields and >10 strongly p53-positive nuclei per 10 high-power fields); grade 2b tumors had a recurrence or progression rate of 38%–73% across validation cohorts (Villa et al. 2025). Dura, bone, sinus mucosa and brain are the sites of invasion seen in pathology specimens (CAP 2025).
Metastatic sites. Metastatic PitNETs spread most often to liver, bone and brain. Discontinuous CNS spread counts as metastasis, and contiguous infiltration of the hypothalamus does not (CAP 2025).
ICD-O coding. The 5th edition codes all PitNETs as malignant (8272/3), a choice criticized because most PitNETs behave as benign or borderline tumors (Casar-Borota et al. 2025).
CAP PitNET 1.0.0.0 element
Responses and rules
Source
Procedure and specimen
Transsphenoidal or transcranial resection; fresh or fixed; intact or fragmented; ectopic or teratoma-associated tumors noted
CAP 2025
Tumor number
Single or multiple; each tumor reported separately (up to 10)
CAP 2025
Type and subtype
TPIT, PIT1, SF1 lineage, no distinct lineage or NOS, with subtype
CAP 2025
Proliferation
Ki-67 percentage with method (required); mitoses per 2 mm² (optional)
CAP 2025
Histologically confirmed invasion
Dura, bone, sinus mucosa or brain
CAP 2025
Immunohistochemistry
TPIT, PIT1 and SF1 required; ACTH for TPIT tumors; GH, prolactin and β-TSH for PIT1 tumors; low-molecular-weight keratin extent and pattern for PIT1, TPIT and no-lineage tumors; GATA3, ERα, alpha-subunit, FSH, LH, p27, ATRX and p53 optional
Hypophysitis, craniopharyngioma, Rathke cleft cyst or acute hemorrhagic necrosis (apoplexy)
CAP 2025
Pituitary hyperplasia
Reticulin. Hyperplasia expands acini that remain intact on reticulin stain, whereas a PitNET breaks down the acinar architecture (CAP 2025).
Lactotroph hyperplasia of pregnancy. Pituitary volume increases by 120%–136% during pregnancy, peaks in the postpartum period and returns to baseline within 6 months of delivery. The enlargement is caused mainly by estrogen-induced lactotroph hyperplasia, with a tenfold rise in prolactin (Donald et al. 2025). Serial MRI of three women showed a first-trimester dip in anterior lobe volume, a rise of about 17.5% to a peak at 34 weeks and a return to baseline about 3 months postpartum, without significant change in the posterior lobe (Picci et al. 2026). Physiologic hyperplasia can compress the optic apparatus: a pituitary 14 mm high caused visual field loss at 34 weeks and measured 11 mm one month after delivery (Peel et al. 2026).
Thyrotroph hyperplasia. In longstanding primary hypothyroidism, high TRH induces thyrotroph hyperplasia and also lactotroph hyperplasia with hyperprolactinemia. MRI shows a smooth projection of the midline of the gland (the "nipple sign" or dome-shaped enlargement). On follow-up MRI of 77 patients treated with levothyroxine, the enlargement regressed completely in 55 and partially in 17; persistent enlargement raises the possibility of a coexisting PitNET (Roux et al. 2024).
Pituitary apoplexy and Sheehan syndrome
Pituitary apoplexy. Pituitary apoplexy is an acute, potentially fatal syndrome caused by hemorrhage and/or infarction of the pituitary gland. The term was introduced in 1950 to describe sudden deaths with hemorrhagic necrosis of PitNETs at autopsy. Precipitating factors are present in up to 30% of cases and include anticoagulant and antiplatelet drugs, dopamine agonists, GnRH agonist therapy and pregnancy. Visual defects occur in up to 75% and ophthalmoplegia in 50%–70%, and about 70% develop central adrenal insufficiency (corticotropin deficiency) (Iglesias 2024).
Sheehan syndrome. Sheehan syndrome is hypopituitarism from necrosis of a pituitary enlarged by pregnancy after massive postpartum hemorrhage. Small sella size, vasospasm and thrombosis predispose, and autoimmunity may contribute to progressive loss. Symptoms range from failure to lactate and fatigue to severe adrenal crisis, usually appear years after delivery, and the syndrome remains an important cause of hypopituitarism in developing countries (Karaca et al. 2016).
Hypophysitis
Hypophysitis is inflammation of the pituitary and/or infundibulum. It is classified as primary or secondary and by location as adenohypophysitis, neurohypophysitis, infundibuloneurohypophysitis or panhypophysitis (Iglesias 2026). Primary hypophysitis is traditionally lymphocytic, granulomatous, necrotizing or IgG4-related, and it often mimics a PitNET and requires histologic confirmation (Turin and Kleinschmidt-DeMasters 2026).
Type
Histology
Clinical associations
Source
Lymphocytic
CD4-positive T cells with B cells and plasma cells
Prototypical primary type; historically young women in pregnancy or postpartum; biopsied cases mainly lack known risk factors
Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Granulomatous
Granulomas with multinucleated giant cells and variable fibrosis; may contain many IgG4-positive plasma cells
Rare; secondary causes excluded first
Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Xanthomatous
Foamy CD68-positive histiocytes, S100 and CD1a negative; preserved reticulin and vascular networks
Mimics a neoplasm clinically and radiologically
Deodhare et al. 1999
Necrotizing
Less histologically uniform than lymphocytic hypophysitis; may contain many IgG4-positive plasma cells
Less common than lymphocytic hypophysitis
Turin and Kleinschmidt-DeMasters 2026
IgG4-related
Dense IgG4-positive plasma cells and storiform fibrosis with lymphoplasmacytic inflammation
Autoimmune pancreatitis, salivary or lacrimal enlargement, retroperitoneal fibrosis, pachymeningitis; IgG4-positive cells are also abundant in granulomatosis with polyangiitis
Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Immune checkpoint inhibitor-related
Inflammatory infiltration with gland enlargement after CTLA-4 blockade
CTLA-4 inhibitors (ipilimumab, tremelimumab): multiple axes and enlargement; PD-1/PD-L1 inhibitors: isolated ACTH deficiency with little radiologic inflammation
Iglesias 2026
Anti-PIT1 hypophysitis
Cytotoxic T cells targeting PIT1-expressing cells
Thymoma or other malignancy; GH, prolactin and TSH deficiency
Iglesias 2026
Secondary hypophysitis and mimics. Germ cell tumors, Langerhans cell histiocytosis, metastases, lymphoma, sarcoidosis and tuberculosis enter the differential diagnosis and may require transsphenoidal biopsy (Iglesias 2026).
Rathke cleft cyst and craniopharyngioma
Rathke cleft cyst. A true Rathke cleft cyst is lined by ciliated cuboidal or columnar epithelium with occasional goblet cells and squamous metaplasia, and it contains mucoid or serous fluid. A large autopsy series found Rathke cleft cysts in 11.3% of pituitaries (Hacioglu et al. 2025).
BRAF VE1 staining of cilia. The BRAF V600E (VE1) antibody cross-reacts with axonemal dyneins and stains cilia, so ciliated Rathke cleft cyst epithelium can stain without a BRAF mutation, and sequencing has not shown BRAF mutations in Rathke cleft cysts. CTNNB1 mutations were found in 77% of craniopharyngiomas, all adamantinomatous, and in none of 10 Rathke cleft cysts (Hacioglu et al. 2025).
Genetics of craniopharyngioma. Whole-exome sequencing found CTNNB1 mutations in 11 of 12 adamantinomatous craniopharyngiomas and BRAF V600E in all 3 papillary tumors. Targeted genotyping confirmed BRAF V600E in 95% (36 of 39) of papillary and CTNNB1 mutations in 96% (51 of 53) of adamantinomatous craniopharyngiomas. The mutations are clonal, mutually exclusive and the only recurrent alterations (Brastianos et al. 2014).
Feature
Adamantinomatous craniopharyngioma
Papillary craniopharyngioma
Source
Age
Bimodal, 5–14 and 50–74 years; almost all childhood craniopharyngiomas
Almost exclusively adults, 40–55 years
Meyer et al. 2025
Imaging
Lobulated, frequent calcification
Spherical, predominantly solid
Meyer et al. 2025
Histology
Cords, lobules and nodular whorls bordered by palisaded columnar epithelium; anucleate "ghost cells" (wet keratin); cysts with debris, fibrosis and cholesterol; finger-like invasive protrusions
Monomorphic sheets of well-differentiated squamous epithelium around fibrovascular cores; may contain ciliated epithelium and PAS-positive goblet cells resembling Rathke cleft cyst
Meyer et al. 2025
Driver
CTNNB1 (β-catenin) mutation with nuclear β-catenin accumulation
BRAF p.V600E
Brastianos et al. 2014; Hacioglu et al. 2025
Targeted therapy. The BRAF V600E mutation of papillary craniopharyngioma allows treatment with BRAF inhibitors (dabrafenib, vemurafenib) and MEK inhibitors (Meyer et al. 2025).
Posterior pituitary tumors: the pituicyte tumor family
Tumors of the posterior pituitary and infundibulum share nuclear TTF-1 expression and lack chromogranin A, INSM1, pituitary hormones and lineage-restricted pituitary transcription factors. They account for about 0.2% of adult sellar tumors and peak at 50–60 years. The 2022 endocrine classification treats them as one entity with variants, whereas the 2021 CNS classification keeps pituicytoma, spindle cell oncocytoma and granular cell tumor as distinct tumors and omits sellar ependymoma (Roncaroli and Giannini 2025; Asa et al. 2022). Previous rule (4th edition, 2017): pituicytoma, spindle cell oncocytoma, granular cell tumor of the neurohypophysis and sellar ependymoma were a morphologic spectrum of a single TTF-1-expressing entity (Mete and Lopes 2017).
WHO 2022 name
Former name
Histology and immunohistochemistry
Behavior
Source
Pituicytoma
Pituicytoma
Fascicles of bipolar spindle cells; TTF-1, S100 and vimentin positive, GFAP variable
Most common tumor of the group
Roncaroli and Giannini 2025
Oncocytic pituicytoma
Spindle cell oncocytoma
Spindle or epithelioid cells with granular eosinophilic cytoplasm from abundant mitochondria; TTF-1, S100, vimentin; hypervascular, hemosiderin on MRI; MAPK alterations including HRAS and BRAF V600E
Recurrence or progression in 27%; responses to MAPK inhibitors reported
Roncaroli and Giannini 2025
Granular cell pituicytoma
Granular cell tumor of the sellar region (neurohypophysis)
Sheets of large cells with intensely eosinophilic granular PAS-positive cytoplasm; TTF-1, S100, CD68, alpha-1-antitrypsin, cathepsin B
Recurrence or progression in 5%
Roncaroli and Giannini 2025
Ependymal pituicytoma
Sellar ependymoma
Spindled to epithelioid cells with perivascular pseudorosettes, true ependymal rosettes and follicle-like structures; EMA membranous, luminal and paranuclear dot-like
Very rare
Roncaroli and Giannini 2025; Asa et al. 2022
TTF-1 in oncocytic sellar tumors. TTF-1 positivity separates oncocytic pituicytoma from an oncocytic null cell tumor or thyrotroph PitNET (Pandit et al. 2026).
Lesions outside the 2022 classification. Primary papillary epithelial tumor of the sella (TTF-1-positive) and sellar atypical teratoid/rhabdoid tumor are not described in the 2022 endocrine classification (Roncaroli and Giannini 2025).
Pituitary blastoma, hypothalamic tumors and other sellar lesions
Pituitary blastoma. Pituitary blastoma is a dysontogenetic tumor of infancy, first described in 2008 and strongly suggestive of DICER1 syndrome. In 17 children (median age 11 months, range 2–24), Cushing syndrome was the most frequent presentation (10 patients), 16 tumors were attributed to DICER1 abnormalities, 8 patients died, and extent of resection was associated with survival, whereas Ki-67 index and adjuvant therapy were not (Liu et al. 2021). DICER1 RNase IIIb hotspot mutations distort microRNA processing, PRAME is upregulated about 500-fold, the genome is otherwise quiet, and the methylation profile is distinct from other CNS tumors and pituitary adenomas (Nadaf et al. 2021).
Hypothalamic neuronal tumors. Tumors with hypothalamic neuronal differentiation are classified as gangliocytoma (large cells) or neurocytoma (small cells) (Asa et al. 2022).
Sellar lesion
Diagnostic points
Source
Metastasis to the pituitary
Lung (27.7%), breast (18.7%) and renal (14.5%) primaries among 166 reported patients; diabetes insipidus in 41 and hypopituitarism in 55; median survival 9.9 months
Differential diagnosis of hypophysitis and PitNET; biopsy may be required
Iglesias 2026
Craniopharyngioma, germinoma and meningioma
The common non-PitNET sellar tumors
Roncaroli and Giannini 2025
Hypothalamic hamartoma
Developmental lesion attached to the hypothalamus with gelastic seizures, drug-resistant epilepsy, endocrine dysfunction and developmental delay; somatic variants in Sonic hedgehog and primary cilia pathway genes in about half of nonsyndromic cases, with GLI3, OFD1 or PRKACA variants in 7 of 9 resected lesions in one cohort
Jacobs and Hildebrand 2025; Sami et al. 2024
Sellar chordoma
Arises from notochordal remnants, usually in bone adjacent to or above the sella; about 1% of malignant bone tumors and 0.2% of intracranial tumors; brachyury, EMA and keratin (CK8/18) positive; can coexist with a PitNET as a collision tumor
Gao et al. 2025
References
Agaimy A, Witkowski L, Stoehr R, et al. Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations: is the term "thyroblastoma" more appropriate? Virchows Arch. 2020;477(6):787–798. doi:10.1007/s00428-020-02853-1. PMID 32507920
Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95(1):14–21. PMID 6691181
Akirov A, Asa SL, Larouche V, et al. The clinicopathological spectrum of parathyroid carcinoma. Front Endocrinol (Lausanne). 2019;10:731. doi:10.3389/fendo.2019.00731. PMID 31708875
Albright S, Isaacson A, Robinson R. Discrepancies with final diagnosis in head and neck intraoperative frozen section. Head Neck Pathol. 2026;20(1):91. doi:10.1007/s12105-026-01959-3. PMID 42599558
Aloini ME, Manella S, Biondo I, et al. Bilateral adrenal hemorrhage: learning notes from clinical practice and literature review. Front Endocrinol (Lausanne). 2023;14:1233710. doi:10.3389/fendo.2023.1233710. PMID 38027193
Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471–1482. doi:10.1038/sj.bjc.6605014. PMID 19401703
Araujo-Castro M, Acitores Cancela A, Vior C, et al. Radiological Knosp, revised-Knosp, and Hardy–Wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases. Front Oncol. 2021;11:807040. doi:10.3389/fonc.2021.807040. PMID 35127519
Arcovito G, Franchi A. Thyroid angiosarcoma: a comprehensive review. Semin Diagn Pathol. 2026;43(1):150979. doi:10.1016/j.semdp.2025.150979. PMID 41418536
Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6–26. doi:10.1007/s12022-022-09703-7. PMID 35291028 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition; abstract)
Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612–1619. doi:10.1097/00000478-200212000-00009. PMID 12459628
Bai Y, Kakudo K, Jung CK. Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization classification. Endocrinol Metab (Seoul). 2020;35(4):696–715. doi:10.3803/EnM.2020.807. PMID 33261309
Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022;33(1):27–63. doi:10.1007/s12022-022-09707-3. PMID 35288841
Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020;96:8–33. doi:10.1016/j.humpath.2019.12.002. PMID 31857137
Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol. 2004;12(3):231–243. doi:10.1177/106689690401200304. PMID 15306935
Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol. 2011;42(12):1873–1877. doi:10.1016/j.humpath.2011.02.004. PMID 21663937
Botros MA, Estafanous LA. Adrenal collision tumors: a practical application of the existing evidence. Endocr Pract. 2026. doi:10.1016/j.eprac.2026.10.001. PMID 42906884
Boyraz B, Sadow PM, Asa SL, et al. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol. 2021;32(3):327–335. doi:10.1007/s12022-021-09683-0. PMID 34019236
Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2005;257(1):18–26. doi:10.1111/j.1365-2796.2004.01421.x. PMID 15606373
Brancatella A, Torregrossa L, Viola N, et al. In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features. J Endocrinol Invest. 2023;46(8):1695–1703. doi:10.1007/s40618-023-02044-0. PMID 36840841
Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46(2):161–165. doi:10.1038/ng.2868. PMID 24413733
Camatti J, Santunione AL, Cecchi R, et al. Fatal Waterhouse–Friderichsen syndrome at autopsy: a systematic review and forensic diagnostic framework. Int J Legal Med. 2026. doi:10.1007/s00414-026-03978-9. PMID 42665693
Cameselle-Teijeiro JM, Eloy C, Sobrinho-Simões M. Pitfalls in challenging thyroid tumors: emphasis on differential diagnosis and ancillary biomarkers. Endocr Pathol. 2020;31(3):197–217. doi:10.1007/s12022-020-09638-x. PMID 32632840
Capalbo D, Esposito A, Gaeta V, et al. The multiple faces of autoimmune Addison's disease in children. Front Endocrinol (Lausanne). 2024;15:1411774. doi:10.3389/fendo.2024.1411774. PMID 39351530
Carlsen ED, Davis AR, Cook JR, et al. The distinctive nature of thyroid MALT lymphomas including IRTA1 expression. Am J Surg Pathol. 2023;47(3):370–378. doi:10.1097/PAS.0000000000002005. PMID 36729757
Carney JA, Moore SB, Northcutt RC, et al. Palpation thyroiditis (multifocal granulomatous folliculitis). Am J Clin Pathol. 1975;64(5):639–647. doi:10.1093/ajcp/64.5.639. PMID 1242618
Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32(4):676–680. doi:10.1038/ng1048. PMID 12434154
Casar-Borota O, Burman P, Lopes MB. The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathol. 2025;35(1):e13302. doi:10.1111/bpa.13302. PMID 39218431
Casey RT, Lussey-Lepoutre C. Paraganglioma and phaeochromocytoma: a review of current guidelines and new diagnostic and therapeutic approaches. Endocr Relat Cancer. 2026;33(10). doi:10.1530/ERC-26-0310. PMID 42820462
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391–397. doi:10.1016/j.autrev.2014.01.007. PMID 24434360
Cavarzere P, Mancioppi V, Battiston R, et al. Primary congenital hypothyroidism: a clinical review. Front Endocrinol (Lausanne). 2025;16:1592655. doi:10.3389/fendo.2025.1592655. PMID 40862110
Chaurasia S, Ganvir R, Pandey RK, et al. Gross changes in adrenal glands in suicidal and sudden death cases: a postmortem study. Cureus. 2023;15(12):e51175. doi:10.7759/cureus.51175. PMID 38283486
Chu YH, Kobrossy B, Schwartz D, et al. Secretory carcinoma of the thyroid: a case report and update of literature. Head Neck Pathol. 2024;18(1):84. doi:10.1007/s12105-024-01693-8. PMID 39306639
Clark JR, Lai P, Hall F, et al. Variables predicting distant metastases in thyroid cancer. Laryngoscope. 2005;115(4):661–667. doi:10.1097/01.mlg.0000161337.46892.e0. PMID 15805877
Conti L, Vatrano S, Bertero L, et al. Mitochondrial DNA "common deletion" in post-fine needle aspiration infarcted oncocytic thyroid tumors. Hum Pathol. 2017;69:23–30. doi:10.1016/j.humpath.2017.09.004. PMID 28962946
Cracolici V, Ritterhouse LL, Segal JP, et al. Follicular thyroid neoplasms: comparison of clinicopathologic and molecular features of atypical adenomas and follicular thyroid carcinomas. Am J Surg Pathol. 2020;44(7):881–892. doi:10.1097/PAS.0000000000001489. PMID 32282345
Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken). 2010;62(9):1312–1318. doi:10.1002/acr.20215. PMID 20506114
Decmann Á, Perge P, Tóth M, et al. Adrenal myelolipoma: a comprehensive review. Endocrine. 2018;59(1):7–15. doi:10.1007/s12020-017-1473-4. PMID 29164520
Deodhare SS, Bilbao JM, Kovacs K, et al. Xanthomatous hypophysitis: a novel entity of obscure etiology. Endocr Pathol. 1999;10(3):237–241. doi:10.1007/BF02738885. PMID 12114704
Donald DM, Tomkins M, O'Reilly MW, et al. Pituitary disorders in pregnancy. Clin Med (Lond). 2025;25(5):100488. doi:10.1016/j.clinme.2025.100488. PMID 40744144
Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771–787. doi:10.1136/jclinpath-2015-203186. PMID 26163537
Dufour DR, Durkowski C. Sudan IV stain. Its limitations in evaluating parathyroid functional status. Arch Pathol Lab Med. 1982;106(5):224–227. PMID 6176209
Dufour DR, Wilkerson SY. The normal parathyroid revisited: percentage of stromal fat. Hum Pathol. 1982;13(8):717–721. doi:10.1016/s0046-8177(82)80293-1. PMID 7106734
Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37(9):1433–1440. doi:10.1097/PAS.0b013e31828d387b. PMID 23774167
Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol. 2022;33(1):64–89. doi:10.1007/s12022-022-09709-1. PMID 35175514 (summarizes the WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition)
Fackelmayer OJ, Rodriguez ED, Sisk AE Jr, et al. Adrenal schwannoma can be FDG-avid on PET/CT: case report and review of historic institutional pathology. Diagn Pathol. 2023;18(1):112. doi:10.1186/s13000-023-01399-5. PMID 37833805
Falhammar H, Juhlin CC, Barner C, et al. Riedel's thyroiditis: clinical presentation, treatment and outcomes. Endocrine. 2018;60(1):185–192. doi:10.1007/s12020-018-1526-3. PMID 29380231
Farhat NA, Onenerk AM, Krane JF, et al. Primary benign and malignant thyroid neoplasms with signet ring cells: cytologic, histologic, and molecular features. Am J Clin Pathol. 2017;148(3):251–258. doi:10.1093/ajcp/aqx074. PMID 28821194
Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1–G46. doi:10.1530/EJE-18-0608. PMID 30299884
Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1–G42. doi:10.1093/ejendo/lvad066. PMID 37318239
Fatourechi MM, Hay ID, McIver B, et al. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976–2008. Thyroid. 2011;21(7):765–772. doi:10.1089/thy.2010.0453. PMID 21568724
Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88(5):2100–2105. doi:10.1210/jc.2002-021799. PMID 12727961
Folpe AL, Lloyd RV, Bacchi CE, et al. Spindle epithelial tumor with thymus-like differentiation: a morphologic, immunohistochemical, and molecular genetic study of 11 cases. Am J Surg Pathol. 2009;33(8):1179–1186. doi:10.1097/PAS.0b013e31819e61c8. PMID 19417583
Fuchs TL, Bell SE, Chou A, et al. Revisiting the significance of prominent C cells in the thyroid. Endocr Pathol. 2019;30(2):113–117. doi:10.1007/s12022-019-9567-6. PMID 30694510
Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell. 2018;34(2):256–270.e5. doi:10.1016/j.ccell.2018.07.002. PMID 30107176
Gao S, Liu P, Yang S, et al. Case report: collision tumors of the sellar region: pituitary adenoma and chordoma coexist in the sellar region. Front Endocrinol (Lausanne). 2025;16:1605605. doi:10.3389/fendo.2025.1605605. PMID 40600012
Gheorghe AM, Nistor C, Carsote M. Parathyromatosis: the pathogenic background (post-parathyroidectomy seeding or exceptional embryologic remnant) and the importance of a fine clinical index for recurrent primary hyperparathyroidism (a narrative review). J Clin Med. 2025;14(19):6937. doi:10.3390/jcm14196937. PMID 41096017
Ghossein RA, Rosai J, Heffess C. Dyshormonogenetic goiter: a clinicopathologic study of 56 cases. Endocr Pathol. 1997;8(4):283–292. doi:10.1007/BF02739930. PMID 12114789
Gokozan HN, Scognamiglio T. Advances and updates in parathyroid pathology. Adv Anat Pathol. 2023;30(1):24–33. doi:10.1097/PAP.0000000000000379. PMID 36315270
Gopal RK, Kübler K, Calvo SE, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma. Cancer Cell. 2018;34(2):242–255.e5. doi:10.1016/j.ccell.2018.06.013. PMID 30107175
Graff-Baker A, Roman SA, Thomas DC, et al. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery. 2009;146(6):1105–1115. doi:10.1016/j.surg.2009.09.020. PMID 19958938
Grisales J, Sanabria A. Utility of routine frozen section of thyroid nodules classified as follicular neoplasm. Am J Clin Pathol. 2020;153(2):210–220. doi:10.1093/ajcp/aqz152. PMID 31732728
Guan J, Zhao C, Li H, et al. Adenomatoid tumor of the adrenal gland: report of two cases and review of the literature. Front Endocrinol (Lausanne). 2021;12:692553. doi:10.3389/fendo.2021.692553. PMID 34248850
Hacioglu A, Tekiner H, Altinoz MA, et al. Rathke's cleft cyst: from history to molecular genetics. Rev Endocr Metab Disord. 2025;26(2):229–260. doi:10.1007/s11154-025-09949-6. PMID 39939491
Han Q, Xu H. Sclerosing mucoepidermoid carcinoma of the thyroid with eosinophilia: a case report and review of the literature. J Med Case Rep. 2025;19(1):84. doi:10.1186/s13256-025-05096-3. PMID 40022195
Hanaoka D, Shimada S, Miyaoka Y, et al. Presacral myelolipoma mimicking liposarcoma complicated by massive intraoperative hemorrhage: a case report. Surg Case Rep. 2026;12(1):26-452. doi:10.70352/scrj.cr.26-0452. PMID 42996258
Hannan FM, Babinsky VN, Thakker RV. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127–R142. doi:10.1530/JME-16-0124. PMID 27647839
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020. PMID 26462967
Hernandez-Prera JC, Riddle N, Gonzalez RS, et al. Endocrine and neuroendocrine tumors: updates from the 5th edition of the World Health Organization "Blue Book". Arch Pathol Lab Med. 2025;149(12):1114–1135. doi:10.5858/arpa.2024-0315-RA. PMID 40335070
Herndon J, Nadeau AM, Davidge-Pitts CJ, et al. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018;62(3):721–728. doi:10.1007/s12020-018-1737-7. PMID 30178435
Hicks DG, LiVolsi VA, Neidich JA, et al. Clonal analysis of solitary follicular nodules in the thyroid. Am J Pathol. 1990;137(3):553–562. PMID 1975986
Hoekstra AS, Devilee P, Bayley JP. Models of parent-of-origin tumorigenesis in hereditary paraganglioma. Semin Cell Dev Biol. 2015;43:117–124. doi:10.1016/j.semcdb.2015.05.011. PMID 26067997
Holm LE, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312(10):601–604. doi:10.1056/NEJM198503073121001. PMID 3838363
Iacovazzo D, Flanagan SE, Walker E, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A. 2018;115(5):1027–1032. doi:10.1073/pnas.1712262115. PMID 29339498
Iglesias P. Immune-mediated hypophysitis: an updated review. J Clin Med. 2026;15(9):3313. doi:10.3390/jcm15093313. PMID 42123046
Iglesias P. Pituitary apoplexy: an updated review. J Clin Med. 2024;13(9):2508. doi:10.3390/jcm13092508. PMID 38731037
Jacobs J, Hildebrand M. New insights to hypothalamic hamartoma syndrome. Epilepsy Behav. 2025;170:110468. doi:10.1016/j.yebeh.2025.110468. PMID 40393150
Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol. 2021;32(1):17–34. doi:10.1007/s12022-020-09656-9. PMID 33269427
Juhlin CC, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30(2):e220293. doi:10.1530/ERC-22-0293. PMID 36445235
Juhlin CC, Mete O. Avoiding overdiagnosis of parathyroid carcinoma. Virchows Arch. 2026;488(1):159–171. doi:10.1007/s00428-025-04274-4. PMID 41238829
Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab (Seoul). 2022;37(5):703–718. doi:10.3803/EnM.2022.1553. PMID 36193717 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition)
Kakudo K, Bai Y, Liu Z, et al. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules. Gland Surg. 2018;7(Suppl 1):S8–S18. doi:10.21037/gs.2017.08.02. PMID 30175059
Kemp S, Engelen M, Jaspers YRJ. The complex lipidome as a driver of tissue-specific pathology in adrenoleukodystrophy. Mol Neurodegener. 2026;21(1):66. doi:10.1186/s13024-026-00975-9. PMID 42469918
Kemp WL, Koponen MA, Meyers SE. Addison disease: the first presentation of the condition may be at autopsy. Acad Forensic Pathol. 2016;6(2):249–257. doi:10.23907/2016.026. PMID 31239896
Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405–414. doi:10.1530/ERC-13-0494. PMID 24521857
Kimura N. Double faces of pheochromocytoma and paraganglioma: a review of integrated pathologic diagnosis. Endocr J. 2026;73(7):799–810. doi:10.1507/endocrj.EJ25-0559. PMID 41922199
Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472–E1476. doi:10.1210/jc.2011-1043. PMID 21752896
Lam AK. Adrenocortical carcinoma: updates of clinical and pathological features after renewed World Health Organisation classification and pathology staging. Biomedicines. 2021;9(2):175. doi:10.3390/biomedicines9020175. PMID 33578929
Lam AK. Squamous cell carcinoma of thyroid: a unique type of cancer in World Health Organization classification. Endocr Relat Cancer. 2020;27(6):R177–R192. doi:10.1530/ERC-20-0045. PMID 32252028
Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28(3):213–227. doi:10.1007/s12022-017-9484-5. PMID 28477311 (summarizes the WHO Classification of Tumours of Endocrine Organs, 4th edition)
Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf). 2002;56(1):95–101. doi:10.1046/j.0300-0664.2001.01435.x. PMID 11849252
Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066. doi:10.1172/JCI85271. PMID 26878173
Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63–78. doi:10.1159/000345670. PMID 23652671
Li Y, Inomata K, Nishihara E, et al. IgG4 thyroiditis in the Asian population. Gland Surg. 2020;9(5):1838–1846. doi:10.21037/gs-20-417. PMID 33224859
Li Y, Zhou G, Ozaki T, et al. Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease. Mod Pathol. 2012;25(8):1086–1097. doi:10.1038/modpathol.2012.68. PMID 22555173
Liu APY, Kelsey MM, Sabbaghian N, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab. 2021;106(2):351–363. doi:10.1210/clinem/dgaa857. PMID 33236116
Liu Y, Huang X, Hu Y, et al. Hyalinizing trabecular tumor of the thyroid: a clinicopathological analysis of four cases and review of the literature. Int J Clin Exp Pathol. 2017;10(7):7616–7626. PMID 31966606
Liu Y, Liu X, Huang M, et al. The clinical consequences of diagnostic delay in sporadic pediatric MEN2B: a case series of 6 children. Eur J Pediatr. 2026;185(5):253. doi:10.1007/s00431-026-06935-1. PMID 41961175
Liu Z, Zhou G, Nakamura M, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011;102(1):288–294. doi:10.1111/j.1349-7006.2010.01769.x. PMID 21070478
Ljungberg O, Tibblin S. Peroperative fat staining of frozen sections in primary hyperparathyroidism. Am J Pathol. 1979;95(3):633–641. PMID 88183
Lobo M, Johansson E, Kumari S, et al. Resolving thyroid lineage cell trajectories merging into a dual endocrine gland in mammals. Nat Commun. 2026;17(1):6811. doi:10.1038/s41467-026-73385-6. PMID 42185281
Lopes MB. The 5th edition of the WHO classification of pituitary tumors: strengths and limitations. Brain Pathol. 2025;35(1):e13323. doi:10.1111/bpa.13323. PMID 39617421
Mansour Y, Chaltiel L, Cavillon A, et al. Can we improve the diagnosis of invasion in encapsulated follicular-patterned thyroid tumors? Data from a massive international e-learning initiative. Virchows Arch. 2025;487(1):105–116. doi:10.1007/s00428-025-04045-1. PMID 39992439
Martiradonna M, Mazzilli R, Zamponi V, et al. Clinical impact of rare subtypes of parathyroid adenoma: a systematic review. J Pers Med. 2026;16(4):211. doi:10.3390/jpm16040211. PMID 42042578
Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study. Endocr Connect. 2019;8(1):1–7. doi:10.1530/EC-18-0494. PMID 30550378
Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–E765. doi:10.1210/jc.2013-3734. PMID 24476079
Mete O, Asa SL, Gill AJ, et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90–114. doi:10.1007/s12022-022-09704-6. PMID 35285002 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition; abstract)
Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24(12):1545–1552. doi:10.1038/modpathol.2011.119. PMID 21804527
Mete O, Erickson LA, Juhlin CC, et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022;33(1):155–196. doi:10.1007/s12022-022-09710-8. PMID 35288842 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition)
Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228–243. doi:10.1007/s12022-017-9498-z. PMID 28766057 (summarizes the WHO Classification of Tumours of Endocrine Organs, 4th edition; abstract)
Meyer S, Shah SN, Dancel-Manning K, et al. A case-based review of adult-onset craniopharyngioma. Front Endocrinol (Lausanne). 2025;16:1527161. doi:10.3389/fendo.2025.1527161. PMID 40444237
Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298–303. doi:10.1200/JCO.2008.16.6876. PMID 19047290
Morrison R, Khan J, Galloway P, et al. Use of cortisol and adrenal weight at pediatric postmortem. Fetal Pediatr Pathol. 2017;36(3):246–255. doi:10.1080/15513815.2017.1307475. PMID 28394668
Nadaf J, de Kock L, Chong AS, et al. Molecular characterization of DICER1-mutated pituitary blastoma. Acta Neuropathol. 2021;141(6):929–944. doi:10.1007/s00401-021-02283-6. PMID 33644822
Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990;86(1):120–125. doi:10.1172/JCI114673. PMID 1973172
Nasi-Kordhishti I, Hladik M, Kandilaris K, et al. Transcription factor-based classification of pituitary adenomas/PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases. Acta Neuropathol Commun. 2025;13(1):135. doi:10.1186/s40478-025-02050-8. PMID 40579705
Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab. 2011;96(12):E2063–E2071. doi:10.1210/jc.2011-1616. PMID 21956414
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–1029. doi:10.1001/jamaoncol.2016.0386. PMID 27078145
Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–2326. doi:10.1210/jc.2002-021907. PMID 12727991
Nikiforova MN, Nikitski AV, Panebianco F, et al. GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland. Thyroid. 2019;29(2):161–173. doi:10.1089/thy.2018.0791. PMID 30648929
Nilsson M, Mölne J, Jörtsö E, et al. Plasma membrane shedding and colloid vacuoles in hyperactive human thyroid tissue. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;56(2):85–94. doi:10.1007/BF02890006. PMID 2907207
Nixon IJ, Whitcher M, Glick J, et al. Surgical management of metastases to the thyroid gland. Ann Surg Oncol. 2011;18(3):800–804. doi:10.1245/s10434-010-1408-2. PMID 21046263
Nonaka K, Aida J, Takubo K, et al. Correlation between telomere attrition of zona fasciculata and adrenal weight reduction in older men. J Clin Endocrinol Metab. 2020;105(3):dgz214. doi:10.1210/clinem/dgz214. PMID 31745564
Nosé V, Gill A, Teijeiro JMC, et al. Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol. 2022;33(1):197–227. doi:10.1007/s12022-022-09705-5. PMID 35285003
Noussios G, Anagnostis P, Goulis DG, et al. Ectopic thyroid tissue: anatomical, clinical, and surgical implications of a rare entity. Eur J Endocrinol. 2011;165(3):375–382. doi:10.1530/EJE-11-0461. PMID 21715415
Noussios G, Anagnostis P, Natsis K. Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp Clin Endocrinol Diabetes. 2012;120(10):604–610. doi:10.1055/s-0032-1327628. PMID 23174995
Obara T, Fujimoto Y, Aiba M. Stromal fat content of the parathyroid gland. Endocrinol Jpn. 1990;37(6):901–905. doi:10.1507/endocrj1954.37.901. PMID 2101794
Oh HS, Kim SJ, Song E, et al. Modified transverse-vertical gross examination: a better method for the detection of definite capsular invasion in encapsulated follicular-patterned thyroid neoplasms. Endocr Pathol. 2019;30(2):106–112. doi:10.1007/s12022-019-9565-8. PMID 30661168
Orsatti A, De Leo A, Chiarucci F, et al. Multifocal fibrosing thyroiditis: an under-recognized mimicker of papillary thyroid carcinoma. Endocr Pathol. 2022;33(3):335–345. doi:10.1007/s12022-022-09726-0. PMID 35819567
Palumbo VD, Damiano G, Messina M, et al. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241–246. doi:10.7417/CT.2021.2322. PMID 33956045
Pandit N, Wehbeh Y, Itani O, et al. Transcription factor-based classification of pituitary neuroendocrine tumors: practical immunohistochemical algorithms, molecular correlates, and diagnostic challenges in the 5th WHO era. Int J Mol Sci. 2026;27(5):2307. doi:10.3390/ijms27052307. PMID 41828530
Papavramidis TS, Chorti A, Pliakos I, et al. Parathyroid cysts: a review of 359 patients reported in the international literature. Medicine (Baltimore). 2018;97(28):e11399. doi:10.1097/MD.0000000000011399. PMID 29995785
Pavlidis ET, Pavlidis TE. A review of primary thyroid lymphoma: molecular factors, diagnosis and management. J Invest Surg. 2019;32(2):137–142. doi:10.1080/08941939.2017.1383536. PMID 29058491
Peel A, Teasdale S, Morton A. Visual loss during pregnancy due to physiological pituitary hyperplasia. Obstet Med. 2026;19(2):133–136. doi:10.1177/1753495X251338154. PMID 40417147
Peng Y, Wang HH. A meta-analysis of comparing fine-needle aspiration and frozen section for evaluating thyroid nodules. Diagn Cytopathol. 2008;36(12):916–920. doi:10.1002/dc.20943. PMID 18855886
Pennanen M, Heiskanen I, Sane T, et al. Helsinki score: a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol. 2015;46(3):404–410. doi:10.1016/j.humpath.2014.11.015. PMID 25582500
Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018;68(1):55–63. doi:10.3322/caac.21439. PMID 29092098
Picci G, Arora R, Grotzinger H, et al. Dense sampling for mapping pituitary growth dynamics before, during, and after pregnancy. J Neuroendocrinol. 2026;38(2):e70141. doi:10.1111/jne.70141. PMID 41644106
Piórek A, Płużański A, Kowalski DM, et al. Recent clinical and molecular advances in the management of thymic carcinoids: a comprehensive review. Cancers (Basel). 2025;17(12):1975. doi:10.3390/cancers17121975. PMID 40563625
Pollak MR, Seidman CE, Brown EM. Three inherited disorders of calcium sensing. Medicine (Baltimore). 1996;75(3):115–123. doi:10.1097/00005792-199605000-00001. PMID 8965680
Prajapati S, Hernandez-Prera JC. Putting all the pieces together: clinical, macroscopic and microscopic characteristics of subacute thyroiditis. Head Neck Pathol. 2019;13(2):231–234. doi:10.1007/s12105-018-0890-x. PMID 29427032
Queipo FJ, Panizo A, Yagüe A, et al. Metastatic clear cell renal cell carcinoma to the thyroid gland: a clinico-pathological and immunohistochemical study of 8 cases and review of the literature. Rev Esp Patol. 2019;52(2):81–86. doi:10.1016/j.patol.2018.08.004. PMID 30902382
Reimann JD, Dorfman DM, Nosé V. Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. Am J Surg Pathol. 2006;30(8):994–1001. doi:10.1097/00000478-200608000-00010. PMID 16861971
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786. doi:10.1038/s41379-018-0110-y. PMID 30140036
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740 (abstract)
Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35(8):841–985. doi:10.1177/10507256251363120. PMID 40844370
Roncaroli F, Giannini C. Posterior pituitary tumors and other rare entities involving the pituitary gland. Brain Pathol. 2025;35(1):e13307. doi:10.1111/bpa.13307. PMID 39350562
Roux A, Rosso D, Cuboni D, et al. Pituitary hyperplasia due to longstanding primary hypothyroidism: a case report and comprehensive review of the literature. Biomedicines. 2024;12(6):1368. doi:10.3390/biomedicines12061368. PMID 38927575
Rutter MM, Jha P, Schultz KA, et al. DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct association. J Clin Endocrinol Metab. 2016;101(1):1–5. doi:10.1210/jc.2015-2169. PMID 26555935
Sami L, Chipaux M, Ferrand-Sorbets S, et al. Genetic insights into hypothalamic hamartoma: unraveling somatic variants. Neurol Genet. 2024;10(5):e200180. doi:10.1212/NXG.0000000000200180. PMID 39246740
Sande CM, Tondi Resta I, LiVolsi VA. The thyroid pathologist meets therapeutic pharmacology. Endocr Pathol. 2023;34(1):48–56. doi:10.1007/s12022-023-09749-1. PMID 36723855
Seabrook AJ, Harris JE, Velosa SB, et al. Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab. 2021;106(4):1163–1182. doi:10.1210/clinem/dgaa957. PMID 33367756
Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86(2):349–363. PMID 10421272
Shimizu M, Hirokawa M, Manabe T, et al. Lithium associated autoimmune thyroiditis. J Clin Pathol. 1997;50(2):172–174. doi:10.1136/jcp.50.2.172. PMID 9155705
Silva LHCD, Pontes LA, Brescia MDG, et al. Prognostic factors and survival in parathyroid carcinoma: a 50-year single-center cohort study. Arch Endocrinol Metab. 2026;70(5):e260080. doi:10.20945/2359-4292-2026-0080. PMID 42485575
Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89(1):96–102. doi:10.1210/jc.2003-030675. PMID 14715834
Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab. 2012;97(2):334–342. doi:10.1210/jc.2011-2576. PMID 22312089
Staniforth JUL, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves' disease: a meta-analysis. Int J Surg. 2016;27:118–125. doi:10.1016/j.ijsu.2015.11.027. PMID 26626367
Stergianos S, Juhlin CC, Zedenius J, et al. Metastasis to the thyroid gland: characterization and survival of an institutional series spanning 28 years. Eur J Surg Oncol. 2021;47(6):1364–1369. doi:10.1016/j.ejso.2021.02.018. PMID 33642087
Stoupa A, Carré A, Polak M, et al. Genetics of primary congenital hypothyroidism: three decades of discoveries and persisting etiological challenges. Eur Thyroid J. 2025;14(2). doi:10.1530/ETJ-24-0348. PMID 40100854
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785. PMID 29072975
Suzuki A, Hirokawa M, Takada N, et al. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma. Endocr J. 2018;65(12):1171–1175. doi:10.1507/endocrj.EJ18-0282. PMID 30210064
Taïeb D, Wanna GB, Ahmad M, et al. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023;11(5):345–361. doi:10.1016/S2213-8587(23)00038-4. PMID 37011647
Takeshima K, Li Y, Kakudo K, et al. Proposal of diagnostic criteria for IgG4-related thyroid disease. Endocr J. 2021;68(1):1–6. doi:10.1507/endocrj.EJ20-0557. PMID 33311000
Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30(1-2):65–76. doi:10.1016/j.beha.2016.07.006. PMID 28288719
Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327
Thompson LD, Herrera HB, Lau SK. A clinicopathologic series of 685 thyroglossal duct remnant cysts. Head Neck Pathol. 2016;10(4):465–474. doi:10.1007/s12105-016-0724-7. PMID 27161104
Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551–566. doi:10.1097/00000478-200205000-00002. PMID 11979086
Tognato E, Ceratto S, Enrico G, et al. Neonatal adrenal hemorrhage: a case series. Am J Perinatol. 2020;37(S 02):S57–S60. doi:10.1055/s-0040-1713407. PMID 32898884
Toklu A, Mesa H, Collins K. Incidental adrenal hemangioma clinically suspicious for malignancy: diagnostic considerations and review of the literature. Int J Clin Exp Pathol. 2022;15(11):444–458. PMID 36507066
Toschetti T, Parenti C, Ricci I, et al. Acute suppurative and subacute thyroiditis: from diagnosis to management. J Clin Med. 2025;14(9):3233. doi:10.3390/jcm14093233. PMID 40364264
Tzen CY, Huang YW, Fu YS. Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol. 2003;34(7):666–669. doi:10.1016/s0046-8177(03)00241-7. PMID 12874762
Uccella S, Dottermusch M, Erickson L, et al. Inflammatory and infectious disorders in endocrine pathology. Endocr Pathol. 2023;34(4):406–436. doi:10.1007/s12022-023-09771-3. PMID 37209390
Uljanovs R, Sinkarevs S, Strumfs B, et al. Immunohistochemical profile of parathyroid tumours: a comprehensive review. Int J Mol Sci. 2022;23(13):6981. doi:10.3390/ijms23136981. PMID 35805976
Uludağ M, Aygün N, İşgör A. Main surgical principles and methods in surgical treatment of primary hyperparathyroidism. Sisli Etfal Hastan Tip Bul. 2019;53(4):337–352. doi:10.14744/SEMB.2019.67944. PMID 32377107
van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery. 1992;112(6):1130–1138. PMID 1455315
Villa C, Birtolo MF, Perez-Rivas LG, et al. Grading and staging for pituitary neuroendocrine tumors. Brain Pathol. 2025;35(1):e13299. doi:10.1111/bpa.13299. PMID 39182993
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–1264. doi:10.1097/PAS.0b013e3180309e6a. PMID 17667551
Volante M, Papotti M, Roth J, et al. Mixed medullary-follicular thyroid carcinoma: molecular evidence for a dual origin of tumor components. Am J Pathol. 1999;155(5):1499–1509. doi:10.1016/S0002-9440(10)65465-X. PMID 10550306
Wallace A, Angelos P, Cipriani NA. The controversy of lateral aberrant thyroid and the use of BRAF immunostain. Int J Surg Pathol. 2022;30(2):217–220. doi:10.1177/10668969211033526. PMID 34279125
Wang L, Lu L, Lu ZL, et al. [Etiology and clinical features of primary adrenal insufficiency]. Zhonghua Yi Xue Za Zhi. 2020;100(12):915–921. doi:10.3760/cma.j.cn112137-20191009-02178. PMID 32234166 (English abstract)
Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163–169. doi:10.1097/00000478-198403000-00001. PMID 6703192
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335. PMID 25810047
Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27(7):867–881. doi:10.1097/00000478-200307000-00001. PMID 12826878
Williams MD, DeLellis RA, Erickson LA, et al. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:73–82. doi:10.1016/j.humpath.2020.07.008. PMID 32687943
Wong KS, Dong F, Telatar M, et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome. Thyroid. 2021;31(6):933–940. doi:10.1089/thy.2020.0668. PMID 33143568
Wong KS, Lewis JS Jr, Gottipati S, et al. Utility of birefringent crystal identification by polarized light microscopy in distinguishing thyroid from parathyroid tissue on intraoperative frozen sections. Am J Surg Pathol. 2014;38(9):1212–1219. doi:10.1097/PAS.0000000000000204. PMID 24618617
Xing Y, Lerario AM, Rainey W, et al. Development of adrenal cortex zonation. Endocrinol Metab Clin North Am. 2015;44(2):243–274. doi:10.1016/j.ecl.2015.02.001. PMID 26038200
Xu B, David J, Dogan S, et al. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology. 2022;80(2):322–337. doi:10.1111/his.14550. PMID 34449926. Cited as Xu et al. 2022b.
Xu B, Fuchs TL, Ahmadi S, et al. International Medullary Thyroid Carcinoma Grading System: a validated grading system for medullary thyroid carcinoma. J Clin Oncol. 2022;40(1):96–104. doi:10.1200/JCO.21.01329. PMID 34731032. Cited as Xu et al. 2022a.
Yang K, Begley SL, Lynch D, et al. Pituitary metastases: a case series and scoping review. Pituitary. 2023;26(5):538–550. doi:10.1007/s11102-023-01349-w. PMID 37698666
Ye D, Gan N, Yang Y, et al. Clinical characteristics of nine cases of adrenal tuberculosis and literature review. Int Urol Nephrol. 2026;58(6):2207–2232. doi:10.1007/s11255-025-04897-1. PMID 41214357
Zhu Y, Li Y, Jung CK, et al. Histopathologic assessment of capsular invasion in follicular thyroid neoplasms: an observer variation study. Endocr Pathol. 2020;31(2):132–140. doi:10.1007/s12022-020-09620-7. PMID 32236857